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1.1.1 Definition and staging of Chronic Kidney Disease 
In 2002, the National Kidney Foundation’s Kidney Disease Outcomes Quality 
Initiative (KDOQI) defined chronic kidney disease (CKD) as abnormalities of kidney 
structure or decreased renal function, defined as a glomerular filtration rate (GFR) of 
< 60 ml/min/1.73m², present for > 3 months, irrespective of the underlying cause of 
renal disease. (table 1) CKD was classified into 5 stages based on GFR: ≥ 90 
ml/min/1.73m² (stage 1), 60-89 ml/min/1.73m² (stage 2), 30-60 ml/min/1.73m² (stage 
3), 15-30 ml/min/1.73m² (stage 4) and < 15 ml/min/1.73m² or renal replacement 
therapy (stage 5).1 Stages 1 and 2 can as such be accepted only in the presence of 
concomitant kidney damage. (table 1) 
 
 
Table 1: Criteria for the definition of chronic kidney disease (CKD) (either one of the 
following present for > 3 months) 1,2 
Markers of kidney 
damage  
(at least one) 
- Albuminuria: defined as urinary albumin excretion 
ratio (AER) ≥ 30 mg/24 hours or albumin to 
creatinine ratio (ACR) ≥ 30 mg/g (normal < 10 
mg/g) 
- Urine sediment abnormalities, such as hematuria, 
leukocyturia, casts, oval fat bodies 
- Electrolyte and other abnormalities due to tubular 
disorders, e.g. renal tubular acidosis, genetic 
tubular disorders, nephrogenic diabetes insipidus 
- Structural abnormalities detected by kidney imaging, 
e.g. cysts, masses, vascular abnormalities, 
hydronephrosis 
- Renal transplantation 
Decreased GFR GFR < 60 ml/min/1.73m². (normal: healthy young 
individual ~125 ml/min/1.73m²) 
 
 
Mainly based on the GFR criterion, the prevalence of CKD in the general population 
is estimated around 5-10 %.3-6 The aim of this conceptual model for CKD is earlier 
identification of patients at risk for complications, a poor prognosis or adverse 
outcomes.7 In epidemiological studies following the 2002 guidelines, GFR as well as 
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albuminuria were found to be independently associated to mortality, adverse 
cardiovascular outcome and progression of kidney disease.8-13 In 2012, an update of 
the guidelines regarding diagnosis and classification of CKD was published by 
Kidney Disease Improving Global Outcomes (KDIGO), adding albuminuria to GFR in 
the classification system, distinguishing CKD stage 3a (45-59 ml/min/1.73m²) and 3b 
(44-30 ml/min/1.73m²). (figure 1) In addition, the underlying cause of kidney disease 
received more emphasis, resulting in a classification system related to cause, GFR 
and albuminuria category (CGA), although the cause of kidney disease was not 
included in the grid which is proposed to be used for classification and prognosis. 2 
 
 
Figure 1: CKD-stages based on GFR and albuminuria and associated risk score 2 
 
 
 
 
In chapter 2 and chapter 5.2 the association between estimated (e)GFR, as kidney 
function parameter, and uremic retention solutes was investigated. Therefore in this 
chapter, an overview on the value and the use of GFR and eGFR will be given.  
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1.1.2 Glomerular filtration rate 
GFR is considered as the most relevant marker of kidney function, which is often 
believed to also grossly reflect tubular and endocrine functions of the kidney, and is 
defined as the volume of plasma filtered by the glomeruli per unit of time. The normal 
glomerular filtration rate in healthy young individuals is approximately 125 
ml/min/1.73m² (or ~180 L/day) and declines gradually in the general population from 
the age of 40 years on at a rate of approximately 0.5-1 ml/min/1.73m² per year2,14, 
reportedly ranging from 0.4 to 2.6 ml/min/year.15 
 
1.1.2.1 Measurement of GFR (mGFR) via exogenous filtration markers 
GFR can be measured by exogenous filtration markers which are ideally inert, freely 
filtered by glomerular filtration without tubular reabsorption, secretion or 
metabolization, and have no extra-renal clearance and no protein binding. 
Exogenous filtration markers are inulin (MW: 5200 Da), iothalamate (MW: 637 Da), 
iohexol (MW: 821 Da), ethylenediaminetetraacetic acid (EDTA) (MW: 292 Da) and 
diethylenediaminepentaacetic acid (DTPA) (MW: 393 Da). In practice some of them 
are mostly used as radio-isotopically labeled markers, being 125I-iothalamate, 51Cr-
EDTA and 99Tc-DTPA.16,17 
GFR can be measured via an urinary or plasma clearance of one of these markers. 
Due to differences in analytical and physiological aspects of the different markers, 
such as limited tubular handling or minimal extra-renal clearance, there is however 
variability in accuracy between the different methods. Urinary inulin clearance via 
bladder catheterisation and continuous intravenous infusion was the first technique 
described and is considered as the absolute gold standard. This method is however 
only exceptionally applied due to the cumbersome procedure, the analytical 
difficulties and costs. The urinary clearance of inulin or another marker can be 
calculated as GFR = [Xu] x Vu/[Xpl] x t, with [Xu]  being urinary concentration, Vu : 
urinary volume, [Xpl] plasma concentration and t : time. Incompleteness of the urine 
collection is the main source of bias.16,17 Alternatively, plasma clearance after a 
single bolus administration can be performed by sampling at multiple time points to 
calculate GFR from the area under the curve (AUC) of concentration over time.16-19 
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Which technique is used largely depends on local expertise and availability of the 
marker.  
In a meta-analysis comparing the different alternative exogenous filtration markers to 
urinary inulin clearance as the gold standard, urinary clearance of iothalamate and 
51Cr-EDTA and plasma clearance of iohexol and 51Cr-EDTA appeared the methods 
that gave results that were the closest to those from inulin.20 In clinical practice the 
use of these methods is usually reserved for specific indications, such as the 
evaluation of renal function of living kidney donors, before the administration of toxic 
drugs cleared by the kidneys (e.g carboplatin) or when a major influence of non-GFR 
determinants on endogenous markers is expected (see 1.1.2.2 and table 2) . 21 
 
1.1.2.2 Estimation of GFR (eGFR) via endogenous filtration markers 
As already mentioned, measurement of GFR is not routinely done in clinical practice. 
Usually, GFR is estimated from the serum or plasma concentration of endogenous 
filtration markers by incorporating them into a formula together with correction factors 
for important and known non-GFR determinants. 
 
 a. Filtration markers 
Creatinine (MW 113 Da) is the most widely used endogenous filtration marker, 
despite major limitations due to the influence of non-GFR determinants on its serum 
concentration and several analytical flaws. These non-GFR determinants essentially 
are related to muscle mass and nutritional factors. (table 2) Renal excretion occurs 
mainly via free glomerular filtration without tubular reabsorption, but with an 
additional tubular secretion that accounts for 5-10% of the urinary content and is 
different among individuals.17,21,22 A small fraction is excreted via the intestine; the 
degree of removal via this route may increase in renal failure.23 
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Table 2: Major determinants influencing serum creatinine concentration 
GENERATION 
Muscle mass  
Gender Male ↑ 
Race Black ↑ 
Age Old ↓ 
Body composition Amputation ↓ 
Muscular ↑ 
Chronic illness e.g. inflammation, immobilization ↓ 
Diet  
Meat ↑ 
 Vegetarian  ↓ 
REMOVAL 
Renal excretion  
Glomerular filtration Main excretion route 
Tubular reabsorption None 
Tubular secretion 5-10%, can be blocked by medication e.g. cimetidine, 
trimetoprim 
Intestinal excretion  
Limited, may be increased in uremia 
 
 
Although the analytical measurement of creatinine has much improved due to 
standardization to the international creatinine-reference material (National Institute 
for Standard and Technology, NIST 967) and calibration to an isotope dilution mass 
spectrometry (IDMS) traceable reference method, i.e. either gas chromatography 
(GC)/MS or liquid chromatography (LC)/MS, creatinine concentration determination 
remains challenging. In routine clinical laboratories the Jaffé method or enzymatic 
method are used. The traditional Jaffé method is based on the colorimetric reaction 
due to complex formation between picric acid and creatinine in alkaline milieu and 
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has the inherent problem of measuring also pseudo-creatinine chromogens, 
especially proteins and glucose. In the compensated Jaffé method, a mathematical 
compensation is performed for these pseudochromogens to approach the values of 
the enzymatic method to achieve IDMS-traceability. The enzymatic creatinine 
measurement is less prone to bias and does not measure these pseudochromogens, 
however inherent imprecision, which is present for every laboratory analysis remains. 
These differences in analysis can result in differences in reference values and are 
relevant when using creatinine in eGFR-formulae, especially for creatinine 
concentrations in the lower range (i.e. higher GFR-values).24-26 Strictu sensu, the 
urinary creatinine clearance on an urine collection can be used to measure renal 
function, but the value obtained overestimated true GFR due to the tubular secretion 
of creatinine. In addition, the accuracy is further skewed by the risk for incomplete 
urine collection.17,20  
 
Cystatin C (MW 13.3 kDa) is present in all nucleated cells and is an alternative 
endogenous filtration marker, which is entirely filtered by the glomeruli, and under 
normal conditions entirely reabsorbed and degraded in the tubuli, so that a renal 
clearance of cystatin C cannot be measured. Although cystatin C is much less 
influenced by muscle mass and was initially thought to be less dependent on non-
GFR determinants compared to creatinine, it has been shown that age, gender, 
inflammation, hyperthyroidism, body mass index, proteinuria, diabetes and high dose 
corticosteroid use can influence cystatin C concentration.27,28 The availability of a 
reference material for cystatin C (ERM-DA 471/IFCC) since 2011 is an important step 
towards the calibration of cystatin C, which is desirable before it is introduced as a 
routine clinical laboratory measurement. However, this standardization is not yet as 
uniform as for creatinine since a standardized analytical method is not yet available.24 
 
Due to the limitations of creatinine and cystatin C as glomerular filtration markers, 
other markers are under investigation. Especially beta-trace protein (MW 19 kDa, 23 
– 29 kDa, depending on degree of glycosylation) or L-type prostaglandin D2 
synthase and beta-2-microglobulin (MW 11.8 kDa) are strongly associated to GFR, 
respectively with a coefficient of determination (R²) around 0.756-0.84229,30 and 
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0.853-0.938.30,31 Their possible advantage in comparison to creatinine is the 
independence on muscle mass, although more and more other non-GFR 
determinants are recognized influencing their serum concentration such as age, 
gender and in the case of beta-2 microglobulin, inflammation and malignancy.31,32 
The insufficient knowledge on non-GFR determinants and the lack of analytical 
standards and validated eGFR-formulae, make them unsuitable for use in current 
clinical practice. Both are also associated to adverse outcome such as mortality in 
the general33,34, CKD35,36 and hemodialysis population.36-39 
 
b. Commonly used eGFR-formulae 
The performance of a GFR-formula is mainly dependent on a combination of bias 
(difference between eGFR and mGFR), precision (i.e. variability of eGFR around 
mGFR) and accuracy (combination of bias and precision). The 2002 KDOQI 
guidelines considered a P30, meaning an eGFR within 30% of mGFR, as clinically 
acceptable and recommended that P30 should be achieved in > 90% of the population 
in validation studies of an eGFR formula.1 Although this goal has not yet been 
achieved for none of the available formulae, the use of eGFR is a generally accepted 
approach for the assessment of kidney function.  
Due to the cheap and easily accessible analysis of creatinine, creatinine-based 
formulae are the most commonly used in clinical practice. The Cockroft-Gault formula 
was the first formula that was widely used for this purpose. It estimates creatinine 
clearance, but is not recommended anymore by nephrological societies, amongst 
others due to its poor accuracy and development based on non standardized 
creatinine and in a small study population.40 
Nowadays, the Modification in Diet and Renal Disease-formula (MDRD)41,42 and the 
creatinine-based Chronic Kidney Disease Epidemiology Collaboration-formula (CKD-
EPIcrea)
43 formulae are recommended and the most extensively validated. According 
to the 2012 KDIGO guidelines the use of the CKD-EPIcrea formula is preferred.
2 The 
overall performance of the CKD-EPIcrea formula is better compared to the MDRD (P30: 
84.1% vs. 80.6% respectively)43, especially when eGFR is > 60 ml/min/1.73m², with 
MDRD tending to underestimate GFR in the higher range.44 A systematic review 
including 12 studies45 and comparing the performance of CKD-EPIcrea and MDRD 
Chapter 1: Introduction 
24 
formula, found a P30 ranging from 59-95% for both formulae and confirmed the 
superior accuracy for the CKD-EPIcrea in the majority of the studies. However, when 
GFR was < 60 ml/min/1.73m², MDRD was slightly more accurate compared to the 
CKD-EPIcrea, with a tendency for the CKD-EPIcrea to overestimate GFR.
45 A possible 
explanation for this finding is the difference of mean GFR in the development 
population of both formulae, being 39 ml/min/1.73m² for the MDRD-formula41,42 and 
68 ml/min/1.73m² for the CKD-EPI formula.43 
In advanced CKD, the use of eGFR is more debatable. Evans et al.46 investigated the 
performance of different formulae in a large cohort of patients with advanced CKD 
(mGFR of < 30 ml/min/1.73m²).  The accuracy of the formulae was lower compared 
to the higher GFR-range, with P30 being 66.8% for the CKD-EPIcrea and 65.2% for the 
MDRD. The best P30 was found for the revised Lund-Malmö formula
47 (75.6 %), a 
formula developed in a Swedisch cohort.46 In CKD stage 5, the influence of non-GFR 
determinants on creatinine is more pronounced compared to the populations in which 
the formulae have been developed, for example due to malnutrition or reduced 
muscle mass.48,49 Therefore the use of eGFR is not recommended in CKD stage 5.50 
In advanced CKD, a measured urinary creatinine clearance, especially when 
measuring an average creatinine and urea clearance can still be a useful 
alternative.51 
 
In general CKD populations, Cystatin C-based formulae perform in most of the 
studies better compared to creatinine-based formulae, although the absolute 
increase in P30 is often limited to a few percentages. Especially combined creatinine-
and cystatine C-formulae have shown to improve the performance of eGFR-
formulae. The high analytical costs and lack of standardization of the analytical 
method limit its introduction in routine clinical practice. However, when eGFR is 
between 45-59 ml/min/1.73m² without any indication for kidney damage, the 2012 
KDIGO-guidelines suggest using the CKD-EPIcystC (P30: 85.9%) or CKD-EPIcystC-crea 
(P30: 91.5%) formulae as a confirmatory test.
52 (table 3) 
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Multiple other formulae based on creatinine and/or cystatin C have been developed, 
although most of these were not studied as thoroughly as the ones described above. 
Formulae used in specific populations will be discussed in the next section.  
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Table 3: Overview of eGFR-formulae discussed in the text 
Reference Formula Development cohort External validation cohort 
MDRD-formula(4variable) 
42 
175 x Screa-1.154 x age-0.203 [x 0.742 if female] [x 
1.21 if black] 
N= 1628 
Mean GFR = 39 ml/min/1.73m² 
Initially: none 
N=5504: P30: 83% 
53 
N= 3896: P30: 80.6% 
43 
CKD-EPIcrea 
43 eGFR= 141 x min(Screa/κ,1)α x max(Screa/κ,1)-
1.209 x 0.993Age [x 1.018 if female] [x 1.159 if black] 
(κ: 0.7 if female, 0.9 if male; α: -0.329 if female, -
0.411 if male) 
N= 5504 
Mean GFR =  68 ml/min/1.73m² 
N= 3896 
P30: 84.1% 
CKD-EPIcystC 
52 133 × min(ScystC/0.8, 1)−0.499 × max (ScystC/0.8, 
1)−1.328 × 0.996Age [× 0.932 if female], where min 
indicates the minimum of Screa/κ or 1, and max indicates the 
maximum of Screa/κ or 1 
N= 3522 
Mean GFR = 68 ml/min/1.73m² 
N = 1830 
P30: 85.9% 
CKD-EPIcystC-crea 
52 135 × min(Screa/κ, 1)α × max(Screa/κ, 1)−0.601 × 
min(ScystC/0.8, 1)−0.375 × max(ScystC/0.8, 1)−0.711 
× 0.995Age [× 0.969 if female] [× 1.08 if black], 
where κ is 0.7 for females and 0.9 for males, α is −0.248 for 
females and −0.207 for males, min indicates the minimum of 
Screa/κ or 1, and max indicates the maximum of Screa/κ or 1 
N= 3522 
Mean GFR = 68 ml/min/1.73m² 
N = 1830 
P30: 91.5% 
Cockroft-Gault 40  [(140-age) x weight] x [0.85 if female]/(Screa  x  
72) 
N= 249 
Creatinine clearance: 30-130 
ml/min 
Initially: none 
(Cohorts independent of 
investigators of development) 
Lund-Malmö 47 expX – 0.0158 X age + 0.438 X ln(age) 
Female and Pcrea <150: X = 2.50 + 0.0121 × (150−Pcrea) 
Female and Pcrea ≥150: X = 2.50 − 0.926 × ln(Pcrea/150) 
N = 850 
 
Mean GFR = 55 ml/min/1.73m² 
Initially none 
(Cohorts independent of 
investigators of development) 
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Male and Pcrea <180: X = 2.56 + 0.00968 × (180−Pcrea) 
Male and Pcrea ≥180: X = 2.56 − 0.926 × ln(Pcrea/180) 
Pcrea in µmol/L, (conversion from mg/dl: x 88.4) 
 
P30: 85.8% 
BIS1crea (> 70 years) 
54 3736 x Screa-0.87 x age-0.95 [x 0.82 if female] N= 570, > 70 years 
Mean GFR =60.3 ml/min/1.73m² 
P30: 95.1% 
Initially none 
(Cohorts independent of 
investigators of development: see 
text) 
BIS2cystC-crea (>70years) 
54 
767 x ScystC-0.61 x Screa-0.4 x age-0.95 [x 0.87 if 
female] 
N= 570, > 70 years 
Mean GFR =60.3 ml/min/1.73m² 
P30: 96.1% 
Initially none 
(Cohorts independent of 
investigators of development: see 
text) 
Schwartz (revised) 
(children) 55 
0.413 x [height/Screa] N= 349 
Mean GFR = 41 ml/min/1.73m² 
P30= 79.4% 
Initially none 
eGFR: estimated glomerular filtration rate, Screa: serum creatinine, SCystC: serum cystatin C, N: number of patients, P30: accuracy P30, Pcrea: 
plasma creatinine. The use of serum and plasma for the measurement of creatinine is equivalent.
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1.1.2.3 Use of eGFR formulae in specific populations/conditions 
a. Elderly 
The number of patients older than 70 in the development population of the MDRD41,42 
and CKD-EPI formulae (creatinine and cystatin C-based)43,52 was small, so that 
theoretically they should not be used in patients > 70-75 years. Some studies 
investigated the performance of MDRD and CKD-EPI in elderly and found a P30 
accuracy ranging from 70 to 86%56-60, comparable to results found in other 
populations, with superiority for CKD-EPIcrea (P30: 74.7%-83%) and especially CKD-
EPIcrea-cystC (P30: 85,3%-86%) compared to MDRD (P30: 70.5%-81%), while the results 
with CKD-EPIcystC (P30: 65.3%-86%) were inconsistent.
58,60 
Recently, the Berlin Initiative Study (BIS), consisting of a healthy cohort aged > 70 
years, developed a specific creatinine-based (BIS 1) and creatinine-cystatin C- based 
(BIS 2) formula to be used in the elderly.54(table 3)  These formulae were validated in 
independent external cohorts of older patients with good performance (P30: 75-
88%)56-59, which was superior 57,59or equivalent 56,58 to the CKD-EPI .   
 
b. Children  
The Schwarz formula, introduced in 1979 and based on a constant, height and serum 
creatinine, is the most widely used formula in children. This formula was recently 
updated for enzymatically determined and IDMS traceable serum creatinine 
concentrations in a population of 349 children, aged between 1 and 16 years. 55 
(table 3)  
Also in children, cystatin C-based formulae generally perform better compared to 
creatinine-based formulae, probably partly due to the fact that cystatin C is less 
dependent on muscle mass. 61  
 
c. Race 
In the MDRD42 and CKD-EPI43 formulae, ethnicity coefficients for blacks are 
incorporated, to compensate for higher creatinine values at similar GFR compared to 
whites probably due to a higher muscle mass. This is based on African-American 
subpopulations in the development cohorts of the formula. To estimate eGFR in 
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Africans living on the African continent, the use of MDRD or CKD-EPI without the 
ethnicity coefficients is more appropriate.62,63 
Various ethnicity coefficients are suggested to be included in the MDRD or CKD-EPI 
in diverse Asian populations64-67, although other investigators did not find an 
improvement in accuracy adding specific correction factors.68,69 
 
d. Kidney transplant patients 
In kidney transplant patients, the performance of the CKD-EPIcrea and MDRD are 
comparable, although the MDRD performed better when GFR was < 60 
ml/min/1.73m² and CKD-EPIcrea when GFR was > 60 ml/min/1.73m².
70-73 In stable 
transplant patients, cystatin C-based formulae (P30: ~80%) were superior compared 
to creatinine-based formulae (P30: 68-75%). 
70,74  
 
e. Drug dosing 
Pharmacokinetic studies for drug dosing are generally based on creatinine clearance 
or the Cockcroft-Gault formula (table 3) as kidney function parameter. Although 
initially considered as inappropriate, it is now generally accepted to use eGFR with 
the same cut-off values for drug dosing, which was supported by the Food and Drug 
Administration (FDA) in 2010. It is however unlikely that a re-evaluation will be made 
for the majority of already registered drugs. In patients with extremes in body size, it 
is advisable to exclude the bias induced by an extrapolated body surface area (i.e. 
1.73m²) by multiplying eGFR in ml/min/1.73m² with true individual body surface area 
to obtain an absolute eGFR in ml/min.75  
 
1.1.3 Summary 
Chronic kidney disease is classified based on the cause of underlying kidney 
disease, glomerular filtration rate and albuminuria, in order to stratify patients at 
increased risk. The CKD-EPIcrea formula is acceptable to estimate GFR in the general 
and CKD populations, although the goal of an accuracy of P30 > 90% is not reached. 
On an individual patient level precision often is lower due to variable influences of 
non-GFR determinants on the creatinine concentration. Cystatin C- based formulae 
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or combined creatinine-cystatin C-based formulae often provide a superior 
performance compared to formulae based on creatinine, but are not yet used in 
routine clinical practice. mGFR using an exogenous marker can be a suitable 
alternative in specific indications.  
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1.2.1  Abstract 
In the last decade, uremic toxicity as a potential cause for the excess of 
cardiovascular disease and mortality observed in chronic kidney disease gained 
more and more interest. This review focuses on uremic toxins with known 
cardiovascular effects and their removal. For protein-bound solutes, for example, 
indoxylsulfate and the conjugates of p-cresol, and for small water-soluble solutes, for 
example, guanidines, such as ADMA and SDMA, there is a growing evidence for a 
role in cardiovascular toxicity in vitro (e.g., affecting leukocyte, endothelial, vascular 
smooth muscle cell function) and/or in vivo. Several middle molecules (e.g., beta-2-
microglobulin, interleukin-6, TNF-alpha and FGF-23) were shown to be predictors for 
cardiovascular disease and/or mortality. Most of these solutes, however, are difﬁcult 
to remove during dialysis, which is traditionally assessed by studying the removal of 
urea, which can be considered as a relatively inert uremic retention solute. However, 
even the effective removal of other small water-soluble toxins than urea can be 
hampered by their larger distribution volumes. Middle molecules (beta-2-
microglobulin as prototype, but not necessarily representative for others) are cleared 
more efﬁciently when the pore size of the dialyzer membrane increases, convection 
is applied and dialysis time is prolonged. Only adding convection to diffusion 
improves the removal of protein-bound toxins. Therefore, alternative removal 
strategies, such as intestinal adsorption, drugs interfering with toxic biochemical 
pathways or decreasing toxin concentration, and extracorporeal plasma adsorption, 
as well as kinetic behaviour during dialysis need further investigation. Even more 
importantly, randomized clinical studies are required to demonstrate a survival 
advantage through these strategies.  
 
1.2.2 Introduction  
Knowledge on uremic toxicity has grown spectacularly over the past decades. 
Although barely discussed until late in the previous century, interest increased 
exponentially since then. Taking the example of one of the few compounds that have 
rarely been studied outside the context of uremia, indoxylsulfate, while in 1990 no 
single publication was devoted to this solute, in 2011 alone the number exceeded 60 
(Fig. 1).  
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Fig. 1 Number of publications on indoxylsulfate, a prototype protein-bound uremic toxin, over the 
recent years. Whereas there were virtually no publications in the early nineties, last year over 60 
papers were devoted to this issue 
 
In this review, we summarize our view on the most relevant uremic toxins and their 
toxicity. Although the uremic syndrome affects almost every organ system and 
function (Table 1), we mainly focus on cardiovascular effects, one of the major 
sources of morbidity and mortality in uremia [1].  
Based on the removal pattern during dialysis, uremic toxins are subdivided into three 
major classes [2]: (1) the small water-soluble compounds, with an arbitrary upper 
molecular weight limit of 500 D, easy to remove by any dialysis strategy; (2) the 
larger middle molecules (>500 D) only removed through dialyzer membranes with 
enhanced transport capacity and large enough pores (high ﬂux); and (3) protein-
bound molecules, mostly with a molecular weight <500 D, but a hampered removal 
pattern due to protein binding. Representative molecules will be discussed with 
regard to in vitro and in vivo toxicity, and clinical removal and outcome studies.  
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1.2.3 The small water-soluble compounds  
Of the large number of known small water-soluble uremic compounds [2, 3], we will 
only discuss urea and the guanidines.  
Although urea (60 D) is the prototype of this class, data corroborating its biochemical 
or biological effects are scanty. In a study from the Mayo Clinic, urea was added for 
three consecutive months to dialysate up to a concentration substantially exceeding 
that normally observed pre-dialysis [4]. While all other solutes were removed as 
usual, blood urea concentration markedly rose, however, without discriminate effects 
on uremic symptoms. Two randomized controlled trials (RCTs) increased urea 
removal above standard without improvement in survival rate [5, 6]. In two 
observational trials, next to urea removal, other factors such as length of dialysis or 
serum albumin were at least as much associated with outcome [7, 8]. In at least two 
studies, increasing solute removal without improving urea removal per se improved 
outcomes [9, 10]. Data in favor of a biochemical effect of urea were often obtained 
only at supra-physiologic concentrations, with the exception of a recent study, where 
urea at disease-relevant concentrations in vitro induced free radical production and 
insulin resistance in adipocytes [11].  
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The question may be raised whether other water-soluble compounds are 
characterized by a similar inertia as urea. An important group is composed of the 
guanidines (Table 2), which have been identiﬁed since many years as neurotoxins 
[12, 13]. Only recently, these compounds were also studied for their cardiovascular 
impact. Several guanidines were shown to be pro-inﬂammatory, by activating 
leukocyte function at the concentrations found in uremia [14, 15]. In addition, these 
data show that the different uremic toxin groups interfere with each other, as small 
water-soluble guanidines were responsible for the generation of TNF-α and IL-6, two 
middle molecules [15, 16].  
 
 
 
Since the guanidines are structurally similar to urea, also a comparable removal 
pattern could be expected. However, the distribution volume of several guanidines is 
signiﬁcantly larger than that of urea, resulting in a decrease in effective removal [17]. 
Only guanidinosuccinic acid displays a smaller distribution volume than urea [17]. 
These calculated values were corroborated by direct experimental measurements, 
showing that guanidino compound concentrations during hemodialysis in the 
erythrocytes lagged behind versus plasma [18]. Mathematical simulations revealed 
that the most effective improvement in removal of the guanidines with a large 
distribution volume was obtained by increasing dialysis length [19]. For 
guanidinosuccinic acid, however, with its smaller distribution volume, removal was 
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more effective after increasing dialysis frequency [19]. For all compounds, the 
combination of frequent and long dialysis was optimal [19]. These differences in 
kinetic characteristics can only be explained by the low resistance imposed by the 
cellular wall to urea, which is almost unique for this molecule [20, 21].  
Also, the dimethylarginines are guanidines; asymmetric dimethylarginine (ADMA) has 
since long been recognized as an inhibitor of nitric oxide synthase (NOS) causing 
endothelial dysfunction and vascular damage [22], a propensity that affects both the 
general and the uremic population [23–25]. Infusion of ADMA in healthy volunteers to 
a concentration as in uremia resulted in a decrease in cardiac output and a rise in 
vascular resistance [26]. In a dialysis population, ADMA concentration was correlated 
to intima-media thickness, an index of vascular damage [25].  
Symmetric dimethylarginine (SDMA), a structural analogue of ADMA, has long been 
considered inert [22, 27]. Biologic activity was at ﬁrst suggested by Bode-Boger et al. 
[28], showing a dose–responsive inhibition of NO synthesis by a mechanism different 
from that elicited by ADMA. SDMA plays as well a prominent role in leukocyte 
activation by enhancing generation of radical oxygen species (ROS), which is 
attributable to increased calcium inﬂux via store-operated Ca2+ channels [29] and to 
activation of NF-κB resulting in cytokine production [16]. Inhibition of NF-κB by N-
acetylcysteine (NAC) and of ROS production with SKF96365 and captopril prevented 
this leukocyte activation [16, 29]. A clinical study in 142 patients with different stages 
of chronic kidney disease (CKD) demonstrated a correlation of SDMA with TNF-α 
and interleukin-6 (IL-6) [16], which was markedly more signiﬁcant than for ADMA 
[16].  
The intradialytic kinetics of both ADMA and SDMA has not thoroughly been studied. 
Some data suggest that the removal of ADMA in standard dialysis is hampered, 
eliciting the hypothesis that the compound is protein bound [30], but more likely, 
removal is hindered by complex kinetics and distribution.  
Especially for ADMA, alternative removal pathways have been assessed. In renal 
failure, ADMA is retained at least in part by the inhibition of the enzyme 
dimethylarginine dimethylaminohydrolase (DDAH) [31]. Increased expression of this 
enzyme decreases coronary damage in mice that received a cardiac allograft [32] 
and decreases angiotensin II-induced organ damage [33]. Vice versa, disruption of 
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DDAH impairs vascular homeostasis [34]. These studies offer proof of concept that 
ADMA concentration can be changed by modifying metabolism, with impact on the 
vascular status. As DDAH is inhibited by hyperhomocysteinemia, a more feasible 
approach for metabolic manipulation of DDAH and ADMA could be obtained by 
decreasing homocysteinemia. In a study by Koyama et al. [35], the combination of 
folate and methylcobalamin decreased ADMA in parallel with a decrease in 
homocysteinemia.  
 
1.2.4 The middle molecules  
The group of middle molecules, deﬁned by a molecular weight > 500 D, is mainly 
composed of small peptides. Currently, more than 50 solutes comply with this 
deﬁnition [2, 3, 36] (Table 3); many of these are implied in cardiovascular disease, by 
causing inﬂammation, endothelial damage, smooth muscle cell proliferation, 
activation of coagulation or by interfering with calcium/phosphorus household. There 
is thus a pathophysiologic rationale for optimizing their removal. However, their effect 
on relevant cell mechanisms at the concentrations occurring in uremia has barely 
been studied. Data on the association of middle molecule concentrations with clinical 
outcome parameters are more elaborate. 
 
The most used marker for middle molecule retention and removal is β2-
microglobulin. In general, this molecule is, however, considered inert. Nevertheless, 
Wilson et al. [37] identiﬁed by proteomic analysis β2-microglobulin as the most 
adequate marker of severity of peripheral vascular disease in a population with no or 
moderate chronic kidney disease. In addition, β2-microglobulin has been associated 
with arterial stiffness in the general population [38] and bone remodeling in non-CKD 
postmenopausal women [39]. 
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With regard to outcome studies, in two secondary analyses of the HEMO study 
conducted in hemodialysis patients, β2-microglobulin was related to overall and 
infectious mortality [40, 41]. In a CKD population with several stages of CKD, 
interleukin-6 (IL-6) was related to mortality, whereas there was no association for 
tumor necrosis factor-alpha (TNF-α)[42]. In contrast, in a hemodialysis population, 
TNF-α was a stronger predictor of mortality than IL-6 [43]. Fibroblast growth factor-23 
(FGF-23), a molecule essentially linked to bone mineral homeostasis, has been 
associated with progression of kidney failure [44], cardiac dysfunction [45] and overall 
mortality [46, 47]. Although merely seen as a marker, a recent study in animals 
showed a direct hypertrophic effect on the heart after chronic injection [48]. Also, 
these data thus suggest that middle molecule removal could favour outcome.  
Increasing dialyzer pore size by applying high-ﬂux membranes resulted in an 
increased removal of β2-microglobulin [49] and a decrease in pre-dialysis β2-
microglobulin over time [50], with a further increase by adding convection [51–53] or 
by applying newer high-ﬂux membranes with more homogeneous pores [54].  
Removal of β2-microglobulin is not necessarily representative for that of other middle 
molecules. In a study by Ward et al. [55], the transition from high-ﬂux hemodialysis to 
predilution online hemodiaﬁltration had a different impact on complement factor D 
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versus β2-microglobulin. In a study by Meert et al. [54], the change from ﬁrst-to 
second-generation high-ﬂux membranes resulted in more improvement in removal as 
the molecular weight of the studied molecules increased. All these data stress the 
need for thorough studies of the removal pattern of middle molecules at large, but 
kinetic analysis has up to now only been applied to β2-microglobulin. When 
evaluating the concentration pattern of β2-microglobulin during high-ﬂux hemodial-
ysis, Leypoldt et al. [56] demonstrated a ± 25 % decrease at the end of dialysis, 
which was, however, to a large extent neutralized by a postdialysis rebound 
phenomenon, pointing to a substantial multicompartmental distribution. Although the 
distribution volume of β2-microglobulin is 3–4 times smaller than that of urea, the 
shift from the extra-plasmatic to the plasmatic compartment is decreased almost 
20-fold, hampering removal [57, 58].  
The slow intercompartmental clearance of β2-microglobulin suggests that extended 
dialysis might beneﬁt removal. Comparing 4-, 6-and 8-h dialyses in the same patients 
while dialyzer surface, total blood ﬂow and dialysate ﬂow per session were kept the 
same, β2-microglobulin removal into the dialysate increased by approximately 80 % 
with longer dialyses in spite of similar Kt/Vurea [17, 59].  
In a series of secondary analyses of randomized controlled trials, increasing dialyzer 
pore size by applying high-ﬂux membranes resulted in better outcomes compared to 
small-pore, low-ﬂux dialysis [5, 60–63]. In the Membrane Permeability Outcomes 
(MPO) study, high-ﬂux hemodialysis resulted in better survival outcomes in the 
subgroup with a serum albumin below 4 g/dL [10], which is the group targeted in the 
original study protocol [64]. Hypoalbuminemia is a feature of a large section of the 
current dialysis population [65].  
When adding convection, RCTs showed a lower incidence of intradialytic 
hypotension [66], and at the borderline of signiﬁcance in a small study, improved 
survival outcomes [9]. In two large RCTs, however, improved survival with online 
hemodiaﬁltration versus hemodialysis could not be demonstrated at primary analysis 
and was present only in the subgroups with the highest ultraﬁltration volumes [67, 
68].  
 
Chapter 1.2: Uremic Toxins 
45 
1.2.5  The protein-bound molecules  
Of the large group of protein-bound uremic substances [69] (Table 4), indoxylsulfate 
and the conjugates of p-cresol, p-cresylsulfate and p-cresylglucuronide have most 
extensively been studied; the section that follows is limited to those compounds.  
Until some years ago, the study of the biochemical impact of the cresols had been 
restricted to the mother compound p-cresol [70], which, however, in reality is not 
present in the body. Its repeated registration in uremic samples was the result of an 
artifact, due to hydrolysis of the conjugates caused by acid deproteinization [70–72].  
Whereas p-cresol is a known inhibitor of leukocyte function [73], p-cresylsulfate is 
pro-inﬂammatory by inducing leukocyte free radical production [74, 75]. Later studies 
indicated p-cresylsulfate also as a source of endothelial microparticle release, an 
indirect parameter of vascular damage [76], of renal ﬁbrosis via epithelial to 
mesenchymal transition induced by the renin angiotensin system [77] and of 
transcriptional suppression of Klotho correlated with hypermethylation of the Klotho 
gene in renal tubular cells [78]. In a recent study, evaluating the cross talk between 
endothelium and leukocytes, p-cresylsulfate caused leukocyte recruitment [79].  
While p-cresylsulfate shows the highest total concentration, p-cresylglucuronide is 
less protein bound, resulting in virtually the same free active concentration for both 
compounds [75]. Although p-cresylglucuronide per se is inactive toward leukocytes, it 
enhances the propensity of p-cresylsulfate to induce free radical generation [75], 
stressing the potential for synergism among uremic toxins. The association of 
p-cresylsulfate with p-cresylglucuronide also provoked endothelial albumin leakage, 
which was absent with p-cresylsulfate alone [79].  
Many studies associated especially free p-cresol as surrogate of p-cresylsulfate with 
negative outcomes: propensity for infectious disease [80], uremic symptoms [81], 
cardiovascular disease [82, 83] and overall mortality [84]. More recently, studies 
analyzing p-cresylsulfate as such found associations with progression of kidney 
failure [85], coronary artery disease [86, 87], vascular calciﬁcation [88], and 
cardiovascular [89] and overall mortality [88, 89].  
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Many of the effects of indoxylsulfate are related to cardiovascular damage, such as 
PAI-1 activation as an index of free radical production [90], osteoblastic resistance 
against parathyroid hormone as a potential source of vascular calciﬁcation [91], 
endothelial micro-particle release [92], disruption of adherens junctions of endothelial 
cells [93], proliferation of smooth muscle cells [94] and renal [77] and cardiac ﬁbrosis 
[95].  
An interaction between leukocytes and endothelium was suggested in vitro by Ito et 
al. [96], showing endothelial NF-κB activation in association with leukocyte adhesion. 
To the best of our knowledge, up till now only one in vivo study showed a damaging 
effect of indoxylsulfate on the vascular structure as a whole: In salt-sensitive 
hypertensive Dahl rats, administration of indoxylsulfate up to uremic concentrations 
induced calciﬁcation of the vessel wall which was not present in wild-type rats and 
Dahl rats not receiving indoxylsulfate [97]. In a recent study, indoxylsulfate caused 
leukocyte recruitment to an extent comparable to that of lipopolysaccharide [79].  
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In clinical outcome studies, indoxylsulfate was associated with IL-6 concentration 
[98], coronary artery disease [87], vascular damage [99], progression of kidney failure 
[85] and mortality [99].  
Removal of protein-bound solutes by dialysis strategies is less efﬁcient than that of 
non-protein-bound solutes of similar molecular weight, due to the resistance induced 
by protein binding. Increasing pore size has no impact [100]. However, adding 
convection to diffusion increases reduction rate as well as clearance [51, 54], 
resulting in a longitudinal decrease in pre-dialysis concentrations [52, 53]; the 
question whether these decreases have clinical relevance remains unanswered.  
Fractionated plasma separation and adsorption, an extracorporeal removal strategy 
usually applied in severe liver failure, approximately doubles the removal of protein-
bound solutes compared to high-ﬂux hemodialysis [101]; however, the study 
evaluating this setup was prematurely arrested because of serious clotting problems 
[102]. Nevertheless, this experiment offers proof of concept that extracorporeal 
adsorption might become a valuable tool in protein-bound solute removal.  
With regard to peritoneal dialysis (PD), Evenepoel et al. [103] demonstrated 
signiﬁcantly higher clearance of protein-bound compounds with high-ﬂux 
hemodialysis compared to peritoneal dialysis even accounting for the better residual 
renal function with PD. Remarkably enough, however, plasma concentration of 
protein-bound compounds, which is conveying toxicity, is lower in PD [103–105], 
pointing to a role of other, possibly metabolic, factors in generating protein-bound 
compounds [106].  
Generation of the precursors of protein-bound solutes largely occurs via amino acid 
metabolism by the intestinal ﬂora [107], a process further accentuated in uremia 
[108]. The role of the intestine in uremic solute generation was deﬁnitely 
demonstrated by the ﬁnding of virtually absent protein-bound solute concentrations at 
metabolomic analysis of patients who had their colon removed [109]. A potential 
pathway to decrease protein-bound solutes might thus be via inﬂuencing these 
intestinal mechanisms [107]. However, protein restriction carries a risk of 
malnutrition. Metabolically more acceptable alternatives are the administration of 
prebiotics such as resistant starch [110] or oligofructose-enriched inulin [111], probio-
tics such as biﬁdobacterium [112] or intestinal sorbents such as AST-120 
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(Kremezin
®
)[113].  
Historically, emphasis has always been on the removal of indoxylsulfate by AST-120, 
but it also likely adsorbs precursors from other protein-bound compounds. Already in 
1993, Niwa et al. [114] demonstrated that in uremic rats, serum p-cresol was 
decreased after AST-120 administration. More recently, Kikuchi et al. [115] 
performed liquid chromatography/electrospray ionization-tandem mass spectrometry 
(LC/ESI-MS/ MS) to serum of uremic rats given AST-120 and showed a decrease 
versus untreated animals of at least 11 solutes, of which indoxylsulfate, hippuric acid, 
phenylsulfate and p-cresylsulfate were identiﬁed.  
Apart from interfering with intestinal generation and metabolism, inﬂuence of renal 
tubular handling of toxins can decrease local toxicity to renal tubular cells. By 
inducing free radical production in renal tubular cells [90], a role for indoxylsulfate in 
the progression of renal failure due to inﬂammatory damage has been hypothesized. 
Indoxylsulfate enters into the renal tubular cells via organic acid pumps [116]; 
inhibiting these pumps, for example, by probenecid, protects against tubular necrosis 
induced by indoxylsulfate [117]. On the other hand, also stimulating organic acid 
pump systems (SLCO4C1) may help in removing organic acids from the tubule and 
so be protective [118]; statins activate SLCO4C1 [118], while uremic toxins inhibit 
efﬂux pumps [119].  
In animal studies, indoxylsulfate or its precursors induced progression of renal failure 
[120, 121], whereas reduction in indoxylsulfate concentration by the intestinal sorbent 
AST-120 was nephroprotective [122] and prevented glomerulosclerosis [123].  
Several trials in humans showed a beneﬁt for AST-120 on progression of kidney 
disease. In a small population, AST-120 could postpone start of dialysis [124]. Based 
on a more elaborated randomized protocol, Akizawa et al. [125] demonstrated a 
slower progression of decrease of estimated glomerular ﬁltration rate (eGFR) in non-
dialyzed CKD patients on AST-120 versus placebo. In another RCT, Shoji et al. [126] 
showed a decrease in the slope of iothalamate clearance after the start of AST-120, 
which was not present in the untreated group. In diabetics with proteinuria and 
moderate CKD, a randomized study showed a less pronounced rise in serum 
creatinine in the AST-treated group [127]. Finally, AST-120 administered in the pre-
dialysis stage also improved survival once hemodialysis was started [128].  
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Although it is conceivable that all protein-bound solutes and uremic toxins at large 
are removed by the kidneys, the question should be raised in how far our current 
marker of renal function, glomerular ﬁltration rate (GFR), is related to concentration of 
these uremic solutes. The correlation between estimated GFR (eGFR) and several 
retention compounds was weak to nonexisting [129]. Although partly attributable to 
the use of eGFR rather than real measured GFR, the extreme differences in the 
correlation coefﬁcients among compounds suggest that more than GFR, other 
elements, such as generation, metabolism, intestinal production or tubular clearance, 
have a crucial impact on uremic solute concentration [130]. Similar data were found 
for middle molecular peptidic compounds [131]. These ﬁndings may explain why 
patients in the Initiating Dialysis Early and Late (IDEAL) trial who were randomized to 
start dialysis with low eGFR did not reach this target, as there was a need to start 
treatment earlier because of clinical uremic symptoms that overrode the preset 
objective starting point based on calculations of GFR [132].  
 
1.2.6 Conclusions  
Although adequacy of dialysis is routinely deﬁned by urea kinetics, uremia and the 
uremic syndrome are the consequences of the retention of more molecules than urea 
alone. Likewise, when analyzing and optimizing uremic solute removal, focus should 
be on more than urea removal alone. Even other small water-soluble compounds of 
similar metabolic origin like the guanidines, for which several ﬁndings point to toxic 
activity, show a different kinetic pattern from urea, which is relatively inert. The data 
with ADMA show that dialysis is not the only way to remove uremic toxins. The use of 
metabolic pathways to affect uremic toxin concentration has up till now insufﬁciently 
been explored. The studies with SDMA disclose another interesting therapeutic 
option, which is the potential to neutralize toxic effects by drugs countering the 
pathways causing this toxicity.  
The relation of middle molecules with uremic toxicity has rather been evidenced in 
observational outcome trials than in vitro. Removal can be enhanced by increasing 
dialyzer pore size, which results in better patient outcomes, and can further be 
improved by adding convection, and using dialyzer membranes with more 
homogeneous pores, but also by prolonging dialysis. A positive impact of convection 
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on survival was only found in the subgroup with the highest exchange volumes.  
Ample data suggest a biological impact and an association with outcomes of protein-
bound uremic solutes. Removal by dialysis strategies remains deceiving compared to 
their non-bound counterparts of similar molecular weight. A better knowledge of the 
kinetics of these solutes is needed to develop strategies improving their removal. 
Adsorption is a promising option, both intestinally and extracorporeally. Whereas 
extracorporeal adsorption was not successful due to concomitant clotting problems, 
intestinal adsorption seems to protect against progression of kidney failure. These 
data need, however, conﬁrmation in larger clinical trials.  
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Cardiovascular disease (40-50%) and infections (~25%) are the leading causes of 
death in CKD and especially end stage kidney disease (ESKD).1-6 Increased 
cardiovascular risk in CKD is not entirely explained by the traditional risk factors such 
as age, gender, smoking, hypertension, dyslipidemia, family history and diabetes 
which are also common in CKD.7,8 Non-traditional risk factors such as inflammation, 
oxidative stress, endothelial dysfunction, vascular calcification and malnutrition are 
common in CKD and could contribute to this increased risk.9 
In the in vitro part of this thesis, the contribution of some uremic peptides to the 
induction of leukocyte oxidative stress was investigated. Therefore a global overview 
on leukocyte dysfunction in uremia and oxidative stress is presented in this chapter. 
 
1.3.1 Uremia-related immune dysfunction: an overview 
Leukocyte dysfunction in uremia is characterized on the one hand by a chronic 
activation of the immune system leading to oxidative stress and systemic micro-
inflammation, which is involved in cardiovascular disease, atherosclerosis 10, 
malnutrition 11 and anemia.12 On the other hand, there is an immune deficient state 
contributing to an increased infectious risk 6, decreased response towards 
vaccination 13 and malignancies.14 (Figure 1) Merely all leukocyte subtypes of the 
innate and adaptive immune system are involved. 15-17 (Table 1) 
 
Innate immune cells 
In CKD, increased as well as impaired functional activity may be present in 
monocytes and granulocytes, contributing to the baseline activation of the immune 
system and to immune deficiency, respectively. Granulocyte counts are in general 
increased in kidney disease, while monocyte counts are unchanged or increased. 
(table 1) Monocytes and granulocytes are the main contributors to the chronic 
immune activation and increased reactive oxygen species (ROS) production in CKD 
leading to chronic micro-inflammation. Upon stimulation however, further increase in 
ROS production may be deficient, which possibly contributes to the impairment of 
host defense during infection.16,18,19 
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Uremia-related 
Leukocyte dysfunction 
 
 
 
Figure 1: Schematic overview of uremia-related immune dysfunction  
Abbreviations: ROS: reactive oxygen species, VSMC: vascular smooth muscle cell 
 
 
Table 1: Main leukocyte types and alterations in uremia 
Cell type Healthy condition Uremia 
 % function counts 
Granulocytes 40-75 % First line antimicrobial activity 
Phagocytosis, Oxidative stress 
↑ 
Monocytes 2-6 % First line antimicrobial activity 
Phagocytosis, Oxidative stress 
Antigen presenting cell 
↑ or ~ 
Dendritic cells < 1% Antigen presentation ↑ 
Lymphocytes 
-Effector T cells 
 
- Regulatory T cells 
- B cells 
- Natural killer cells 
20-45%  
CD4
+
: antigen presentation 
CD8
+
: cytotoxic response against viruses, tumour 
cells 
Modulation of inflammatory and T cell response 
Antigen presentation, antibody production 
Killing of virus-infected cells, tumour cells 
 
↓↓ 
 
↓ 
↓ 
↓ 
Chronic activation  
immune system 
Immune deficiency 
ROS 
Chronic systemic inflammation 
Cardiovascular disease 
Atherosclerosis 
Malnutrition 
Anemia 
Insulin resistence 
Endothelium 
VSMC 
Adipocyte
s 
Infection ↑ 
Response to vaccination ↓ 
Malignancy 
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The same duality is observed regarding the disturbed pro- and anti-apoptotic balance 
in granulocytes. In physiological conditions apoptosis is a tightly regulated process 
important for the resolution of inflammatory reactions. In general, the net effect of 
uremia is pro-apoptotic 18,20 increasing the susceptibility for infections. However, anti-
apoptotic factors 21 have been also found which in turn increase the duration of the 
pro-inflammatory stimulus. Also the expression of toll like receptors (TLR), especially 
TLR4, was found to be upregulated in hemodialysis patients 22 while it was 
downregulated in predialysis CKD patients.23 Furthermore, other factors contributing 
to an impaired anti-bacterial defense are decreased phagocytosis24,25 and 
chemotaxis. 26 
Activated leukocytes in uremia interact with endothelium contributing to vascular 
damage.27,28  
Three monocyte subtypes can be identified based on the cell surface expression of 
cluster of differentiation (CD)14 and CD16: classical monocytes (CD14++CD16-) and 
the more pro-inflammatory intermediate (CD14++CD16+) and non-classical 
monocytes (CD14+CD16++). These intermediate and non-classical monocytes play an 
important role in the pathophysiology of cardiovascular disease. 29,30 In hemodialysis 
patients, the differentiation of monocytes is shifted towards higher counts of the pro-
inflammatory CD16+ monocyte subtypes 31,32, while this was not observed in 
peritoneal dialysis 31 or CKD patients. 33,34 The intermediate CD14++CD16+ monocyte 
subtype has been associated to adverse cardiovascular outcome in hemodialysis 31 
and CKD patients. 33  
Dendritic cells are the most important antigen-presenting cells and consist of different 
subsets with specific functions mainly involved in host defense, response to 
vaccination as well as in atherosclerosis.35,36  In comparison to healthy controls, the 
number of circulating plasmocytoid dendritic cells are decreased in CKD and in 
patients on hemodialysis.37-39 Regarding myeloid dendritic cells, the results are less 
consistent: compared to healthy control the number was decreased in CKD stage 3 
38, unaltered in CKD (stage 3-5) and peritoneal dialysis and decreased  39 or 
unaltered in hemodialysis.37 In addition, maturation and cytokine production of these 
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dendritic subsets was impaired.40 Also the maturation of and endocytosis by 
monocytic derived dendritic cells was impaired in hemodialysis patients.41 
Natural killer cells, a lymphocyte subtype with direct cytotoxic effects, are decreased 
in number, which may contribute to reduced tumor immune surveillance and 
increased susceptibility to viral infections.42  
 
Adaptive immune system 
Lymphocytopenia with a decrease in CD4, CD8 T cell and B cells is characteristic for 
CKD. In addition, T-cells have shown to have an increased apoptosis and shortened 
telomer length, mainly important in the host defense against infections.15 There is 
also a decrease in regulatory CD4 T cells (Treg) which play in physiological conditions 
a role in termination and modulation of an inflammatory stimulus and have shown to 
decrease inflammation in atherosclerotic plaques.10 Their decreased number in 
uremia can lead to increased inflammation. 
 
1.3.2 Oxidative stress  
The in vitro part of this thesis investigated the role uremic peptides on the induction of 
leukocyte ROS by NADPH-oxidase, hence this review on the role of oxidative stress 
in CKD.  
Oxidative stress is defined as an imbalance between the generation of free radicals 
and the lack of sufficient naturally present endogenous and dietary anti-oxidants. In 
physiological conditions, the main origin of free radicals is from mitochondrial origin 
and is crucial for the regulation of multiple enzyme systems.43 In granulocytes, 
monocytes and macrophages, the increase in ROS is the first line defense against 
bacteria and fungi or other stress stimuli. An excess in reactive oxygen species 
(ROS) and reactive nitrogen species cause oxidation of macromolecules such as 
nucleid acids, lipids, carbohydrates and proteins, leading to tissue damage.43-45 
Furthermore ROS induces inflammation by activation of nuclear-factor kappa B 
(NFκB).46  
The primary ROS is the superoxide anion (O.2
-) resulting from the reduction of 
oxygen (O2) by nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase 
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enzyme. O.2
- is a short-lived and transformed to hydogen peroxide (H2O2) by 
superoxide dismutase. O.2
- and H2O2 can be further reduced to hydroxyl radicals 
(OH.), considered as the strongest known free radical. This reaction is catalyzed by 
free metal ions such as iron (Fe2+) or copper (Cu2+). In the presence of Cl-, 
myeloperoxidase catalyses H2O2 further to hypochlorous acid (HOCL) a major 
contributor in lipid peroxidation and production of oxidized low density lipoprotein (ox-
LDL). Additionally, O.2
- forms reactive nitrogen species in the presence of nitric oxide 
(ONOO-).43,44,47,48  
Five different NADPH-oxidase isoforms (NOX 1-5) are expressed on different cell 
types involved in the cardiovascular system related to cardiovascular damage. They 
differ in their subunits and activation mechanism and each of them catalyze the 
formation of O.2
- as illustrated in figure 2.45,48  
 
 
Figure 2: The members of the NOX-family involved in cardiovascular system: schematic structure and 
distribution on different cell types 
45
 
 
 
NADPH-oxidase in phagocytes is known as NOX2 and is in its active form a 
membrane enzyme constituted of 6 different subunits: p22phox, gp91phox/NOX2, 
p47phox, p67phox, p40phox and the GTP-binding protein Rac1(in monocytes)/2(in 
granulocytes). In resting cells, p47phox, p67phox, p40phox and the G-protein Rac 
1/2 are located in the cytosol, whereas p22phox, gp91phox/NOX2 are located in the 
plasma membrane or membranes of granules where they form flavochrome b558. The 
first step in the activation is the serine phosphorylation of the cytosolic subunit 
p47phox, followed by further phosphorylation of other cytosolic subunits, activation of 
Rac 1/2 and translocation of the cytosolic subunits to the membrane flavochrome 
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b558.
45,47-49 (Figure 3) The activation of NADPH-oxidase can be induced by a large 
number of stimuli such as opsonized bacteria, the chemoattractant bacterial 
formylated peptides such as formyl-methionine-leucine-phenylalanine (fMLP) or 
directly by protein kinase C (PKC) activators, such as phorbol myristate acetate 
(PMA).47,49 
Since ROS are unstable with a short half-life these are difficult to measure in 
practice. The products of lipid peroxidation such as oxidized-LDL and F2-
isoprostanes, of protein oxidation such as advanced glycated end products, 
advanced oxidation protein products, protein thiols, and malondialdehyde or of 
nucleid acid oxidation such as oxidized-DNA can be used as surrogates.44 
 
 
Figure 3: The NADPH-oxidase subunits in resting (A) en activated state (B) 
49
 
 
 
 
Oxidative stress in chronic kidney disease 
CKD is a pro-oxidative state50,51 to which multiple factors such as intravenous iron 
administration, bio-incompatible membranes, circulating endotoxins , malnutrition 
possibly related to a decreased anti-oxidant activity by decreased serum albumin, 
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decreased vitamin C and E, inflammation and uremic toxins can contribute.52 In 
2012, a Cochrane review was published on the use of anti-oxidant therapy in CKD 
and ESKD: no effects on cardiovascular disease or all-cause mortality could be found 
in CKD although a beneficial effect on intermediate outcomes in CKD patients could 
not be excluded. 53  
 
1.3.3 Summary 
The chronic activation of the immune system and increase in oxidative stress in CKD 
can contribute to the pathophysiology of cardiovascular disease in CKD and are 
considered as non-traditional risk factors. NADPH-oxidase is one of the major 
enzymes in the production of ROS as a cause of oxidative stress.  
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The general aim of this thesis is to reveal the duality/discrepancy between the 
biological activity of low molecular weight uremic peptides and their role as markers 
for/in CKD. Since oxidative stress is an important trigger in the uremic micro-
inflammation, selected uremic peptides were investigated on their potential to induce 
leukocyte ROS. Furthermore the association between some uremic peptides and 
adverse outcome was investigated.  
 
More specific aims are:  
 
1) to study the association between eGFR, the common marker of kidney 
function and the serum concentration of different low molecular weight uremic 
peptides. 
 
2) to evaluate the biological activity, assessed as the degree of induction of 
leukocyte oxidative stress, of beta-2-microglobulin, the prototype marker of the 
middle molecules. 
 
3) to evaluate the contribution of cytokines, the typical markers for 
inflammation, to leukocyte oxidative stress, at concentrations relevant for CKD.  
 
4) to evaluate the role of tumor necrosis factor receptors, more recently 
identified markers and members of the tumor necrosis factor-alpha (TNFα) 
system, in CKD by 
 - the investigation of their expression on leukocyte membranes and 
their association to eGFR  
 - the investigation of the association between their concentration and 
adverse outcome in advanced CKD.  
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2.1  Abstract 
Background: Uremic solute concentration increases as Glomerular Filtration Rate 
(GFR) declines. Weak associations were demonstrated between estimated GFR 
(eGFR) and the concentrations of several small water-soluble and protein-bound 
uremic solutes (MW<500Da). Since also middle molecular weight proteins have been 
associated with mortality and cardiovascular damage in Chronic Kidney Disease 
(CKD), we investigated the association between several eGFR formulae and the 
concentration of Low Molecular Weight Proteins (LMWP) (MW>500Da).  
Material and Methods: In 95 CKD-patients (CKD-stage 2-5 not on dialysis), 
associations between different eGFR-formulae (creatinine, CystatinC-based or both) 
and the natural logarithm of the concentration of several LMWP’s were analyzed: i.e. 
parathyroid hormone (PTH), Cystatin C (CystC), interleukin-6 (IL-6), tumor necrosis 
factor-alpha (TNF-α), leptin, retinol binding protein (RbP), immunoglobin light chains 
kappa and lambda (Ig-κ and Ig-λ), beta-2-microglobulin (β2M), myoglobin and 
fibroblast growth factor-23 (FGF-23)).  
Results: The regression coefficients (R²) between eGFR, based on the CKD-EPI-
Crea-CystC-formula as reference, and the examined LMWP’s could be divided into 
three groups. Most of the LMWP’s associated weakly (R² < 0.2) (FGF-23, leptin, IL-6, 
TNF-α, Ig-κ, Ig-λ) or intermediately (R²: 0.2-0.7) (RbP, myoglobin, PTH). Only β2M 
and CystC showed a strong association (R² > 0.7). Almost identical R²-values were 
found per LMWP for all eGFR-formulae, with exception of CystC and β2M which 
showed weaker associations with creatinine-based than with CystC-based eGFR.  
Conclusion: The association between eGFR and the concentration of several 
LMWP’s is inconsistent, with in general low R²-values. Thus, the use of eGFR to 
evaluate kidney function does not reflect the concentration of several LMWP’s with 
proven toxic impact in CKD. 
 
2.2  Introduction 
Chronic Kidney Disease (CKD) is an independent risk factor for mortality and 
cardiovascular disease (CVD) [1]. As Framingham risk calculation cannot correctly 
predict this risk [2,3], other than traditional risk factors are at play. When kidney 
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function declines, retention of uremic solutes with potential to cause vessel damage 
and other toxic effects, conceivably plays a role in this [4,5]. 
Glomerular Filtration Rate (GFR) is used to express kidney function and this can 
accurately be measured by time-consuming and labor-intensive methods [6]. In 
clinical practice, serum creatinine (Crea) based formulae are used to calculate 
estimated GFR (eGFR), which offer an acceptable estimate of measured GFR 
(mGFR) [6–9]. However, if possible, mGFR is to be preferred as it may differ from 
eGRF especially in the lower GFR range in a CKD population or in patients with a 
body constitution that deviates from the average [6,10]. On the other hand, 
measuring GFR by one of these techniques is more costly and labor-intensive than to 
determine eGFR. Also, current guidelines classify CKD based on the Modification of 
Diet in Renal Disease study (MDRD) formula [11,12]. More recently, the CKD-EPI-
Crea formula [13] has been proposed as a valid alternative, especially if eGFR is >60 
ml/min/1.73m² [9], so that it possibly will be incorporated into the upcoming KDIGO 
guideline [14]. 
Since concentrations of uremic solutes rise when GFR deteriorates, it has been 
thought that GFR reflects the retention state of the patient and that the elevation of 
individual solute concentration of uremic toxins is closely related to the gradual 
deterioration of GFR. However, Eloot et al. [15] found very low regression coefficients 
between eGFR and several low molecular weight retention solutes in a CKD 
population.  
The low molecular weight proteins (LMWP) are among the main representatives of 
the middle molecules, the third family of uremic retention solutes [16], and are 
interesting to study for their relationship with eGFR as with normal kidney function 
they are freely filtered through the glomerular basement membrane (GBM) and then 
mainly degraded into amino acids by the proximal tubules [17]. Furthermore the 
concentrations of several of the investigated LMWP’s, such as inflammatory 
parameters and FGF-23, are already elevated in patients with a moderate reduction 
in GFR [18–21] or in more advanced CKD [22]. As a consequence, associations 
between these solutes and eGFR are often assumed. Assessing the predictive value 
of eGFR for their concentration is furthermore also relevant, because several 
LMWP’s, such as interleukin-6 (IL-6) [23–26], tumor necrosis factor-alpha (TNF-α) 
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[27,28], beta-2-microglobulin (β2M) [29,30], and fibroblast growth factor-23 (FGF-23) 
[31–33], have been linked to mortality or surrogate outcomes like vascular damage or 
progression of kidney failure. In addition, active removal of middle molecules by 
dialysis has been associated with better outcome [34]. 
Therefore, we investigated in a CKD population whether the concentration of several 
LMWP’s would associate with eGFR, calculated by several eGFR formulae.  
 
2.3 Material and methods  
Ethics Statement 
The study was approved by the local ethical committee (Comité Consultatif de 
Protection des Personnes dans la Recherche Biomédicale (CCPPRB) de Picardie, 
CHU Amiens, Amiens, France) and performed in accordance to the Declaration of 
Helsinki. Written informed consent was obtained from all patients. 
 
Study population 
This evaluation is a planned sub-analysis of a study undertaken over an 18-month 
period (January ’06- June ’07), which screened 150 Caucasian patients with 
prevalent CKD stage 2-5D from the Nephrology Department at Amiens University 
Hospital, in which uremic retention solutes in relation to clinical outcomes were 
analyzed [23,35–37].  
All patients were over 40 years old and had a confirmed diagnosis of CKD (two 
previous eGFR measures of < 90 ml/min, calculated by the Cockcroft-Gault formula 
with an interval of 6-9 months) [38]. Exclusion criteria were chronic inflammatory 
disease, atrial fibrillation, complete heart block, abdominal aorta aneurysm, an aortic 
and/or femoral artery prosthesis, primary hyperparathyroidism, kidney 
transplantation, and any acute cardiovascular event in a 3 month period prior to 
screening for inclusion.  
From the 140 patients who met the inclusion criteria, 45 were excluded from the 
current study because of hemodialysis treatment, which has an impact on solute 
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concentration and on eGFR. The 95 patients, included in this study, were classified in 
CKD stages according to the CKD-EPI-Crea-CystC formula for further analysis [8]. 
 
Sampling and laboratory methods 
Blood samples of all patients were collected in the morning from 9 a.m. on, 
centrifuged, aliquoted, frozen and stored at -80°C. Cystatin C (CystC) (MW: 13.3 
kDa) concentration was determined by immune-nephelometry (N latex Cystatin C®, 
Siemens Healthcare, Dade Behring, Marburg, Germany) and that of intact 
parathyroid hormone (PTH) (MW: 9.5kDa) with a chemiluminometric immunoassay 
(Liaison N-tact PTH CLIA®, Diasorin, Stillwater, MN, USA). The determination of 
retinol binding protein (RbP) (MW: 21kDa), beta-2-microglobulin (β2M) (MW: 
11.8kDa), myoglobin (MW: 17kDa) and total immunoglobulin light chains kappa (Ig-κ) 
and lambda (Ig-λ) (MW: 23kDa) was performed by laser nephelometry (BNProSpec®, 
Siemens Healthcare, Dade Behring, Marburg, Germany). ELISA’s were used to 
determine the levels of interleukin-6 (IL-6) (MW: 23kDa), tumor necrosis factor-alpha 
(TNF-α) (MW: 17kDa) (R&D Systems, Wiesbaden, Germany), and leptin (MW: 
16kDa) (DRG diagnostics, Marburg, Germany). Intact fibroblast growth factor-23 
(FGF-23) (MW: 32kDa), was measured by a two-site (N-terminal and C-terminal) 
ELISA (Immunotopics, San Clemente, CA, USA). Serum creatinine (Crea) (MW: 
113Da) was measured colorimetrically by standard laboratory methods.  
 
eGFR- calculation  
Six different formulae were used to estimate GFR:  the CKD-EPI formula, based on 
Crea and CystC (CKD-EPI-Crea-CystC) eGFR=177.6·Crea-0.65·CystC- 0.57·age-
0.20·0.82 (if female) [8]; two formulae based on Crea alone: the MDRD eGFR = 
175·Crea-1.154·age-0.203·(0.742 if female)·(1.21 if black) [7] and the CKD-EPI creatinine 
(CKD-EPI-Crea) eGFR=141.min(Crea/κ,1)α.max(Crea/κ,1)-1.209.0.993Age.1.018 (if 
female). 1.159 (if black) (κ: 0.7 if female, 0.9 if male; α: -0.329 if female, -0.411 if 
male) [13]; and three formulae based on CystC alone: Stevens eGFR=127.7·CystC-
1.17·age-0.13·0.91 (if female)·1.06 (if black) [8], Le Bricon eGFR = [78·(1/CystC)]+4 [39] 
and Rule eGFR=66.8·(CystC)-1.3 [40]. 
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Statistical analysis  
The data are expressed as mean ± standard deviation and analysed by ANOVA if 
they were normally distributed. For data that were not normally distributed, median 
with interquartile range and Kruskall-Wallis test were used. Linear regressions and 
Pearson correlations were calculated on semi-logarithmic (LN) concentrations as a 
function of eGFR. Multifactorial analysis was performed to correct for well-known 
influencing factors for the concentration of several solutes. The regression model of 
CystC, β2M, IL-6, TNF-α, Ig-κ and Ig-λ was adjusted for C-reactive protein (CRP), the 
one of FGF-23 and PTH for calcium, phosphorus and vitamin D-supplementation, the 
one of leptin for body mass index (BMI) and gender, and  the one of RbP for BMI, 
1/CRP and diabetes mellitus. A P < 0.05 was considered as statistically significant. 
All statistical analyses were performed using SPSS Statistics 19 (SPSS Inc, Chicago, 
IL) for Windows (Microsoft Corp, Redmond, WA). 
 
2.4  Results  
Ninety-five patients at different stages of CKD were included: 11.5% CKD stage 2, 
39.0% CKD stage 3, 39.0% CKD stage 4, and 10.5% CKD stage 5 not on dialysis. 
Table 1 summarizes the demographic and clinical characteristics of the study 
population.  
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The concentrations of the studied LMWP’s, except for the immunoglobulin light 
chains, increased progressively with declining kidney function (Table 2). 
 
 
 
Our analysis primarily focused on the linear regression analysis with the natural 
logarithm (LN) of the concentration of each studied uremic retention solute 
concentration as dependent variable and the CKD-EPI-Crea-CystC eGFR as 
independent variable. This formula was chosen as reference because it is considered 
as one of the most accurate ones at this time while it incorporates both Crea and 
CystC, in contrast to all other studied formulae which are based on either Crea or 
CystC [8]. Associations between eGFR and LMWP’s were expressed as regression 
coefficients (R²) and are summarized in table 3 and figure 1.  
The R²-values per individual solute were divergent; according to these, associations 
could be arbitrarily divided into three groups: strong (R² > 0.7), moderate (R² 0.2-0.7) 
and weak (R² < 0.2) (Figure 1). As expected, CystC (R² = 0.828) was strongly 
associated as it is one of the used parameters in the formula. Only β2M showed a 
similar association (R² = 0.770). Retinol binding protein (RbP), myoglobin and 
parathyroid hormone (PTH) were moderately associated to eGFR with R²-values of 
0.423, 0.303 and 0.231, respectively. The association with eGFR was only weak for 
IL-6 (R² = 0.117), leptin (R² = 0.084), FGF-23 (R² = 0.058) and TNF-α (R² = 0.056). 
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There was even no association for immunoglobulin light chain kappa (Ig-κ) (R² = 
0.021) and immunoglobulin light chain lambda (Ig-λ) (R² = 0) (P = N.S.).  
 
 
 
 
 
 
Figure 2 shows the dot plots of solute concentrations as a function of eGFR. 
Whereas the relation is strong with little scatter around the linear regression line for 
β2M (Panel A), the scatter is much larger for solutes with moderate to weak R²-
values, as illustrated for myoglobin (Panel B), IL-6 (Panel C) and especially Ig-λ 
(Panel D) for which there is no association at all. The large standard deviations or 
wide interquartile ranges of the individual solute concentrations per CKD-stage also 
illustrate the large inter-individual variability of LMWP concentration within the same 
eGFR-range (Table 2).  
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In addition we analyzed the correlation coefficients between the concentrations of the 
different LMWP and eGFR (CKD-EPI-Crea-CystC) in the group CKD stage 2-3 
versus CKD stage 4-5. The correlation between RbP, PTH, myoglobin, FGF-23 and 
eGFR was significant in CKD-stage 2-3 while not in CKD stage 4-5. For the other 
investigated solutes, the R²-values in CKD stage 2-3 and CKD stage 4-5 were more 
conform to each other. The respective R²-values are summarized in table 4. 
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In a second step, the same analysis was performed with the other formulae under 
evaluation and compared to the results with the CKD-EPI-Crea-CystC-formula. The 
R²-values between all eGFR formula and individual solutes were strikingly similar 
with only one exception (Table 3). β2M was only moderately associated to Crea-
based eGFR, with R²-values of approximately 0.55, as compared to CystC-based 
eGFR (R² > 0.8). In this way β2M followed the same pattern as CystC, for which this 
discrepancy could be attributed to whether CystC was included as a factor in the 
formula or not. Considering the other studied LMWP’s, only PTH showed a 
moderately similar trend, with R² approximately 0.27 compared to R² approximately 
0.13, with CystC- or Crea- based eGFR-formulae, respectively. 
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Finally, we performed multifactorial regression analysis for the different LMWP’s with 
adjustment for several relevant variables. However, only two models induced a 
marked increase in R²-value: for leptin the association rose from weak to moderate 
when BMI was added to the regression model (R² from 0.084 to 0.346), with BMI as 
an independent predictor for the leptin concentration. Likewise, after adjustment for 
CRP, IL-6 became moderately associated with eGFR (R² from 0.117 to 0.305 after 
adjustment). For all other solutes there was no change in R². (Data not shown) 
 
2.5  Discussion 
We analyzed the linear regression coefficients between the concentrations of several 
LMWP’s retained in CKD and different eGFR-formulae in a CKD population, stage 2-
5 not on dialysis. As a main finding, the R²-values diverged considerably, ranging 
from high, R² > 0.7, to low, R² < 0.2. The majority of the evaluated LMWP’s 
associated weakly (R² < 0.2 for IL-6, TNF-α, FGF-23 and leptin) or moderately (R²: 
0.2-0.7 for RbP, myoglobin and PTH). There was no correlation at all for the 
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immunoglobulin light chains. Only CystC and β2M showed a strong association with 
eGFR (R² > 0.7) (Figure 1, Table 3). Although in some studies a correlation was 
sought for individual LMWP’s and eGFR of mGFR, this present study seeked out the 
association of the concentration of several LMWP’s and eGFR formulae together 
allowing their comparison.  
The R²-values for the weakly and moderately associating LMWP’s did not differ 
substantially whether eGFR was calculated with the CKD-EPI-Crea-CystC-formula 
[8], the Crea-based formulae (MDRD [7] and CKD-EPI-Crea [13]), or the three 
different CystC-based formulae, (Stevens [8], Rule [40] and Le Bricon [39]) (Table 3). 
These low regression coefficients can partially be attributed to the known limitations 
of eGFR, as an index of mGFR [6,41]. However in at least four other studies, almost 
identical low regression coefficients were found between mGFR, assessed with 
different techniques, and the concentration of RbP (R² 0.16) [42], myoglobin (R² 0.38) 
[43], leptin (R² 0.0004) [44] and FGF-23 (R² 0.09) [45] as in our study, be it that 
transformation of the concentrations varied from study to study. In addition, the 
imperfect reflection of true GFR by eGFR can explain that regression coefficients are 
substantially lower than 1, but not that the range in between individual molecules is 
so discordant, whereas per molecule they are almost identical (Table 3, Figure 1). 
There was also an unpredictable and large variability in concentrations of different 
solutes within each eGFR stratum (Table 2). These data suggest another reason for 
the sometimes deceiving associations than a discrepancy among mGFR and eGFR, 
namely that uremic solute concentration depends on other factors than GFR as well. 
In this way, our study corroborates findings in an earlier study with small water-
soluble and protein-bound compounds [15,46].  
These results are somewhat unexpected from a physiological point of view as the 
renal clearance of these LMWP’s depends to a large extent on GFR alone. All these 
LMWP’s are freely filtered through the GBM, followed, at normal physiological 
concentrations, by an almost entire uptake by the proximal tubules via a receptor-
mediated process to be degraded subsequently into amino acids in the tubular 
lysosomes [17,47]. In this way, the proximal tubulus plays an important role in LMWP 
metabolism but without a direct contribution to their renal clearance; regarding the 
latter, GFR is the rate limiting step. This probably explains why we did not find any 
association between eGFR and the total (free plus bound) immunoglobulin light 
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chains, in contrast to Hutchison et al who evaluated only free light chains for their 
association to eGFR (free Ig-κ: R²: 0.52; free Ig-λ: R²: 0.44) [48], as only the free 
fraction passes the GBM. This is also in contrast to the small water-soluble and 
protein-bound uremic toxins, for which tubular secretion and/or reabsorption play an 
important role in renal clearance [15,46].  
 
 
 
However, the concentration of small water-soluble and protein-bound solutes may be 
further influenced by many other factors as well, such as enzymatic metabolism, 
intestinal secretion/absorption, generation by intestinal flora, diet and changes in 
distribution volume [15,46]. It is conceivable that also the concentration of the weakly 
and moderately correlating LMWP’s depends on other mechanisms than GFR, which 
even seem to have more important weight than GFR. Some known influencing 
factors such as changes in generation, homeostatic mechanisms and extra-renal 
clearance are summarized in table 5. Multifactorial regression analysis for the 
respective LMWP’s including some of these parameters, increased the R²-value as 
expected. E.g. for leptin, R² rose from 0.084 to 0.346 when corrected for BMI,which 
was an independent covariate for leptin concentration in a model with eGFR and 
BMI. The R²-value between IL-6 and eGFR became 0.305 instead of  0.117, when 
adjusted for CRP, which, in contrast to BMI for leptin concentration, did however not 
independently predict IL-6 concentration in a model with eGFR and CRP. The 
majority of potentially influencing factors did however not importantly affect the R²-
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values. This suggests that other than well known mediators may influence these 
LMWP concentrations as well. In more advanced CKD, the influence of confounders, 
for example bone metabolism, is probably more important, which could explain 
partially that no significant associations were observed between PTH or FGF-23 and 
eGFR in CKD stage 4-5, while they were present in CKD stage 2-3 (table 4). Another 
contributing factor to this discrepancy in associations between CKD stage 2-3 versus 
CKD stage 4-5 might be purely mathematical, as the GFR-range in CKD 2-3 (30-90 
ml/min/1.73m²) is much larger than CKD 4-5 (± 10-30 ml/min/1.73m²). 
This study demonstrates that eGFR is not a reliable predictor of the concentration of 
most of the evaluated LMWP’s, although several of them such as IL-6 [23–26], TNF-
α [27,28] and FGF-23 [31–33,49] have been associated with mortality or with 
intermediate endpoints, such as vascular dysfunction or progression to end stage 
renal disease (ESRD) in CKD- or hemodialysis patients. Presumably, some of these 
solutes, especially if they would be representative for a cluster of other solutes, might 
by themselves become useful predictors of morbidity or mortality in CKD 
independently from eGFR. Based on the data collected in the present study, we 
investigated the mutual correlations between the concentrations of the different 
LMWP’s; however, we could not identify such a marker, correlating strongly to other 
LMWP’s without correlating to eGFR, among the investigated solutes (data not 
shown). This question, however, would be worthwhile to be investigated in larger 
populations. 
In contrast to these weakly and moderately correlating LMWP’s, there is a 
remarkable similarity in regression coefficients between CystC and β2M. First, these 
molecules are the sole LMWP’s studied that result in acceptably high associations 
with eGFR (Table 3). Second, they associate better with CystC-based eGFR 
formulae [8,39,40] than with Crea-based ones [7,13], the CKD-EPI-Crea-CystC [8] 
which contains both factors being intermediate (Table 3). Whereas this is no surprise 
for CystC which is included in some formulae and not in others, the pattern for β2M 
seems to be identical. This suggests that the kinetics of both molecules during 
progression of CKD depend on similar factors or at least factors with a similar impact 
on solute concentration. Of note, some of the non-renal elements with impact on both 
concentrations [50,51], like chronic inflammatory disease or malignancy were among 
the exclusion criteria of this study. CystC was a superior marker of the association of 
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GFR with outcome in a study by Peralta et al., who showed that the predictive value 
for mortality or CVD of eGFR < 60ml/min/1.73m², based on a CystC-based eGFR, 
was better than eGFR based on the CKD-EPI-Crea-formula [45]. Recently, in a 
general population, CystC and β2M were stronger predictors of mortality, CVD and 
evolution to ESRD than eGFR based on the CKD-EPI-Crea [52]. 
The present study has some shortcomings. First, the study population was rather 
small, with even smaller subgroups per CKD-stage. Second, we used eGFR which 
gives only an approximate value for glomerular filtration in comparison to more exact 
methods such as EDTA-clearance. We preferred to use methods which are applied 
on a day to day basis. As the differences in correlations are so striking, it is very likely 
that these findings can be extrapolated to GFR in general. The strengths of this study 
lie in the fact that several LMWP’s are evaluated together in the same population for 
different eGFR formulae based on Crea, CystC or both.  
Our present data, together with the previous ones [15], showing extremely variable 
associations between uremic retention solutes and a surrogate of GFR, suggests that 
eGFR per se is an inadequate indicator of the uremic status. This is also suggested 
by other studies. In a CKD population, Lilitkarntakul et al. [53] demonstrated that 
renal function did not independently predict arterial stiffness or endothelial 
dysfunction while the uremic retention solutes asymmetric dimethylarginine (ADMA), 
isoprostanes or endothelin-A did. In the Initiating Dialysis Early and Late (IDEAL) trial 
[54], approximately 75% of the patients randomized to start dialysis at low eGFR (5-7 
ml/min/1.73m²), initiated dialysis earlier, mainly because of uremic symptoms.  
In this study, the regression coefficients of different LMWP’s in relation to eGFR are 
diverse and in general low. This shows that other factors than GFR are important for 
the development of the ‘uremic status’. Further research is needed to evaluate 
whether these uremic toxins can be used as biomarkers for the risk stratification 
associated to uremic toxicity within the different CKD-stages and beyond eGFR.  
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2.6  Supporting Information 
Table S1: Main factors influencing the concentrations of the studied LMWP’s, other 
than GFR 
CystC: Cystatin C, 2M: beta-2-microglobulin, RbP: retinol binding protein, PTH: parathyroid 
hormone, IL-6: interleukin-6, TNF-α: tumor necrosis factor-alpha, FGF-23: fibroblast growth 
factor-23, Ig-κ: immunoglobulin light chain kappa, Ig-λ: immunoglobulin light chain lambda, 
Zn: Zinc, DM: diabetes mellitus, Ca: Calcium, P: Phosphorus, VitD: Vitamin-D 
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3.1  Abstract 
Background: Chronic kidney disease (CKD) is characterized by low-grade 
inflammation and increased risk for cardiovascular disease. Interest in beta-2-
microglobulin (B2M) as a marker for cardiovascular outcome both with and without 
CKD has grown. Clinical studies suggested that B2M could be involved in the 
pathogenesis of vascular disease, for which chronic leukocyte activation is a 
pathogenic factor. We investigated whether B2M is pro-inflammatory by inducing 
oxidative burst in leukocytes.  
Methods: Oxidative burst was measured at baseline and after stimulation with fMLP, 
E.coli or PMA (Phagoburst™) in whole blood of healthy volunteers in absence 
(saline) and presence of human B2M (hB2M) (10mg/l and 50mg/l) versus uremic 
whole blood. Due to suspicion of contamination, hB2M was dialyzed for purification 
and both purified B2M (dB2M) and dialysates were tested in the bursttest. As 
comparator, ROS in response to LPS was measured.  
Results: Unpurified hB2M strongly enhanced ROS in monocytes and granulocytes 
after E.coli and PMA, and moderately after fMLP stimulation compared to control 
(p<0.01) and uremia (p<0.01), while at baseline hB2M only induced ROS in 
granulocytes (p<0.05). After purification, dB2M no longer increased burst activity, 
suggesting that contamination was responsible for the initial effect. An endotoxin 
concentration of <1.5EU/ml, as observed in hB2M, could not induce oxidative stress. 
Conclusion: This study suggests that B2M, a traditional marker for middle molecule 
retention and a novel marker for cardiovascular outcome, may not by itself cause 
vascular damage by influencing inflammatory response due to induction of leukocyte 
free radical production. However, an effect on other cell types involved cannot be 
excluded. Our data further reveal that this type of research might be skewed by non-
LPS contaminants, and that care should be taken to exclude this bias. 
 
3.2  Introduction  
Beta-2-microglobulin (B2M), a low molecular weight (MW) protein of 11.8 kDa, is 
more and more recognized as an independent marker for different outcomes linked to 
cardiovascular disease (CVD). Wilson et al. 1 identified B2M as a strong and 
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independent predictor for peripheral artery disease (PAD) in a population without 
known PAD or major chronic kidney disease (CKD). Others have associated B2M to 
intima media thickness 2 and pulse pressure 3 in hemodialysis patients, and to pulse 
wave velocity in the general population 4 and a population with known PAD5. 
Furthermore B2M was an independent predictor for cardiovascular events and 
mortality in the general population 6-8, in populations with underlying CVD 9-11 and 
also in patients with CKD and/or end-stage renal disease 12-14.  
In addition to this, B2M is also frequently used as a biomarker of retention of the so-
called middle molecules, the group of uremic retention solutes with MW > 500 Da. Its 
concentration gradually rises while CKD progresses and is strongly associated to 
measured 15 and estimated glomerular filtration rate (GFR) 16, reaching its highest 
concentrations in dialysis patients with mean concentrations up to 50 mg/l (normal 1-
3 mg/l) 17, 18. Due to the increased use of hemodiafiltration and high flux 
hemodialysis, there is a current trend for overall mean concentrations to decrease 
versus previously. However, whatever dialysis strategy used, the B2M concentrations 
generally increase with time 13, 19 essentially due to a loss of residual renal function13, 
indicating that even with the current high efficient techniques, the weekly generation 
exceeds the possible weekly removal by dialysis. In addition, the concentration of 
B2M can also be influenced by non-renal factors such as inflammation or 
malignancy20.  In parallel, there is also an association between progression of CKD 
and cardiovascular outcome21. 
As CKD is characterized by increased oxidative stress and low-grade inflammation, 
which are non-traditional risk factors for the excess of CVD in CKD 22, and as B2M is 
linked to cardiovascular events 7, 10, 11, 14, an active role for B2M in the pathogenesis 
of CVD in CKD could be hypothesized. In normal physiological conditions, B2M is 
part of and stabilizes the major histocompability I (MHC-I) complex in all nucleated 
cells. In dialysis patients, B2M plays an established role in the pathogenesis of 
dialysis related amyloidosis, mainly present in osteoarticular and cartilage tissue 23. 
Other data on biological activity of circulating B2M on circulating leukocytes in CKD 
are scarce, although several studies mainly focusing on bone or fibroblasts and/or on 
AGE-modified B2M suggest pro-inflammatory properties 24-28.  
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Several uremic toxins have already been shown to induce free radical production in 
leukocytes 29-32 by which they may actively contribute to the inflammatory burden in 
CKD. Therefore, we investigated whether B2M, at concentrations as observed in 
CKD, could induce burst activation in leukocytes in vitro. 
 
3.3 Materials and Methods 
Sample collection 
After informed consent, a sample of heparinized whole blood (NH, BD Vacutainer™, 
Becton Dickinson, Plymouth, UK) and serum (Venosafe™, Terumo Europe NV, 
Leuven, Belgium) was collected from non smoking healthy volunteers (n = 10). 
Additionally, predialysis heparinized whole blood samples were taken from stable 
hemodialysis patients (HD), as representative sample for the uremic condition (n = 
10). Both, healthy volunteers and hemodialysis patients, did not have diabetes, 
concurrent infection, or malignancy and were not treated with immunosuppressive 
drugs. 
 
Reagents 
Commercial human beta-2-microglobulin (molecular weight 11.8 kDa), isolated from 
urine (Calbiochem®, Merck-Millipore, Nottingham, UK) (hB2M), was delivered as a 
solution in a phosphate buffered saline (PBS, 150 mM NaCl, 20 mM phosphate 
buffer, pH 7.3) at a stock concentration of 1000 mg/l. This was aliquoted in sterile 
tubes (Sartstedt, Nümbrecht, Germany) and stored at -20°C, according to 
manufacturer instructions. The manufacturer guaranteed more than 98 % purity on 
SDS-PAGE. E. coli lipopolysaccharide (LPS) (Ultrapure-LPS, E coli K12, Invivogen, 
San Diego, California) was reconstituted to a stock solution of 100 µg/ml in sterile 
saline (NaCl 0.9%, B. Braun, Melsungen, Germany). Pipetting was done with sterile 
tips (Biocert, Plastibrand®, Novolab, Belgium) and dilutions were made in sterile 
polystyrene tubes (BD Falcon™, Becton Dickinson, Erembodegem, Belgium), in a 
laminary flow hood. 
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Dialysis procedure 
Due to suspicion of contamination of the hB2M, microdialysis of the solution was 
applied through a microdialysis unit, containing a membrane with a molecular weight 
(MW) cut-off of 10 kDa (Slide-A-Lyzer®, Thermo Scientific, Waltham, MA, USA) in 
order to purify the hB2M solution. Dulbecco’s Phosphate Buffered Saline (DPBS) (1x, 
Gibco®, Life Technologies, UK) was used as dialysis fluid. 200µl hB2M (stock 
concentration 1000 mg/l) was added to the microdialysis cup against 1000 µl of 
DPBS. Under continuous rotation, at room temperature, the total dialysis time was 
11h30. To maintain an optimal concentration gradient, nine dialysate fluid changes, 
with shorter time intervals in the beginning and longer time intervals in the end, were 
performed. At the end of the procedure the dialyzed hB2M solution (dB2M) was 
recovered, aliquoted and stored at -80°C for further analysis. 
Dialysis fluid samples of the first (d1: 0-30 minutes) as well as of the final dialysis 
period (d2: 10 hours 30 minutes to11hours 30 minutes) were collected, aliquoted and 
stored at -80°C for further analysis. 
 
Concentration determinations 
The B2M concentration in hB2M, dB2M and in the dialysate samples was measured 
by ELISA (Orgentec Diagnostica GmbH®, Mainz, Germany). The test solutions were 
diluted 1/10 in serum of healthy volunteers to guarantee samples that were 
compatible for the assay and concentrations were calculated after the correction for 
the dilution factor. 
 
Endotoxin determination 
Endotoxin concentration was measured in hB2M and dB2M to assess which B2M 
concentration could be used without being skewed by the presence of LPS at a level 
inducing ROS production by itself. LPS was also measured in the different dialysis 
fluid samples by means of a kinetic chromogenic LAL (Limulus Amebocyte Lysate)-
assay (Kinetic QCL™, Lonza ltd, Basel, Switzerland). The detection limit of the test is 
0.005 endotoxin (EU) /ml.  
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Oxidative burst 
Test solutions 
Beta-2-microglobulin was tested at a relevant uremic concentration of 50 mg/l, which 
lies in the range of the highest reported mean uremic concentrations mainly observed 
in dialysis patients 17, 18 and a concentration of 10 mg/l, representative for CKD 
patients not on dialysis 14. LPS at a concentration of 1.5 EU/ml, which was the 
maximum LPS concentration present in the hB2M solution (50 mg/l), and saline were 
used as controls. Furthermore LPS at a concentration of 1.5 and 3.0 EU/ml was 
compared.  
Stock solutions of hB2M, dB2M and LPS were diluted in saline (NaCl 0.9%, B Braun, 
Melsungen, Germany) on the day of the experiment to a tenfold of the final test 
concentration (C 10 x), to be further diluted 1/10 in whole blood. The bursttest was 
also applied on the two different dialysate samples as test solution and on uremic 
whole blood from HD patients, as a comparator, relevant for the chronic uremic 
condition and the overall group of uremic toxins as present in vivo.  
 
Oxidative Burst: test procedure 
Saline (control), hB2M, dB2M (C 10x), LPS (C 10x), and dialysates, were diluted 1/10 
in heparinized whole blood of healthy volunteers. Those samples, as well as uremic 
whole blood samples from HD patients were incubated for 10 min at 37°C, after 
which Reactive Oxygen Species (ROS) production in leukocytes was measured. For 
that purpose, the bursttest (Phagoburst™, Orpegen Pharma, Heidelberg, Germany) 
was applied according to manufacturer’s instructions.  
Burst activity in leukocytes was evaluated at baseline and after stimulation with N-
formyl-methionine-leucine-phenylalanine (fMLP), a moderate stimulus, and 
stimulation with E. coli and phorbol-12-myristate-acetate (PMA), two strong stimuli. 
The generation of ROS was measured by assessing the oxidative modification of the 
fluorogenic substrate dihydrorhodamine-123 into rhodamine.  
The samples were analyzed within 30 minutes using a FACScan (Becton Dickinson, 
Erembodegem, Belgium). Monocytes, granulocytes and lymphocytes were gated 
separately and the percentage of rhodamine positive cells (%) per gate was 
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measured at baseline and after fMLP stimulation. After E.coli and PMA stimulation 
the mean fluorescence intensity (MFI) was considered, as the majority of the cells 
were positive for ROS production under these conditions, except for lymphocytes, for 
which the percentage of positive cells after E. coli stimulation was also evaluated, 
due to a lower number of positive cells.  
 
Statistical analysis 
The data were not normally distributed and expressed as medians with interquartile 
range. A Kruskall-Wallis test or Friedman-Ranks test, in case of paired experiments, 
were used to analyse multiple conditions and followed by pairwise comparisons. In 
case of analysis of two groups a Mann-Whitney test was applied. A p-value of < 0.05 
was considered as statistically significant. Statistical analysis was performed using 
SPSS statistics 20 (SPSS Inc, Chicago, IL, USA) for Windows (Microsoft Corp, 
Redmond, WA, USA). Graphs were made in GraphPad Prism 04 (GraphPad 
Software, La Jolla, CA, USA). 
 
3.4 Results 
Determination of endotoxin concentration  
As endotoxin is a major source of contamination with stimulatory effects on burst 
activity, the endotoxin concentration was measured in the hB2M solution. Our test 
solution of hB2M (50 mg/l) contained a maximum of 1.5 EU/ml depending on the 
batch number, so that in the burst experiments a control of LPS at 1.5 EU/ml was 
used.  
The endotoxin concentration was also measured in two other commercially available 
B2M-formulations but as they contained at least a concentration of 15 EU/ml (in 50 
mg/l B2M), they were not used for further analysis (data not shown). 
 
Effects of different endotoxin concentrations 
In order to investigate at which concentration LPS could induce oxidative burst, 
different endotoxin concentrations were evaluated in the bursttest. While LPS did not 
induce burst activity at 1.5 EU/ml, a concentration of 3 EU/ml increased the 
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percentage of ROS producing monocytes and granulocytes at baseline (monocytes: 
12.9% (3 EU/ml) vs. 2.7% (control), p < 0.05; granulocytes: 3.12% vs. 2.4%, p < 
0.05) and after fMLP stimulation (monocytes: 28.8% vs. 10.4%, p < 0.001; 
granulocytes: 14.7% vs. 9.2%, p < 0.001). LPS had no effect on burst activation after 
stimulation with E. coli and PMA in all three leukocyte cell types.  
 
 
 
Effects of unpurified human beta-2-microglobulin on leukocyte oxidative burst  
At baseline, hB2M (50 mg/l), increased the percentage of ROS-producing 
granulocytes (p < 0.05) compared to control, while no significant effects were 
observed in monocytes and lymphocytes (figure 1A). After fMLP stimulation, hB2M 
(50 mg/l) enhanced the percentage of rhodamine positive leukocytes compared to 
control (monocytes and lymphocytes, p < 0.05, granulocytes, p < 0.01) (figure 1B). 
More remarkably even, hB2M enhanced free radical production very strongly in all 
three leukocyte cell types after stimulation with E.coli (p < 0.01) (figure 2A) and PMA 
(p < 0.01) (figure 2B). This stimulation was more robust than expected and did not 
reflect burst activity as observed in whole blood from HD patients. Compared to 
control, in the whole blood samples of HD patients, the percentage of free radical 
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producing monocytes (p < 0.05), granulocytes (p < 0.01) and lymphocytes (p < 0.05), 
at baseline and after fMLP stimulation (figure 1) and the percentage of ROS-
producing lymphocytes after stimulation with E. coli (p < 0.01) (figure 2A) was 
increased. After stimulation with PMA, burst activation was significantly blunted in 
granulocytes (p < 0.05) (figure 2B). Comparing the effects of hB2M to these of the 
uremic milieu, hB2M enhanced ROS-production after stimulation with E. coli and 
PMA in all leukocyte types more substantially (p < 0.01) (figure 2). These results led 
to the suspicion of contamination, other than endotoxin, as the endotoxin 
concentration in the B2M solution could not induce leukocyte activation. 
 
 
 
Purification of human beta-2-microglobulin by dialysis 
hB2M was purified by microdialysis to remove possible contaminants with MW <10 
kDa, so that the effects of B2M per se on burst activation could be investigated. 
Before their assessment by the bursttest, the dB2M and dialysate samples were 
tested for their B2M- and endotoxin concentration (1/10 in healthy serum). In dB2M, 
the B2M concentration was adequately recovered and, as expected, similar 
endotoxin concentrations (1.6 EU/ml) as in the original solution were found, as LPS 
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did not pass the membrane. The dialysate contained, as expected, neither LPS (< 
0.005 EU/ml) nor B2M.  
 
 
 
Effects of purified beta-2-microglobulin on leukocyte oxidative burst  
In contrast to hB2M (figure 1 and 2), dB2M (10 mg/l and 50 mg/l) had no effects on 
burst activity in leukocytes in any condition compared to controls (saline and 
endotoxin 1.5 EU/ml) (table 1, figure 3). Thus after purification, the stimulating effects 
of hB2M disappeared, indicating that one or more contaminants with MW < 10 kDa 
were responsible for the increased free radical production.  
This was confirmed by the observations from the bursttest applied on the dialysates: 
d1, the sample of the first incubation period, in which the highest concentration of 
contaminant(s) could be expected, increased ROS production after E.coli and PMA 
stimulation in all leukocyte cell types, similar to the results observed with hB2M. In 
contrast, d2, at the end of the dialysis procedure, had no longer an effect on burst 
activity, which indicated that the contaminant(s) were entirely removed by dialysis 
during the earlier fluid changes (table 1, figure 3). The DPBS, used as dialysate, did 
not have any effect on the bursttest compared to saline (data not shown). 
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3.5 Discussion 
In this study we demonstrated that 1) after exclusion of effects of endotoxin and after 
purification, beta-2-microglobulin per se had no effect on oxidative burst in leukocytes 
in vitro and 2) extreme effects observed in a biological in vitro assay should be 
interpreted with caution and possible contamination should always be excluded. The 
initial B2M-solution (hB2M) increased very strongly free radical production in all three 
leukocyte cell types especially after stimulation with E. coli and PMA. After exclusion 
of effects of endotoxin and after purification of the hB2M, the effects on oxidative 
burst by the purified B2M disappeared. Although the present study for that reason in 
essence reports negative results, it is important to convey also this kind of data to the 
scientific community, given that the experiments are well described. This will save 
time and money for other researchers working in the same field. 
CKD is an independent risk factor for CVD 33, 34. Since B2M is one of the main uremic 
retention solutes, one could raise the hypothesis that it could be one of the solutes 
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playing an active role in the pathogenesis of CVD related to CKD. Our data suggest 
that B2M could not be considered as a culprit for CVD in CKD by inducing leukocyte 
burst activation, although B2M is related to mortality 6, 7, 9, 10, 12-14 and cardiovascular 
outcome 1-5, 7, 8, 10, 11, 14  in a multitude of studies. Effect on other vascular cell types, 
however, cannot be excluded.  
Oxidative stress is one of the non-traditional risk factors and a pathogenic factor for 
CVD in CKD 22. Our study demonstrated that whole blood samples from HD patients 
indeed are pro-oxidative in the experimental set-up of the bursttest, as free radical 
production was increased at baseline and after fMLP stimulation (figure 1). Several 
uremic retention solutes such as the small water soluble guanidine compounds 32, 35, 
the protein-bound compound p-cresylsulfate 30, 31 and the middle molecules, 
dinucleoside polyphosphates 36 have already been shown to stimulate leukocyte 
oxidative burst. However, based on our data, the oxidative effect of uremic serum on 
leukocytes cannot be attributed to the presence of B2M (table 1 and figure 3). This 
finding might also imply that at least in the context of uremic oxidative stress, specific 
removal of B2M as has been depicted in a number of occasions 37, 38 might not be 
very helpful, whereas its aspecific removal as a marker together with other 
compounds with similar MW of which a number has a pro-inflammatory potential 39, 
40, might be a more logical approach. It should however be noticed that decreasing 
B2M levels in dialysis patients might remain important to reduce the occurrence of 
B2M related amyloidosis and its complications 41.  
Other in vitro studies with B2M were mainly conducted in the context of dialysis 
related amyloidosis and suggested, somewhat in contradiction with the present data, 
that B2M or B2M variants had pro-inflammatory properties. But to the best of our 
knowledge, none of the studies combined genuine B2M with circulating leukocytes 
like the present study does. B2M per se induced osteoclastogenesis in cultured mice 
calvaria 42 and was biologically active on synovial fibroblasts by increasing the 
expression of VCAM-1 25, 26 or matrix metalloproteïnase-3 43. B2M modified by 
advanced glycation end-products (AGE-B2M), induced monocyte chemotaxis and 
secretion of tumor necrosis factor-alpha and interleukin-1-beta in macrophages 24 
and monocytes 27, 44. Furthermore, AGE-B2M delayed monocyte apoptosis and 
induced monocyte to macrophage-like transition 44. Whether these effects of AGE-
B2M on monocyte cell cultures are representative for B2M per se in circulation 
Chapter 3: β2M and Leukocyte ROS 
112 
should be interpreted with caution. First of all, these effects were due to the 
interaction of AGE to its receptor (RAGE) and not due to a B2M effect per se 44, 45. 
Second, in serum of dialysis patients only a small percentage of the total B2M is 
AGE-modified 25, so that the concentration in circulation is likely to be much lower 
than the used concentration in the experiments. To the best of our knowledge, it is 
not known whether there exists a strong correlation between B2M and AGE-B2M 
concentrations. Finally, the AGE-B2M in these studies was prepared in vitro, which 
does not necessarily reflect the in vivo present AGE-B2M. Only in the study by 
Miyata et al. 24, AGE-B2M isolated from urine from two long term dialysis patients 
was investigated next to AGE-B2M prepared in vitro, which demonstrated the same 
pro-inflammatory properties on monocytes for both. In our study, the in vitro set-up 
was as relevant as possible for the in vivo situation by studying B2M at appropriate 
uremic concentrations in whole blood.  
In any way, this study also demonstrated that strong effects observed in biological in 
vitro assays should be interpreted with caution. A well known contaminant with 
effects on burst activation is LPS. However, we demonstrated that the maximal LPS 
concentration of 1.5 EU/ml in our test solutions did not induce burst activation neither 
at baseline nor after stimulation. Although LPS from different sources could have 
different biological effects 46, it is unlikely that LPS was responsible for the increased 
free radical production in the presence of hB2M in our experiments, since the purified 
B2M (dB2M) still contained LPS, but had no effects on leukocytes anymore (table 1, 
figure 3).  
Molecules in solution that are added as buffer or preservative can also interfere with 
biological effects: if known, they can be included as controls 47. The original PBS 
buffer of reconstituted B2M solution contained NaCl and a phosphate buffer. DPBS 
compared to saline however did not induce free radical production (data not shown). 
We performed a microdialysis with a membrane with MW cut off of 10 kDa in order to 
remove small solutes. The results of the bursttest on the dialysate samples showed 
that the responsible solute(s) could be easily removed: the dialysate sample of the 
first incubation period could induce similar ROS production as the original B2M-
solution, indicating a rapid and easy diffusion over the membrane. The dialysate 
sample of the last incubation period did not have any effect anymore, which indicated 
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that substances with MW < 10 kDa, which induced oxidative burst, had in the 
meanwhile been cleared from the solution (table 1 and figure 3).  
This study has some weaknesses. We only tested commercially available beta-2-
microglobulin isolated from human urine. We did not test the structural variants of 
B2M occurring in dialysis patients. Although their concentration is only a fraction of 
total B2M 25, 48, biological activity in leukocytes is not excluded. Especially AGE-B2M 
could have pro-inflammatory properties, but probably rather due to the AGEs than 
due to B2M 44, 45. Furthermore, we limited this study to a screening of the effect of 
B2M on leukocyte oxidative burst. One might argue that effects on other cell types, 
such as endothelium could be relevant. Those have not been excluded. However 
also at endothelial level, micro-inflammation and free radical production are essential 
damaging factors, and at least with regard to these key elements, B2M does not 
seem to play a major role, based on our data.  
In conclusion, our study suggests that beta-2-microglobulin, an established marker 
for middle molecules and an emerging marker for cardiovascular outcome in CKD by 
itself, does not play a direct pathogenic role in cardiovascular disease by inducing 
free radical production in leukocytes. However effects on other vascular cell types 
cannot be excluded.  
 
3.6 Practical application 
This study provides data whether beta-2-microglobulin is only a biomarker or whether 
it could contribute to the pathogenesis of cardiovascular disease in chronic kidney 
disease by induction of leukocyte oxidative stress. 
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4.1  Abstract 
Background: Pro-inflammatory cytokines are elevated in chronic kidney disease 
(CKD), a condition characterized by micro-inflammation with oxidative stress as key 
feature. However, their role in the inflammatory response at uremic concentrations 
has not yet been defined. In this study, the contribution of cytokines on induction of 
leukocyte oxidative stress was investigated.  
Methods: Whole blood from healthy donors was incubated with 20-1400pg/mL 
TNFα, 5-102,8pg/mL IL6, 20-400pg/mL IL1β and 75-1200pg/mL IL18 separately or in 
combination. Oxidative burst was measured, at baseline and after stimulation with 
fMLP (Phagoburst™). The effect of the TNFα blocker, adalimumab (Ada), was 
evaluated on TNFα-induced ROS-production. Finally, the association between TNFα 
and the composite endpoint all-cause mortality or first cardiovascular event was 
analysed in a CKD population stage 4-5 (n= 121). 
Results: While IL6, IL1β and IL18 alone induced no ROS-activation of normal 
leukocytes, irrespective of concentrations, TNFα induced ROS-activation at baseline 
(p<0.01) and after fMLP stimulation (p<0.05), but only at uremic concentrations in the 
high range (400 and 1400pg/ml). A similar pattern was observed with all cytokines in 
combination, but already at intermediate uremic concentrations (all p<0.05, except for 
monocytes after fMLP stimulation: n.s.), suggesting synergism between cytokines. 
ROS-production induced by TNFα (400pg/ml) and the cytokine combination was 
blocked with Ada. Uremia related oxidative stress in leukocytes of hemodialysis 
patients was however not blocked by Ada. In patients, TNFα was not associated to 
adverse events (HR: 1.52, 95% CI 0.81-2.85, p = 0.13). 
Conclusion: Among several pro-inflammatory cytokines, TNFα alone was pro-
oxidative but only at high range uremic concentrations. Adding a TNFα-blocker, 
adalimumab, blocked this ROS-production, but not the oxidative stress in blood 
samples from hemodialysis patients, suggesting that other uremic toxins than TNFα 
are more crucial in this process. This finding was corroborated by the lack of  
association between TNFα and mortality. 
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4.2 Introduction 
The concentration of cytokines gradually increases in chronic kidney disease (CKD) 
[1], which is mainly attributed to an increased generation in response to uremic toxins 
[2-4] and reduced renal clearance [5,6]. In clinical studies in CKD, pro-inflammatory 
cytokines are used as a hallmark of micro-inflammation [7]. Both in pre-dialysis and 
dialyzed CKD, cytokines, especially interleukin (IL)-6, have been associated to 
multiple CKD-related adverse outcomes such as malnutrition [8], muscle wasting [9], 
atherosclerosis [8,10], anemia [11] and all-cause or cardiovascular mortality [12-20]. 
Surprisingly, data on the pathophysiological role of cytokines in leukocytes at 
concentrations as occurring in CKD are to the best of our knowledge not available. 
Excessive oxidative stress is one of the key features of CKD-related micro-
inflammation, to which a host of factors such as intra-venous iron administration, bio-
incompatibility of dialysis membranes, endotoxemia and uremic solute retention, are 
contributing [21].  
In vitro, IL6, tumor necrosis factor alpha (TNFα) and IL18 induce leukocyte oxidative 
stress at concentrations in the range or in excess of those observed in extreme 
clinical conditions, such as sepsis [22-25]. In contrast, whether cytokines at lower 
levels, as observed in CKD, could induce free radical production, has not yet been 
investigated.  
A better understanding of the interaction between cytokines and oxidative stress in 
CKD could provide more insight in the mechanisms of uremic leukocyte activation, 
one of the triggers for CKD-related cardiovascular disease, and on potential 
therapeutic pathways to prevent these problems.  
Therefore, the aim of the present study was to investigate the effects of four pro-
inflammatory cytokines, at relevant uremic concentrations, separately and in a 
combination, on the induction of leukocyte oxidative burst in whole blood of healthy 
donors. The effect of a TNFα-blocker, adalimumab, on free radical production by 
TNFα was also evaluated. These findings were then compared to the impact of 
adalimumab on free radical production in leukocytes of hemodialysis patients. Finally, 
we analysed the in vivo association between TNFα and adverse outcome in a 
population with  CKD stage 4-5. 
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4.3 Material and Methods 
4.3.1 In vitro study 
Samples 
After informed consent, heparinized whole blood (NH, BD Vacutainer™, Becton 
Dickinson, Plymouth, UK) and coagulated blood (Venosafe™, Terumo Europe NV, 
Leuven, Belgium) samples were collected from non-smoking healthy volunteers and 
from stable, non-smoking hemodialysis patients before dialysis and heparinization. 
Patients with diabetes, concurrent infection, malignancy or treatment with 
immunosuppressive drugs were excluded. Patients underwent online-
hemodiafiltration 3 times 4 hours a week. The quality of the dialysis fluid met the 
ultrapure standards (bacteria <0.1 CFU/ml,  endotoxin <0.03 EU/ml) as checked on a 
regular basis. Blood was allowed to coagulate for 30 min and was then centrifuged 
(10 min, 3000rpm) in order to store the serum in aliquots at -80 °C. The protocol of 
the study was approved by the local ethics committee. 
 
Reagents 
The human recombinant cytokines interleukin (IL)-6, tumor necrosis factor alpha 
(TNFα) and IL1β (R&D Systems®, Abingdon, UK) were reconstituted in Dulbecco’s 
phosphate buffered saline (DPBS) (1x, Gibco®, Life Technologies, UK) with 0.5% 
albumin (Sigma-Aldrich, St Louis, MO, USA) (DPBS-0.5%alb). Human recombinant 
IL18 (MBL International, Woburn, MA, USA), was reconstituted in sterile water 
(Sigma Aldrich, St Louis, MO, USA). The cytokine stock solutions were aliquoted and 
stored at -80°C. A commercially available TNFα-blocker, adalimumab (50mg/ml) 
(Abbvie, North Chicago, Illinois, USA), was stored at 4°C and diluted in sterile saline 
(NaCl 0.9%, B. Braun, Melsungen, Germany) immediately before use. The stock 
solutions of the appropriate reagents were further diluted immediately before addition 
to whole blood. The concentration (10, 20, 40 or 50 times of the final concentration) 
of the prepared stock solutions was such that, after addition, the dilution of the blood 
was similar for each condition and that solute concentrations were as described 
below. 
 
Chapter 4: Cytokines and Leukocyte ROS in uremia 
122 
Oxidative burst 
Test solutions and experimental set-up 
Controls 
Saline and DPBS-0.5%alb were used as controls (co) for the experiments with 
respectively adalimumab and the cytokine solutions, as they were the solutions in 
which these compounds were diluted. 
 
Dose response experiments of cytokines  
The cytokines were tested individually in dose response at relevant uremic 
concentrations, varying from an average to high range [26-28]. The added test 
concentrations were: for TNFα 20; 70; 400 and 1400 pg/ml, for IL6: 5; 10; 21.5; 95.4 
and 102.8 pg/ml, for IL1β: 20, 80 and 400 pg/ml and for IL18: 75; 150; 300; 600 and 
1200 pg/ml. As the cytokines were added to whole blood of healthy donors, it should 
be noted that the final concentration in the blood was slightly higher than the aimed 
test concentration since these cytokines are present as such at very low 
concentrations in normal blood. It is highly unlikely that this would have influenced 
the results of the experiments, since the background concentration of cytokines in 
donor blood is much lower compared to the added concentrations of the cytokines. 
 
Effects of a combination of pro-inflammatory cytokines 
Also the combination of the four pro-inflammatory cytokines at a uremic concentration 
in the intermediate range was tested in whole blood of healthy donors. The 
combination contained TNFα at 70 pg/ml, IL6 at 10 pg/ml, IL1β at 20 pg/ml and IL18 
at 150 pg/ml.  
 
Effects of blocking TNFα with adalimumab in healthy controls  
The effect of adalimumab (17.5 mg/l [29]) on burst activity was evaluated as such 
and in the presence of TNFα (400 pg/ml), which was the lowest TNFα concentration 
that induced burst activation per se or of the cytokine combination mentioned above. 
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Studies of oxidative burst activity in whole blood of hemodialysis patients 
Leukocyte burst activation in heparinized whole blood of hemodialysis patients and 
healthy volunteers was compared. Furthermore, adalimumab was added to whole 
blood of hemodialysis patients to evaluate the possible influence of the TNFα-blocker 
on uremia-related oxidative stress.  
 
Oxidative Burst test 
Whole blood of healthy donors or hemodialysis patients was incubated for 10 min at 
37°C with control solution or the different experimental solutions, after which 
Reactive Oxygen Species (ROS) production in monocytes and granulocytes was 
measured. For that purpose, the Burst test (Phagoburst™, Orpegen Pharma, 
Heidelberg, Germany) was applied according to manufacturer’s instructions. Burst 
activity in leukocytes was evaluated at baseline and after stimulation with N-formyl-
methionine-leucine-phenylalanine (fMLP), a moderate stimulus. The generation of 
ROS was measured by assessing the oxidative conversion of the fluorogenic 
substrate dihydrorhodamine-123 into rhodamine.  
The samples were analyzed within 30 minutes by flow cytometry using a FACScan 
(Becton Dickinson, Erembodegem, Belgium). Monocytes and granulocytes were 
gated separately and the percentage of rhodamine positive cells (%) per gate was 
measured at baseline and after fMLP stimulation.  
 
4.3.2 In vivo study 
Study population 
All non-transplanted chronic kidney disease (CKD) patients stage 4 and 5 not on 
dialysis, attending the Nephrology outpatient clinic, included in the biobank sample 
collection of the Nephrology Department of the Ghent University Hospital between 
January 2011 and July 2012, were eligible for this study (n = 121). Patients were 
sampled after written informed consent and outcomes were registered prospectively. 
Plasma samples were processed immediately after collection and stored at –80°C. 
The study was approved by the local ethical committee.  
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Baseline clinical parameters (age, gender, blood pressure, pulse, height and weight) 
were registered. Body mass index (BMI) was calculated as weight/height² (kg/m²), 
mean arterial pressure (MAP) as the sum of 1/3 of the systolic and 2/3 of the diastolic 
blood pressure and pulse pressure (PP) as the difference between systolic and 
diastolic blood pressure. Estimated glomerular filtration rate (eGFR) was calculated 
based on the creatinine-based CKD-EPI formula [30]. The following comorbidities 
were recorded: cardiovascular history when at least one of the following was present: 
arterial cardiovascular disease (coronary, cerebral or peripheral), atrial fibrillation or 
heart failure (requiring hospitalisation); malignancy; diabetes mellitus, defined as a 
history of diabetes or treatment with insulin or oral antidiabetic drugs; hypertension, 
defined as current hypertension (>140/90 mmHg) or the use of antihypertensive 
drugs; hypercholesterolemia, defined as history of or treatment with lipid lowering 
drugs, and smoking status (active versus no/former smoker).  
Patients were followed until March 12th 2014 for the occurrence of cardiovascular 
events (acute coronary syndrome, de novo atrial fibrillation, acute heart failure, 
coronary artery bypass graft, percutaneous transluminal coronary angioplasty, 
cerebrovascular accident, percutaneous transluminal angioplasty) or all-cause 
mortality whichever came first. 
 
4.3.3 Concentration determination 
In the in vitro study, ELISA’s for IL6, TNFα, IL1β (R&D Systems, Abingdon, UK) and 
IL18 (MBL International, Woburn, MA, USA) were used to verify the concentrations of 
the reconstituted recombinant cytokines in the stock solutions. Therefore they were 
diluted to a defined concentration within the standard curve of the ELISA. 
Furthermore, the TNFα concentration in the serum of the HD patients used for 
evaluation of oxidative burst activity as well as those in plasma samples of patients 
with CKD 4 and 5 in the in vivo study were quantified by ELISA (R&D Systems, 
Abingdon, United Kingdom). Serum creatinine and C-reactive protein (CRP) were 
measured by routine laboratory tests.  
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4.3.4 Statistical analysis 
In vitro study 
The data of the Burst-test were non-normally distributed and consequently expressed 
as medians with interquartile range and analyzed with Friedman-ranks test, Wilcoxon 
signed-rank test or Mann-Whitney test as appropriate..  
For the in vivo study, Continuous data were expressed as mean with standard 
deviation or median with interquartile range depending on their distribution, and 
analysed by Student’s t-test or Mann Whitney-test. Binary categorical data were 
expressed as frequencies and analysed with chi-square test. The association 
between TNFα concentration as continuous variable and outcome was analyzed by 
univariate Cox proportional hazards model. The primary outcome was the composite 
endpoint of mortality or first non-fatal cardiovascular event. The analysis was 
repeated with all-cause mortality as outcome. In a multivariate analysis, variables 
with a p-value of <0.1 in univariate analysis together with TNFα were included into 
the model. The results are reported as hazard ratios with their 95% confidence 
interval (CI). A p-value <0.05 was considered as significant. Kaplan Meier survival 
curves were made for both outcomes using the median TNFα as cut-off.  
 
Statistical analysis was performed using SPSS statistics 22 (SPSS Inc, Chicago, IL, 
USA) for Windows (Microsoft Corp, Redmond, WA, USA). Graphs were made with 
GraphPad Prism 04 (GraphPad Software, La Jolla, CA, USA) or SPSS statistics 22. 
A p-value of < 0.05 was considered as statistically significant. 
 
4.4 Results 
4.4.1 In vitro study 
Control solutions (n = 10) 
The two control solutions, saline and DPBS-0.5%alb, had no effect on oxidative burst 
(data not shown). 
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Effect of cytokines on leukocyte oxidative burst in healthy donors.  
Dose response of TNFα (n = 8) 
TNFα increased ROS-production dose dependently in monocytes and granulocytes, 
at baseline and after stimulation with fMLP (figure 1). In monocytes, TNFα at 400 
pg/ml and 1400 pg/ml induced free radical production at baseline and after fMLP-
stimulation compared to control (all p < 0.01) and to 20 pg/ml (400 pg/ml: p < 0.05; 
1400 pg/ml: baseline: p < 0.05, fMLP: p < 0.01) (figure 1A and 1C). In granulocytes, 
TNFα, at 400 pg/ml and 1400 pg/ml, induced ROS at baseline compared to control (p 
< 0.01) (figure 1B), while after fMLP stimulation, only TNFα at 1400 pg/ml increased 
free radical production compared to control (p < 0.05) (figure 1D).  
 
 
Figure 1: Dose response of oxidative burst in monocytes and granulocytes from healthy donors in 
dose response to TNFα at baseline and after stimulation with fMLP. Y-axis: percentage of rhodamine 
positive cells (%), X-axis: concentration of TNF-α in pg/ml; Co: control (DPBS-0.5%alb); *, **: p < 0.05, 
< 0.01 vs. co; #, ##: p < 0.05, < 0.01 vs. 20 pg/ml. 
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Dose response of other cytokines (n = 8) 
The tested concentrations of IL6, IL1β and IL18 did neither induce nor inhibit free 
radical production in monocytes or granulocytes (data not shown).  
 
Effect of the combination of the four cytokines (n = 8) 
The combined cytokines had a stimulatory effect on leukocyte oxidative burst at 
baseline in monocytes and granulocytes (both p < 0.05) and after stimulation with 
fMLP in granulocytes (p < 0.05) (table 1). The pro-oxidative effects were similar to the 
ones observed with TNFα alone (400 pg/ml), although it is of note that the 
concentration of 70 pg/ml TNFα used in the combination solution did not induce ROS 
when added to normal blood by itself (figure 1). 
 
Effects of adalimumab on leukocyte oxidative burst  
Effects of adalimumab alone (n = 10) 
Compared to control, adalimumab had neither an effect on free radical production at 
baseline (figure 2A-B) nor after stimulation with fMLP (figure 2C-D) in healthy donor 
blood.  
 
Effects of adalimumab on oxidative burst induced by TNFα (n = 10)  
Adalimumab blocked the free radical production induced by TNFα (400 pg/ml) in 
monocytes (6.9% vs. 3.3%, p < 0.05) (figure 2A) and granulocytes (5.5% vs. 2.6%, p 
< 0.05) (figure 2B), at baseline. In contrast, adalimumab did not completely inhibit the 
stimulatory effects of TNFα in monocytes (figure 2C) or granulocytes (figure 2D) after 
fMLP-stimulation. 
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Figure 2: Effect of TNFα +/- adalimumab on basal and fMLP stimulated oxidative burst in healthy 
leukocytes. 
%: percentage of rhodamine positive cells, co: control of healthy donor (DPBS-0.5%alb), Ada: 
adalimumab, TNFα: tumor necrosis factor alpha (400 pg/ml), TNFα+Ada: combination of TNFα and 
adalimumab, fMLP: N-formyl-methionine-leucine-phenylalanine. *: p < 0.05, **: p < 0.01 vs. co, †: p < 
0.05, ‡: p < 0.01 vs. ada, §: p < 0.05 vs.TNFα.   
 
 
Effect of adalimumab on oxidative burst induced by the cytokine combination (n = 8) 
The pro-oxidative effects of the cytokine combination could be partially or entirely 
blocked by adalimumab at baseline in monocytes and granulocytes and after fMLP-
stimulation in granulocytes (table 1). Despite the probable synergisms between the 
cytokines at this intermediate concentration (see above), the blockade with 
adalimumab suggests that TNFα plays a primordial role in these in vitro data.  
 
Effects of  adalimumab on uremia-related leukocyte oxidative burst in hemodialysis 
patients (n = 10) 
Compared to healthy donors, monocytes and granulocytes from hemodialysis 
patients showed increased burst activaty at baseline (p < 0.001) and after fMLP 
stimulation (p < 0.001). Adalimumab, however, did not blunt this increased uremia-
related oxidative stress present in blood from hemodialysis patients (figure 3).  
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Figure 3: Effect of adalimumab on basal and fMLP stimulated oxidative burst in uremic leukocytes 
%: percentage of rhodamine positive cells, co: healthy control, HD: oxidative stress due to uremia in 
hemodialysis patient, HD + Ada: adalimumab added to whole blood of hemodialysis patients fMLP: N-
formyl-methionine-leucine-phenylalanine.*** p < 0.001 versus co. 
 
 
TNFα concentrations in samples of hemodialysis patients used for in vitro 
assessment 
The serum concentration of TNFα in the samples of our hemodialysis patients was 
9.9 ± 3.3 pg/ml which was lower than the concentrations reported in major reviews on 
uremic toxin concentrations (table 2) [26-28], be it close to the average mean 
reported by Duranton et al in 2013 (22 ± 25 pg/ml) [28] and within the range reported 
in clinical studies in hemodialysis patients between 2011 and 2014 (TNFα mean 13.6 
± 13.6 pg/ml, median of 6.4 pg/ml) (supplementary table 1). This observation, 
together with the lack of effect of adalimumab described above, point towards other 
factors than TNFα being at least as preponderant for causing leukocyte burst activity 
in dialysis patients treated according to today’s standards. Synergistic effects, 
however, cannot be excluded. 
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4.4.2 In vivo study 
Baseline clinical characteristics of the CKD 4-5 population (n = 121) divided 
according to the median of TNFα are presented in table 3. Patients with TNFα 
concentrations above the median, had a higher CRP, higher BMI and pulse pressure. 
There were no differences in age, gender or eGFR. After a total median [range] 
follow-up of 33 months [20-38 months], 41 patients reached the composite endpoint 
of mortality or non-fatal cardiovascular event (33.9%). Twenty-two patients died 
(18.2%) and 19 had a non-fatal cardiovascular event (15.7%), of which 6 patients 
died later on during follow-up, resulting in a total all-cause mortality of n = 28 
(23.1%). In univariate analysis, TNFα was neither associated to the composite 
endpoint (HR: 1.52, 95% CI 0.81-2.85, p = 0.13), nor to all-cause mortality (HR: 1.01, 
95% CI 0.93-1.10, p = 0.85). The Kaplan Meier curves for TNFα < or ≥ median (4.62 
pg/ml) for the composite endpoint of death or first non-fatal cardiovascular event, as 
well as for all-cause mortality, show no difference in outcome according to TNFα 
concentration (figure 4). In univariate analysis, only higher age (HR: 1.05, 95% CI: 
1.02-1.08), higher CRP (HR: 1.01, 95% CI: 1.01-1.01), a history of cardiovascular 
disease (HR: 2.90, 95% CI: 1.48-5.67) and diabetes (HR: 2.11, 95% CI: 1.14-3.91) 
were associated to increased risk for the composite endpoint. The same variables 
were also significantly associated to all-cause mortality in univariate analysis, except 
for a history of cardiovascular disease which showed only a trend (p = 0.09) 
(supplementary table 2). In a multivariate model, CRP and age remained significantly 
associated to the composite endpoint and CRP, age and gender were significantly 
associated to all-cause mortality (table 4). 
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Figure 4: Kaplan-Meier survival curve for TNFα < or ≥ median (4.62 pg/ml) with the composite 
endpoint death or first non-fatal cardiovascular event in panel A and all-cause mortality in panel B. X-
axis: follow-up in months, Y-axis: cumulative survival. 
 
 
4.5 Discussion 
The present study evaluated the role of four pro-inflammatory cytokines, IL6, TNFα, 
IL1β and IL18 in the context of CKD. The main findings of this study, indicating that 
the cytokines evaluated in this study at best are only ancillary contributors to 
inflammatory morbidity and mortality of uremia, are as follows: 1) At high uremic 
concentrations, only TNFα and not IL6, IL18 and IL1β increased the percentage of 
ROS producing monocytes and granulocytes at baseline and after fMLP-stimulation, 
in whole blood of healthy controls (figures 1 and 2); 2) The free radical production, 
induced by the combination of the four cytokines, at concentrations at which the 
individual cytokines induced no free radical production, showed a similar pro-
oxidative pattern in monocytes and granulocytes as TNFα alone at higher 
concentrations (table 1); 3) The human monoclonal TNFα-antibody, adalimumab, 
could block partially or entirely the ROS production induced by TNFα alone (figure 2) 
and by the combination of cytokines (table 1); 4) In contrast, adalimumab could not 
blunt uremia-related oxidative stress in blood from hemodialysis patients (figure 3), 
suggesting that TNFα is not a main contributor to the ROS-production as observed 
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nowadays in uremia; 5) Finally, TNFα was not associated to adverse outcome in a 
population with CKD stage 4-5 (figure 4).  
This study demonstrated for the first time that TNFα increased dose-dependently free 
radical production in monocytes and granulocytes, at baseline as well as after fMLP-
stimulation at concentrations as observed in uremia, but only significantly at values in 
the high concentration range of what has been reported in uremia (400 and 1400 
pg/ml) (figure 1); this is congruent with data obtained in other in vitro studies at 
concentrations at least tenfold above those used in the present study [22,23]. In 
combination with IL6, IL1β and IL18, TNFα induced already a similar increase in 
oxidative burst as 400 pg/ml TNFα alone at an intermediate uremic concentration of 
70 pg/ml (table 1). Since TNFα at 70 pg/ml as well as the three other cytokines at any 
concentration did not induce ROS by themselves, this points to synergisms between 
the different cytokines. Synergism between uremic retention solutes was previously 
shown for p-cresylsulfate and p-cresylglucuronide on induction of leukocyte oxidative 
stress [31] and leukocyte rolling and capillary leakage in rat peritoneal vasculature 
[32]. 
Our data suggest that it is unlikely that TNFα by itself is one of the main responsible 
toxins in uremia-related leukocyte oxidative burst. Although the test concentrations in 
this study were within the range that is proposed as uremic (table 2) [26-28], the 
TNFα concentration (400 pg/ml) that provoked ROS production per se, is far above 
the concentrations that are found in studies in hemodialysis patients over the recent 
years; those ranged from 0.4-43 pg/ml with a mean and median concentration of 14 
pg/ml and 6 pg/ml respectively (table 2, supplementary table 1). This concentration 
range is congruent with the mean TNFα concentration of only 9.9 pg/ml measured in 
our HD samples. Possible explanations for this trend in decreasing cytokine 
concentrations in HD patients are the use of ultrapure water for preparation of 
dialysis fluid [33], the better uremic toxin removal, the use of more biocompatible 
dialyzer membranes and the use of bicarbonate instead of acetate buffers [34]. 
Moreover, specifically for this in vitro study, in the hemodialysis patients, presence of 
comorbidities that could have caused additional inflammation, such as acute or 
chronic infection, smoking or malignancy were an exclusion criterion.  
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Furthermore, the TNFα-blocker, adalimumab, did not blunt the increased free radical 
production present in the whole blood of hemodialysis patients (figure 3). TNFα-
blockade is clinically used in the treatment of rheumatoid arthritis, a condition which 
is also characterized by systemic micro-inflammation and associated to 
cardiovascular disease [35,36]. Also in studies in rheumatoid arthritis patients, TNFα-
blockade could not attenuate the increased ROS production present in these patients 
[37,38], while for example chemotaxis could be decreased [37]. 
Finally, in our population with advanced CKD, which already have increased TNFα-
concentrations, but are not yet affected by possible negative effects of dialysis 
therapy, the concentration of TNFα was not associated to adverse outcome (figure 
4), as also shown earlier in a CKD population stage 2 to 5D [12]. This is in contrast to 
IL6 which has repeatedly been shown to be a strong predictor for outcome in 
CKD/dialysis [12,15-18,20] as well as in sepsis [39,40]. A possible explanation for 
this finding could be the difference in occurrence pattern of these two cytokines in the 
inflammatory cascade, with TNFα appearing earlier compared to IL6. TNFα initiates 
the inflammatory response, while IL6 is generated after NF-kB has been activated 
and is as such the result of the activated inflammatory system [41]. In the same vein, 
also CRP which is further downstream the cascade [42], was associated to adverse 
outcome in this (table 4) and other studies in CKD [13,15].  
All arguments taken together, the results in the present study raise the question 
whether the reduction of cytokine activity by the administration of targeted 
monoclonals should be a goal in CKD, even if TNFα is pro-oxidative at high uremic 
concentrations. It is reasonable to accept, based on the present data,  that TNFα 
concentration, as observed nowadays in most patients with CKD, are insufficiently 
high to expect a therapeutic benefit of TNFα blockage. It might be more important to 
prevent the sustained generation of TNFα and other cytokines by targeting first line 
uremic toxins such as intestinal derived protein-bound uremic toxins and SDMA 
which are pro-oxidative and pro-inflammatory [2,3,31,43]. Blocking TNFα in the 
context of uremia-related oxidative stress may happen too late in the cascade of 
effects to reduce ROS production. In line with this hypothesis, the results of a small 
randomized controlled trial evaluating the use of anti-TNFα therapy, etanercept, in 
hemodialysis patients, failed to reduce inflammatory markers after 44 weeks of 
treatment [44].  
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In summary, pro-inflammatory cytokines are not the main contributors to uremia-
related oxidative stress. Out of the four investigated pro-inflammatory cytokines, only 
TNFα was pro-oxidative in normal monocytes and granulocytes at high uremic 
concentrations. This free-radical production could be blocked by a TNFα-blocker, 
adalimumab, but the uremia- related oxidative stress could not be blunted by this 
TNFα-blockade. Furthermore, TNFα concentration was not linked to hard clinical 
endpoints in a population with CKD stage 4-5. The present study suggests that 
preventing the rise in TNFα could be a more useful therapeutic strategy than 
targeting TNFα itself to reduce oxidative stress in uremia. 
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Summary sentence:  
Among several pro-inflammatory cytokines, only TNFα was pro-oxidative in normal 
leukocytes at high concentrations. In combination with the other pro-inflammatory 
cytokines, TNFα increased free radical production already at a lower but still 
intermediate concentration, suggesting synergism between the different cytokines. 
Although TNFα-blockade could block TNFα-related ROS-production in normal 
leukocytes, it did not blunt uremia-related oxidative stress, suggesting that other 
uremic toxins than TNFα are more crucial in this process. Furthermore, in a CKD-
population stage 4-5, TNFα was not associated to all-cause mortality or 
cardiovascular events. 
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4.6 Tables 
Table 1: Oxidative burst in leukocytes of healthy donors in the presence of a mixture 
of pro-inflammatory cytokines 
 
Stimulus Control Cytokine mix Blocking with Ada 
Monocytes 
Baseline 
(%) 
2.4  
(2.1-2.9) 
5.9 
a
 
(3.7-7.4) 
3.1 
c 
(2.4-5.8) 
fMLP (%) 
7.7  
(5.1-11.1) 
13.0  
(8.0-16.1) 
11.6  
(10.4-21.0) 
Granulocytes 
Baseline 
(%) 
2.7  
(2.5-3.0) 
5.2 
a
 
(4.0-9.8) 
3.1 c 
(1.2-4.2) 
fMLP (%) 
11.4  
(8.0-17.9) 
17.1 a 
(12.8-20.0) 
11.1 
b
 
(9.7-13.4) 
 
Medians with interquartile range between brackets. %: percentage of rhodamine 
positive cells, Ada: adalimumab. fMLP: N-formyl-methionine-leucine-phenylalanine. a: 
p < 0.05 vs. control; b: p < 0.05 vs. cytokine mixture; c: p 0.05-0.2 vs. cytokine 
mixture. 
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Table 2: Tumor necrosis factor alpha concentrations in uremia 
 
Uremic TNFα 
concentration  
Reference 
 Major reviews on uremic toxins concentrations Literature 
search 
Vanholder et 
al., Kidney Int, 
2003 [27] 
Meert et al., 
Artif Organs, 
2007 [26] 
Duranton et 
al., J Am Soc 
Nephrol, 2013 
[28] 
Period  
2011-2014 
Maximum  408 pg/ml 1400 pg/ml - - 
Mean  
- high mean 
- average 
mean 
114 pg/ml 70 pg/ml  
58 ± 10 pg/ml 
22 ± 25 pg/ml 
14 pg/ml* 
range: 
0.4 - 43 pg/ml 
 
TNFα: tumor necrosis factor alpha. *The mean uremic concentration of the literature 
search is based on concentrations found in hemodialysis patients and is the 
calculated mean from the mean/median concentrations reported in the individual 
studies in the period 2011-1014 (based on 9 studies). For the original mean/median 
TNFα-concentrations, see supplementary table 1. The range is the minimum and 
maximum mean concentration of all individual studies. The time period of the 
literature search started from the year when the search of Duranton et al. stopped 
until 05/2014. 
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Table 3: Clinical characteristics of the entire study population and according to a 
TNFα concentration < or ≥ median of 4.62 pg/ml 
Variable Entire 
population 
TNFα median p-value 
  < 4.62 pg/ml ≥ 4.62 pg/ml  
 N = 121 N = 58 N = 63  
Age (years) 74 [63-81] 73.5 [67.0-82.0] 74.0 [65.0-81.0] 0.919 
Gender (M)  74 (61.2) 35 (60.3) 39 (61.9) 0.860 
BMI (kg/m²) 28.4 ± 5.8 27.1 ±  4.3 29.6 ± 6.7 <0.05 
MAP (mmHg) 100 ± 13 100 ± 14 98 ± 11 0.314 
PP (mmHg) 62 ± 19 66 ± 21 59 ±16 <0.05 
HR (/min) 69 ± 13 69 ± 13 70 ± 14 0.565 
eGFR 
(ml/min/1.73m²) 
23.0 [16.2-27.0] 21.1 [16.1-27.0] 23.9 [16.6-26.9] 0.705 
CVH n (%) 60 (49.6) 24 (41.4) 36 (57.1) 0.083 
DM n (%) 49 (40.5) 25 (43.1) 24 (38.1) 0.575 
Malignancy n (%) 31 (25.6) 15 (25.9) 16 (25.4) 0.953 
Cholesterol n (%) 83 (68.6) 39 (67.2) 44(69.8) 0.758 
AHT n (%) 101 (83.5) 49 (84.5) 52 (82.5) 0.774 
Smoking  n (%) 10 (8.6) 3 (5.4) 7 (11.7) 0.226 
TNFα (pg/ml) 4.62 [3.68-6.00] 3.60 [2.62-4.03] 5.72 [4.89-7.97] <0.001 
CRP (mg/l) 3.0 [1.0-8.0] 2.0 [0.9-5.3] 4.0 [2.0-13.0] <0.001 
Composite 
endpoint 
41 (33.9) 16 (27.6) 25 (39.7) 0.160 
All-cause 
mortality 
28 (23.1) 13 (22.4) 15 (23.8) 0.856 
Continuous data are presented as mean ± standard deviation or median with 
interquartile range between square brackets and categorical data as frequencies with 
percentages between brackets. TNFα: tumor necrosis factor alpha, BMI: body mass 
index, MAP: mean arterial pressure, PP: pulse pressure, HR: heart rate, eGFR: 
estimated glomerular filtration rate, CVH: history of cardiovascular disease, DM: 
diabetes mellitus, cholesterol: hypercholesterolemia, AHT: arterial hypertension, 
CRP: C-reactive protein, composite endpoint: death or non-fatal cardiovascular 
event. Variables in bold: p-value < 0.05 
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Table 4: Multivariate Cox proportional hazards model for the composite endpoint 
(Model A) and for all-cause mortality (Model B). 
 
Variable B HR [95% CI] p-value 
Model A: Composite endpoint: death or first cardiovascular event 
CRP (per mg/l) 0.014 1.01 [1.01-1.02] 0.001 
Age (per year) 0.052 1.05 [1.02-1.09] 0.002 
Model B: All-cause mortality 
CRP (per mg/l) 0.022 1.02 [1.01-1.03] < 0.001 
Age (per year) 0.093 1.10 [1.04-1.16] 0.001 
Gender (male) 1.187 3.28 [1.27-8.47] 0.014 
 
Variables with a p-value in univariate analysis <0.1 (see supplementary table 2) and 
TNFα were included in the multivariate model. Included variables: Model A: age, 
CRP, diabetes mellitus, history of cardiovascular disease and TNFα. Model B: age, 
gender, CRP, history of cardiovascular disease, malignancy, pulse pressure and 
TNFα.  
HR: hazard ratio, CI: confidence interval, CRP: C-reactive protein, TNFα: tumor 
necrosis factor alpha. 
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4.8 Supplementary tables 
Supplementary table 1: Tumor necrosis factor alpha concentrations in literature 
Reference TNFα-concentration 
Fontseré et al., Antimicr 
Agents Chemoth, 2014 [45] 
3.1 pg/ml 
Mean 13.6 ± 13.7 pg/ml 
 
Median 6.4 pg/ml, 
interquartile range: 4.3-25.7 
pg/ml 
Dukkipati et al., Sem Dial, 
2013 [46] 
5.4 pg/ml 
6.3 pg/ml 
Kir et al., Clin Lab, 2012 [47] 24.3 pg/ml 
Izquierdo et al., BMC Nephrol, 
2012 [48] 
6.2 pg/ml 
Tayyebi-Khosroshahi et al., 
Saudi J Kidney Dis, 2012 [49] 
6.9 pg/ml 
González-Espinoza et al., 
Nephrol Dial Transplant, 2012 
[50] 
0.4 pg/ml 
Guo et al., Clin Biochem, 2011 
[51] 
43.2 pg/ml 
 
Kuragano et al., Nephrol Dial 
Transplant, 2011 [52] 
27.0 pg/ml 
Meuwese et al., Nephrol Dial 
Transplant, 2011 [53] 
13.9 pg/ml 
 
TNFα: tumor necrosis factor alpha. The concentrations are the mean/median 
concentrations as reported in the original study.  
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Supplementary table 2: Univariate Cox proportional hazards model for the 
composite endpoint and all-cause mortality 
Variable Composite end-point:  
death or first non-fatal 
cardiovascular event 
All-cause mortality 
 HR   
[95% CI] 
p-value HR  
[95% CI] 
p-value 
TNFα (per pg/ml) 1.52  
[0.81-2.85] 
0.192 1.01  
[0.93-1.10] 
0.850 
CRP (per mg/l) 1.01  
[1.01-1.01] 
<0.001 1.02  
[ 1.01-1.03] 
<0.001 
Gender (male) 0.86 
[0.46-1.63] 
0.648 2.14  
[0.91-5.04] 
0.081 
Age (per year) 1.05  
[1.02-1.08] 
0.001 1.08  
[1.04-1.13] 
0.001 
eGFR  
(per ml/min/1.73m²) 
0.97  
[0.92-1.02] 
0.179 0.10 
[0.91-1.02] 
0.194 
CVH (yes) 2.90  
[1.48-5.69] 
0.002 1.94  
[0.90-4.21] 
0.092 
DM (yes) 2.11  
[1.14-3.91] 
0.017 1.18  
[0.56-2.50] 
0.668 
Maligancy (yes) 1.38  
[0.71-2.66] 
0.343 2.03  
[0.95-4.33] 
0.068 
AHT (yes) 0.72  
[0.33-1.55] 
0.398 0.51  
[0.21-1.19] 
0.118 
Cholesterol (yes) 1.48 
[0.73-3.03] 
0.279 0.92 
[0.41-2.03] 
0.828 
BMI (per kg/m²) 1.01  
[0.96-1.06] 
0.807 0.95  
[0.95-1.08] 
0.787 
Smoking (yes) 0.26  
[0.04-1.87] 
0.179 0.41  
[0.06-2.99] 
0.376 
PP (per mmHg) 1.01  
[0.10-1.03] 
0.107 1.02  
[1.00-1.04] 
0.036 
MAP (per mmHg) 0.99  
[0.97-1.02] 
0.657 1.00  
[0.97-1.03] 
0.836 
HR: hazards ratio, TNFα: tumor necrosis factor alpha, CRP: C-reactive protein, 
eGFR: estimated glomerular filtration rate, CVH: history of cardiovascaulr disease, 
DM: diabetes mellitus, AHT: arterial hypertension, cholerterol: hypercholesterolemia, 
BMI: body mass index, PP: pulse pressure, MAP: mean arterial pressure. P-value 
<0.05 is indicated in bold. 
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5.1.1  Abstract 
Background: Soluble tumor necrosis factor receptors 1 (sTNFR1) and 2 (sTNFR2) 
have been associated to progression of renal failure, end stage renal disease and 
mortality in early stages of chronic kidney disease (CKD), mostly in the context of 
diabetic nephropathy. The predictive value of these markers in advanced stages of 
CKD irrespective of the specific causes of kidney disease has not yet been defined. 
In this study, the relationship between sTNFR1 and sTNFR2 and the risk for 
cardiovascular events (CVE) and all-cause mortality was investigated in a population 
with CKD stage 4-5, not yet on dialysis, to minimize the confounding by renal 
function.  
Patients and methods: In 131 patients, CKD stage 4-5, sTNFR1, sTNFR2 were 
analysed for their association to a composite endpoint of all-cause mortality or first 
non-fatal CVE by univariate and multivariate Cox proportional hazards models. In the 
multivariate models, age, gender, CRP, eGFR and significant comorbidities were 
included as covariates. 
Results: During a median follow-up of 31 months, 42 events (32.1%) occurred of 
which 22 deaths (16.8%) and 20 (15.3%) first non-fatal CVE. In univariate analysis, 
the hazard ratios (HR) of sTNFR1 and sTNFR2 for negative outcome were 1.43 (95% 
confidence interval (CI): 1.23-1.73) and 1.13 (95% CI: 1.06-1.20) respectively. After 
adjustment for clinical covariables (age, CRP, eGFR, diabetes, a history of 
cardiovascular disease and pulse pressure) both TNFR remained independently 
associated to outcomes (HR: sTNFR1: 1.51, 95% CI: 1.31-1.75; sTNFR2: 1.13, 95% 
CI: 1.06-1.20). A subanalysis of the non-diabetic patients in the study population 
confirmed these findings.  
Conclusion: sTNFR1 and sTNFR2 are independently associated to all-cause 
mortality or an increased risk for cardiovascular events in advanced CKD irrespective 
of the cause of kidney disease. 
 
5.1.2  Introduction 
Chronic kidney disease (CKD) has been linked to increased risk for cardiovascular 
disease and mortality independent of traditional cardiovascular risk factors [1]. This 
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has at least in part been attributed to micro-inflammation, since inflammatory markers 
were associated to cardiovascular disease or mortality in different CKD cohorts not 
on dialysis [2–5] as well as on dialysis [6–8]. 
Soluble tumor necrosis factor receptor 1 (sTNFR1) and soluble tumor necrosis factor 
receptor 2 (sTNFR2) are the circulating forms of their membrane bound counterparts 
(mTNFR1 and mTNFR2) which are essential for tumor necrosis factor alpha (TNFα)-
signalling via different pathways. Interaction between TNFα and both mTNFR leads 
to a pro-inflammatory stimulus via activation of nuclear factor kappa B (NF-κB) or 
activator protein 1 (AP-1), while only mTNFR1 contains a death domain through 
which signalling leads to apoptosis [9]. The soluble receptors are released into 
circulation via shedding of membrane receptors, in exosomes or via alternative 
splicing of mRNA transcripts which leads to a loss of the transmembrane and 
cytoplasmic domains [10]. 
In contrast to TNFα, which failed to be associated to mortality or cardiovascular 
events in CKD [2], both circulating receptors are potential biomarkers in chronic 
kidney disease as predictors for outcome, be it in selected populations with diabetic 
nephropathy [11–13] or in early or moderate CKD [12,14]. Whereas diabetes can be 
seen as a pro-inflammatory stimulus per se and a broad range of GFR implies a 
higher risk for confounding because of the known relationship of sTNFRs with kidney 
function, the association of both sTNFRs to mortality and cardiovascular events has 
not yet been evaluated in a CKD population that was not selected on a specific cause 
nor in patients who suffer from advanced stages of disease.  
In the present study, we evaluated the predictive value of sTNFR1 and sTNFR2 for 
the risk for all-cause mortality or cardiovascular events in a population with advanced 
CKD (stage 4-5 not on dialysis). Evaluating outcome in advanced CKD minimizes the 
influence of eGFR on outcomes and on the concentration of the evaluated marker. 
This may allow to generate hypotheses on the contribution of other important 
mechanisms in the pathophysiology of CKD, such as inflammation, while reducing 
the impact of their intrinsic association to kidney function.  
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5.1.3  Patients and Methods 
Ethics statement 
This study was approved by the local Ethics Committee (Ethical Committee, Ghent 
University Hospital, Ghent, Belgium) and performed in accordance to the Declaration 
of Helsinki. Written informed consent was obtained from all participants. 
 
Study population 
All non-transplanted CKD patients stage 4 and 5 not on dialysis, attending the 
Nephrology outpatient clinic and included in the biobank sample collection of the 
Nephrology Department of the Ghent University Hospital between January 2011 and 
August 2012, were included in this study (n = 131). Samples were processed 
immediately after collection and stored at –80°C. Outcomes were registered 
prospectively. 
Baseline clinical parameters (age, gender, blood pressure, heart rate, height and 
weight) and etiology of the underlying kidney disease (vascular, diabetic 
nephropathy, glomerular disease/auto-immune, interstitial/postrenal, others and 
unknown) were registered. Body mass index (BMI) was calculated as weight/height² 
(kg/m²), mean arterial pressure (MAP) as the sum of 1/3 of the systolic and 2/3 of the 
diastolic blood pressure and pulse pressure (PP) as the difference between systolic 
and diastolic blood pressure. Estimated glomerular filtration rate (eGFR) was 
calculated based on the creatinine-based CKD-EPI formula [15]. The following 
comorbidities were recorded: cardiovascular history when at least one of the 
following was present: arterial cardiovascular disease (coronary, cerebral or 
peripheral), atrial fibrillation or heart failure (requiring hospitalisation); malignancy; 
diabetes mellitus, defined as a history of diabetes or treatment with insulin or oral 
antidiabetic drugs; hypertension, defined as current hypertension (>140/90 mmHg) or 
the use of antihypertensive drugs; hypercholesterolemia, defined as history of 
elevated serum cholesterol or treatment with lipid lowering drugs and smoking status 
(active versus no/former smoker).  
Patients were followed and cardiovascular events (acute coronary syndrome, de 
novo atrial fibrillation, acute heart failure, coronary artery bypass graft, percutaneous 
transluminal coronary angioplasty, cerebrovascular accident, percutaneous 
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transluminal angioplasty) and all-cause mortality were registered until March 12th 
2014. The composite endpoint in this study was all-cause mortality or a first non-fatal 
cardiovascular event, whichever occurred first. 
 
Measurements 
The concentrations of sTNFR1, sTNFR2 and TNFα, were determined on plasma 
samples by ELISA (R&D Systems, Abingdon, United Kingdom). Serum creatinine 
and C-reactive protein (CRP) were measured with routine laboratory methods.  
 
Statistical analysis 
Continuous data are expressed as mean with standard deviation or median with 
interquartile range depending on their distribution, and analysed by Student’s t-test or 
Mann Whitney-test as appropriate. Binary categorical data are expressed as 
frequencies and analysed with chi-square test. Linear regression analysis was 
performed between sTNFR1 and sTNFR2 as dependent variables and the different 
clinical parameters as independent variables.  
Univariate and multivariate analyses were performed by using Cox proportional 
hazards models to estimate the relationship between sTNFR1 and sTNFR2, as 
continuous variables and the risk for negative outcome defined as the composite 
endpoint of all-cause mortality or the occurrence of a first non-fatal cardiovascular 
event. Univariate analysis was also performed to assess the association between the 
baseline clinical variables and outcome. 
In multivariate analysis, separate models were built for sTNFR1 and sTNFR2. Due to 
collinearity, sTNFR1 and sTNFR2 were not entered together in a model. First, age 
and gender were forced into a model with sTNFR1 or sTNFR2 (model 1). In the 
second model, possible confounders, which correlated significantly with sTNFR1 or 
sTNFR2, i.e. eGFR, CRP and TNFα (the latter only for sTNFR2), were added to 
model 1. The third model included the clinical covariables which reached a 
significance of p < 0.2 with outcome in univariate analysis (age, CRP, eGFR, history 
of cardiovascular disease, diabetes mellitus and pulse pressure). Model 2 and 3 were 
analysed by forward and backward regression procedures based on the likelihood 
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ratio test and gave similar results. In this publication, only the results of the stepwise 
forward procedure are reported as hazard ratio (HR) with a 95% confidence interval 
(CI).  
The analysis described above was repeated in a subgroup analysis of patients with 
and without diabetes. 
A p-value <0.05 was considered as statistically significant.  
Finally, Receiver Operating Characteristic (ROC) curves were used to compare the 
discriminative power of sTNFR1, sTNFR2 as a single parameter to predict outcome. 
eGFR and age were assessed similarly as comparators.  
All statistical analyses were performed with SPSS statistics 22 (SPSS Inc., Chicago, 
IL, USA) for Windows (Microsoft Corp, Redmond, WA, USA).  
 
5.1.4 Results 
Baseline clinical characteristics 
In this study population including 131 patients with CKD stage 4-5 not on dialysis, the 
etiology of the underlying kidney disease was distributed as follows: renal vascular 
disease, mainly nephrangiosclerosis, n = 37 (28.2%); diabetic nephropathy, n = 28 
(21.4%); glomerular/auto-immune disease, n = 20 (15.3%); interstitial/postrenal, n = 
15 (11.5%); other, mainly autosomal dominant polycystic kidney disease, (unilateral) 
nephrectomy or use of calcineurin inhibitors in liver or heart transplants, n = 23 
(17.5%); and unknown n = 8 (6.1%). Forty-two events (31.1%), defined as the 
composite endpoint of all-cause mortalitiy or first non-fatal cardiovascular event, 
occurred after a total median follow-up of 31 months [interquartile range 23-35 
months]. Twenty-two patients (16.8%) died and 20 (15.3%) had a cardiovascular 
event, of which 6 patients died subsequently during follow-up. Baseline clinical 
characteristics and biochemical parameters of the entire population and those with 
and without event are presented in table 1. Patients who reached the composite 
endpoint, were older, had a higher C-reactive protein (CRP) and had more often a 
history of cardiovascular disease or diabetes. There was no difference in estimated 
glomerular filtration rate (eGFR) between both groups, complying with one of the 
aims of this study, i.e. to restrict the influence of kidney function on outcome among 
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subgroups by selecting a patient population with an eGFR over a narrow range.  Both 
sTNFRs were significantly higher in the group who had an event. 
sTNFR1 and sTNFR2 were strongly correlated (r = 0.76, p < 0.001) (Figure 1). Linear 
regression analysis with sTNFR1 and sTNFR2 as dependent variables showed only 
a correlation with eGFR (sTNFR1: r = -0.64, p <0.001; sTNFR2: r = -0.50, p < 0.001) 
and CRP (sTNFR1: r = 0.52, p < 0.001; sTNFR2: r = 0.54, p < 0.001). TNFα was only 
moderately correlated to sTNFR2 (r = 0.29, p < 0.01) and not to sTNFR1 (r = 0.17, p 
= 0.059). No significant correlations were found between both sTNFR and clinical 
variables listed in table 1. 
 
 
Figure 1: Dot plots showing the association between sTNFR1 and sTNFR2 (panel A), eGFR and 
sTNFR1 (panel B) and sTNFR2 (panel C). sTNFR1: soluble tumor necrosis factor receptor 1. sTNFR2: 
soluble tumor necrosis factor 2. eGFR: estimated glomerular filtration rate. R²: coefficiënt of 
determination. The straight line represents the best fitted linear regression line with 95% confidence 
interval for the mean. 
 
 
sTNFR1, sTNFR2 and outcome (death or first non-fatal cardiovascular event) 
In univariate Cox proportional hazards analysis, sTNFR1 [Hazard ratio (HR): 1.43, 
95% confidence interval (CI): 1.28-1.72] and sTNFR2 [HR: 1.13, 95% CI: 1.06-1.20] 
were associated to adverse outcomes. Older age, a higher CRP, a history of 
cardiovascular disease and diabetes mellitus also showed an association (Table 2). 
Kaplan Meier survival curves for both receptors are depicted in figure 2. For both 
sTNFRs, concentrations above the median were associated with higher event rates.  
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In multivariate models, sTNFR1 and to a smaller extent sTNFR2 remained 
significantly associated to outcome. In the first model (Table 3A) after adjustment for 
age and gender, both sTNFRs had an increased HR of 1.47, 95% CI 1.28-1.72 
(sTNFR1) and 1.14, 95% CI 1.07-1.21 (sTNFR2). When further adjustments were 
made for possible confounders which were correlated to the sTNFRs in linear 
regression analysis (eGFR, CRP, TNFα), sTNFR1 and sTNFR2 together with age 
remained independently associated to outcome (Table 3B). In the third model after 
adjustment for age, eGFR, pulse pressure, CRP, a history of cardiovascular disease 
and diabetes mellitus, both receptors remained independently associated to 
outcome, the hazards ratio for sTNFR1 (HR: 1.51, 95% CI: 1.31-1.75) again being 
higher than for sTNFR2 (HR: 1.13, 95% CI: 1.06-1.20). Age and a history of 
cardiovascular disease were significant covariates in both models (Table 3C). 
In summary, after adjustment for significant clinical covariables, sTNFR1 and 
sTNFR2 remained independently associated to increased risk of death or 
cardiovascular events. This association was stronger for sTNFR1 than for sTNFR2 
(Table 3).  
 
 
Figure 2: Kaplan Meier survival plots for sTNFR1 > or < than the median (4.0 ng/ml) and sTNFR2 > or 
< than the median (7.4 ng/nl). sTNFR1: soluble tumor necrosis factor receptor 1. sTNFR2: soluble 
tumor necrosis factor 2. Y-axis: survival rate 
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Receiver Operating Characteristic (ROC)-analysis 
ROC-analysis showed that the discriminative power of sTNFR1 and sTNFR2 for all-
cause mortality or cardiovascular event was the highest for sTNFR1 [AUC: 0.74, 95% 
CI 0.65-0.83], followed by sTNFR2 [AUC: 0.66, 95% CI 0.56-0.76] (Figure 3). These 
AUC values were in the same order as those for age [AUC: 0.70, 95% CI: 0.61-0.79], 
while eGFR was not discriminative [AUC: 0.57, 95% CI: 0.46-0.68]. 
 
 
Figure 3: Receiver Operating Characteristics (ROC) curves of soluble tumor necrosis factor receptor 1 
and soluble tumor necrosis factor receptor 2 for their discriminative power for all-cause mortality or 
cardiovascular event 
 
 
Subgroup analysis: patients  without and with diabetes 
Twenty of the eighty patients without diabetes had an adverse event (25%). Patients, 
having an event, were older (80 vs. 67.5 years, p < 0.001), had a higher CRP (5.0 vs. 
2.0 mg/l, p < 0.001), had more often a history of malignancy (45% vs. 20%, p < 0.05) 
and had a trend for more prevalent cardiovascular history (60.0% vs. 36.7%, p = 
0.068). There were no differences for the other clinical variables listed in table 1. In 
univariate analysis sTNFR1 and sTNFR2 were significantly associated to adverse 
outcome, as well as age and CRP (data not shown). After adjustment for age, CRP, 
history of cardiovascular disease and malignancy, both sTNFRs remained significant 
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covariables in the model with a HR of 1.59, 95% CI 1.22-2.07 (sTNFR1) and 1.26, 
95% CI 1.09-1.46 (sTNFR2) (Table 4). 
In the subgroup of diabetes patients (n=51), only sTNFR1, and not sTNFR2 was 
associated to adverse outcome in univariate analysis. This significant association 
persisted after adjustment for age, gender and history of cardiovascular disease in 
multivariate analysis (sTNFR1: HR: 1.36, 95% CI, 1.44-1.67). 
 
5.1.5 Discussion 
This study evaluated the value of sTNFR1 and sTNFR2 as biomarkers for their 
association to the composite endpoint of all-cause mortality or first non-fatal 
cardiovascular event in a cohort with advanced CKD irrespective of the underlying 
etiology. The main finding of this study is that sTNFR1 and sTNFR2 are associated to 
adverse outcome, even after adjustment for clinical covariables, such as age, gender, 
eGFR, CRP. The association with outcome was stronger for sTNFR1 than for 
sTNFR2, a finding that was confirmed in the subgroup of patients without diabetes. 
To the best of our knowledge, this is the first study to investigate associations 
between sTNFR1 and sTNFR2 and adverse outcomes in advanced CKD irrespective 
of the etiology. The study may be particularly relevant since by design, the narrow 
range of eGFR (<30 ml/min/1.73m²) minimized the impact of eGFR on outcome, 
which was confirmed by the lack of association to adverse outcomes (Table 2, Table 
3) and there is also no influence of dialysis therapy. In spite of the small eGFR range, 
we found a relatively good correlation between eGFR and  sTNFR1 (r = -0.64) and 
sTNFR2 (r = -0.50), underscoring that sTNFR1 and sTNFR2 with a respective 
molecular weight of approximately 30 and 40 kDa are probably mainly eliminated by 
renal clearance [16–18].  
Also, in large cohort studies in the general population, sTNFR1 [19,20] and sTNFR2 
[19,21] have been associated to an increased risk for major cardiovascular events 
[19,21] or mortality [20], even after adjustment for traditional risk factors [21]. 
However, in these cohorts, and in contrast to our study (table 3), no corrections were 
made for kidney function [21] or the association was only found when creatinine 
clearance ranged up to 75 ml/min, which implies a much broader range of eGFR than 
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in the present study [19]. As a consequence, it cannot be excluded that in these 
studies the sTNFR concentrations rather reflected the association of eGFR with 
adverse outcomes than that of sTNFRs itself. In the present study, sTNFRs were 
more informative for adverse outcome than what could be explained through their 
correlation with eGFR alone, since associations of sTNFRs to adverse outcome 
remained significant after adjustment for eGFR, while eGFR was not significant 
(Table 3). This observation could strengthen the hypothesis that sTNFRs are also 
markers for underlying pathophysiological mechanisms of cardiovascular risk in CKD. 
This is supported by findings in other populations with increased cardiovascular risk. 
sTNFR1 at admission for acute myocardial infarction was associated to infarct size 
and worse left ventricular function 4 months post-infarction [22], to the composite 
endpoint of death and new onset heart failure [23] and to long term cardiac and all-
cause mortality post-infarction even when corrected for relevant covariates such as 
creatinine clearance [24] . 
This is also consistent with the increased mortality risk associated to sTNFR1 in 
patients with diabetic nephropathy [12,13]. In the present study, the association 
between sTNFRs and outcomes was also confirmed in the subgroup of patients 
without diabetes (Table 4). 
In our analysis, CRP was significantly correlated with sTNFR1 (r = 0.52) and sTNFR2 
(r = 0.54). CRP was also significantly associated to a negative outcome in univariate 
analysis (Table 2), while in multivariate models including sTNFR1 or sTNFR2, the 
receptors were stronger covariates and remained independently associated to 
outcome while CRP lost its significance (Table 3).  
Remarkably, although linked to each other in the same inflammatory TNFα–pathway, 
sTNFR1 and sTNFR2 do not entirely yield the same information, despite the strong 
mutual correlation between both receptors as observed in our study (r = 0.76) and 
also reported previously [11]. sTNFR1 did not correlate to sTNFα, while a significant 
but modest correlation was found for sTNFR2 (r = 0.29). In ROC analysis the 
discriminative power of sTNFR1 for adverse outcome was higher compared to 
sTNFR2 (Figure 3). In the subgroup of diabetes patients only sTNFR1 and not 
sTNFR2 was associated to outcome in univariate and multivariate analysis.  
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Constitutively, both sTNFRs are released from cell membranes by shedding [18,25] 
or as full-length receptors in exosomes [26,27]; the full-length sTNFR1 in exosomes 
being the most abundant form of sTNFR1 in serum of healthy controls [27]. Both 
forms are capable of binding TNFα [18,27]. Following acute pro-inflammatory stimuli, 
shedding is intensified, resulting in an increase in circulating sTNFR concentration 
[25,28] and in a possible modulation of immune response [29]. The function of these 
soluble receptors is debated: they are inhibitors for TNFα, especially in acute 
inflammatory settings [18,30], but, in more chronic conditions and in proportion to 
their concentration, they also increase the half-life of TNFα and may act as slow-
release reservoirs of TNFα enhancing its cytotoxicity [31]. Which process prevails in 
CKD still needs to be elucidated, although the TNFR concentration range (3-12 
ng/ml) in which Aderka et al. [31] found a prolonged activity of TNFα function, 
corresponds to concentrations found in CKD. Together with our findings of a 
relationship with adverse outcome, this could indicate that sTNFRs in CKD would 
rather increase the negative effects of TNFα than act as TNFα-inhibitors.  
The limitations of the study are: the results cannot be generalized to all CKD stages, 
since we restricted the evaluation to CKD stage 4 and 5 intentionally to evaluate both 
receptors in a narrow range of eGFR, which also resulted in a rather small 
population. Nevertheless, the study unravelled convincing correlations between 
sTNFRs and outcomes even after adjustment for confounders such as eGFR or 
diabetes. Hence our data underscore the relationship of TNFRs, with hard clinical 
outcomes irrespective of renal function and the presence or absence of diabetes. 
The fact that especially sTNFR1 was consistently associated to different outcomes in 
advanced CKD as shown in this study as well as in community-based and specific 
high risk populations such as post-myocardial infarction, offers a strong argument in 
favour for its further evaluation in larger CKD cohorts. 
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5.1.6  Tables 
Table 1: Baseline characteristics of the entire study population and according to the 
occurrence or not of the studied events  
Variable 
Entire cohort 
 
N = 131 
Death or first cardiovascular event 
No 
N = 89 
Yes 
N = 42 
p-value 
Age (years) 73 [62-89] 70 [58-77] 78 [69-83] <0.001 
Gender (M)  83 (63.4) 56 (62.9) 27 (64.3) 0.88 
BMI (kg/m²) 28.3 ± 5.7 28.2 ± 4.9 28.5 ± 7.2 0.80 
MAP (mmHg) 99 ± 13 100 ± 13 99 ± 13 0.81 
PP (mmHg) 61 ± 19 59 ± 17.7 65.2 ± 20.2 0.12 
HR (/min) 69 ± 13 68 ± 13 72 ± 13 0.12 
eGFR 
(ml/min/1.73m²) 
22.8 [16.1-27.0] 23.0 [17.4-27.4] 20.1[15.4-26.3] 0.21 
CVD 64 (48.1) 34 (38.2) 30 (71.4) <0.001 
DM 51 (38.9) 29 (32.6) 22 (52.6) 0.030 
Malignancy 32 (24.4) 19 (21.3) 13 (31.0) 0.23 
Cholesterol 90 (68.7) 58 (65.2) 32 (76.2) 0.20 
AHT 108 (82.4) 74 (83.1) 34 (81.0) 0.76 
Smoking (active) 12 (9.1) 10 (11.9) 2 (5.0) 0.22 
CRP (mg/l) 3.0 [1.0-8.0] 2.0 [0.6-4.1] 6.5 [2.0-24.3] <0.001 
TNFα (pg/ml) 4.6 [3.7-6.0] 4.5 [3.3-5.5] 4.8 [3.8-6.8] 0.053 
sTNFR1 (ng/ml) 4.0 [3.1-5.1] 3.7 [2.8-4.7] 4.8 [3.9-6.0] <0.001 
sTNFR2 (ng/ml) 7.4 [5.8-9.4] 6.9 [5.2-8.8] 7.9 [6.4-12.1] <0.01 
Data are presented as means ± standard deviation or medians with interquartile range between 
square brackets. For binary variables, frequencies with percentages between brackets are given. N= 
number of patients, M: male, BMI: body mass index, MAP: mean arterial pressure, PP: pulse pressure, 
HR: heart rate, eGFR: estimated glomerular filtration rate, CVD: history of cardiovascular disease, DM: 
diabetes mellitus, cholesterol: hypercholesterolemia, AHT: arterial hypertension,  CRP: C-reactive 
protein, TNFα: tumor necrosis factor alpha,  sTNFR1: soluble tumor necrosis factor receptor 1, 
sTNFR2: soluble tumor necrosis factor receptor 2. n.s.: not significant
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Table 2: Univariate Cox proportional hazards analysis for outcome (death or first 
cardiovascular event) 
Variable B  HR [95% CI] 
sTNFR1 (per ng/ml) 0.391 1.43 [1.23-1.73]*** 
sTNFR2 (per ng/ml) 0.119 1.13 [1.06-1.20]*** 
TNFα (per pg/ml) 0.035 1.04 [0.98-1.09] 
CRP (per mg/l) 0.015 1.02 [1.01-1.02]*** 
Gender (M) 0.111 1.12 [0.59-2.10] 
Age (per year) 0.052 1.05 [1.02-1.07]*** 
eGFR  
(per ml/min/1.73m²) 
-0.033 0.97 [0.92-1.02] 
MAP (per mmHg) -0.004 1.00 [0.97-1.02] 
PP (per mmHg) 0.013 1.01 [1.00-1.03] 
BMI 0.005 1.01 [0.95-1.06] 
CVD 1.112 3.08 [1.58-6.03]*** 
DM 0.726 2.07 [1.13-3.79]* 
Malignancy 0.333 1.40 [0.73-2.68] 
AHT 0.228 1.26 [0.58-2.71] 
Cholesterol 0.432 1.54 [0.76-3.13] 
Smoking -0.703 0.50 [0.11-2.05] 
HR: Hazard ratio, CI: confidence interval. In bold, variables with p-value < 0.2, included in the 
multivariate model (table 3, model 3). *: p < 0.05, ***: < 0.001. sTNFR1: soluble tumor 
necrosis factor receptor 1, sTNFR2: soluble tumor necrosis factor receptor 2, TNFα: tumor 
necrosis factor alpha, CRP: C-reactive protein, eGFR: estimated glomerular filtration rate, 
MAP: mean arterial pressure, PP: pulse pressure, BMI: body mass index, CVD: history of 
cardiovascular disease, DM: diabetes mellitus, AHT: arterial hypertension, cholesterol: 
hypercholesterolemia. 
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Table 3: Multivariate Cox proportional hazards models for death or cardiovascular 
event 
Variable B HR [95% CI] p-value 
A. Model 1: sTNFR1 or sTNFR2, age, gender 
A1. sTNFR1 
sTNFR1 (per ng/ml) 0.396 1.49 [1.28-1.72] < 0.001 
age (per year) 0.015 1.06 [1.02-1.09] < 0.001 
gender (M)   n.s. 
A2. sTNFR2 
sTNFR2 (per ng/ml) 0.129 1.14 [1.07-1.21] < 0.001 
age (per year) 0.058 1.07 [1.03-1.10] < 0.001 
gender (M)   n.s. 
B. Model 2: sTNFR1 or sTNFR2, age, gender, eGFR, CRP, TNFα 
B1. sTNFR1 
sTNFR1 (per ng/ml) 0.395 1.49 [1.28-1.72] <0.001 
age (per year) 0.056 1.06 [1.02-1.09] <0.01 
gender, CRP, eGFR    n.s. 
B2. sTNFR2    
sTNFR2 (per pg/ml) 0.136 1.15 [1.08-1.22] <0.001 
age 0.051 1.05 [1.02-1.09] <0.01 
gender, CRP, eGFR, TNFα   n.s. 
C. Model 3: sTNFR1 or sTNFR2, age, eGFR, CRP, CVD, DM, PP 
C1. sTNFR1 
sTNFR1 (per ng/ml) 0.414 1.51 [1.31-1.75] <0.001 
age (per year) 0.044 1.05 [1.01-1.08] <0.01 
CVD 0.876 2.40 [1.19-4.85] <0.05 
eGFR, CRP, DM, PP  n.s. 
C2. sTNFR2 
sTNFR2 (per ng/ml) 0.118 1.13 [1.06-1.20] <0.001 
age (per year) 0.045 1.05 [1.01-1.08] <0.01 
CVD 0.724 2.06 [1.02-4.19] <0.05 
eGFR, CRP, DM, PP  n.s. 
HR: Hazard ratio, CI: confidence interval. In model 2: TNFα, only included in model with 
sTNFR2. sTNFR1: soluble tumor necrosis factor receptor 1, sTNFR2: soluble tumor necrosis 
factor receptor 2, TNFα: tumor necrosis factor alpha, eGFR: estimated glomerular filtration 
rate, CRP: C-reactive protein, TNFα: tumor necrosis factor alpha, CVD: history of 
cardiovasular disease, DM: diabetes mellitus, PP: pulse pressure, n.s.: not significant 
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Table 4: Multivariate Cox proportional hazards model for death or cardiovascular 
event in the subgroup of non diabetic patients 
Variable B HR [95% CI] p-value 
Full model with sTNFR1 
sTNFR1 (per ng/ml) 0.463 1.59 [1.22-2.07] <0.01 
age (per year) 0.059 1.06 [1.01-1.11] <0.05 
gender, CRP, CVH, 
malignancy 
 
 n.s. 
Full model with sTNFR2 
sTNFR2 (per ng/ml) 0.233 1.26 [1.09-1.46] <0.01 
age (per year) 0.063 1.07 [1.02-1.12] <0.05 
gender, CRP, CVH, 
malignancy 
 
 n.s. 
HR: Hazard ratio, CI: confidence interval, sTNFR1: soluble tumor necrosis factor receptor 1, 
sTNFR2: soluble tumor necrosis factor receptor 2, TNFα: tumor necrosis factor alpha, eGFR: 
estimated glomerular filtration rate, CRP: C-reactive protein, TNFα: tumor necrosis factor 
alpha, CVD: history of cardiovasular disease, DM: diabetes mellitus, PP: pulse pressure, 
n.s.: not significant 
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5.2.1 Abstract 
Introduction: Soluble tumor necrosis factor receptor 1 (sTNFR1) and 2 (sTNFR2) 
are associated to outcome in chronic kidney disease (CKD). Their origin and function 
in CKD are not entirely understood. Concentration changes in circulation as well as 
changes in leukocyte membrane expression could modulate TNFα signalling and 
function in CKD. The aims of the present study were to investigate the relationship 
between sTNFR concentrations on one hand and estimated glomerular filtration rate 
(eGFR) and changes in their membrane expression on leukocytes on the other. 
Methods: Fifty patients with CKD stage 1-5 not on dialysis (ten patients in each 
stage), without diabetes, were matched per stage for age and gender. Linear 
regression analysis was performed between the reciprocals of sTNFR1, sTNFR2, 
measured with ELISA, and eGFR. In addition, we also explored whether an impact of 
the uremic status on leukocyte membrane expression of the TNFRs (mTNFR1, 
mTNFR2) and membrane (m)TNFα, could influence the soluble receptor 
concentrations by comparing the leukocyte membrane TNFR expression in 
hemodialysis patients (HD) (n=8) and controls (C) (n=8) by flow cytometry. 
Results: The mean age of the CKD population was 49.9 ± 13.6 years. There was a 
strong correlation between eGFR and 1/sTNFR1 (r=0.932) and 1/sTNFR2 (r=0.889) 
in CKD stage 1-5 (both p<0.001), which remained significant in multivariable analysis 
after correction for covariables such as age and CRP. In HD, the concentrations of 
sTNFR1, sTNFR2 increased further compared to CKD stage 5 (sTNFR1: 9.8 vs. 5.8 
ng/ml, p<0.01; sTNFR2: 18.2 vs. 8.7 ng/ml, p<0.001). In contrast and in spite of 
assessing subjects at the two extremes of kidney dysfunction, there was no 
difference in the global leukocyte membrane expression of mTNFR1, mTNFR2 and 
mTNFα between HD and C.  
Conclusion: This study demonstrates that increased concentrations of sTNFR1 and 
sTNFR2 in CKD are mainly associated to decreased renal clearance but not to 
changes in leukocyte membrane expression. 
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5.2.2 Introduction 
The concentrations of soluble tumor necrosis factor receptor 1 (sTNFR1) and soluble 
tumor necrosis factor receptor 2 (sTNFR2) increase in chronic kidney disease (CKD) 
[1–3] and dialysis patients [4,5]. Higher concentrations are associated to progression 
of kidney disease in patients with early or moderate CKD (CKD stage 1-3) [6–9] and 
to mortality in patients with diabetic nephropathy [7,10]. Although these molecules 
are members of the tumor necrosis factor alpha (TNFα)-system, they outperform 
circulating TNFα (sTNFα) in their predictive value for outcome [6,7].  
The concentration of sTNFR1 and sTNFR2 in circulation is theoretically the sum of 
what is released from the cell surface and what is cleared from the body. In vitro 
studies [11–13] and animal studies in mice [14]  have shown that sTNFRs are shed 
from the cell membrane mediated via TNFα converting enzyme (TACE) [11,14] and 
are present as full length receptors in circulating exosomes [12,13]. Animal studies in 
mice with normal renal function have shown that both sTNFRs are eliminated via the 
kidneys [14,15]. Acute inflammatory stimuli induce intensified shedding causing a rise 
in plasma concentration [14,16]. 
Progression of CKD at the same time leads to a decreased renal clearance but also 
to an enhanced inflammatory status, raising the question which of both factors 
prevails in the increased sTNFR levels in CKD and whether uremia has an influence 
on leukocyte membrane expression of sTNFRs. To the best of our knowledge, this 
question has not yet been assessed in renal failure conditions. Increased 
understanding of the origin of circulating TNFRs in CKD and the impact of uremia on 
membrane expression will extend the knowledge on their potential biological function 
and their possible influence on TNFα signalling in CKD. 
Therefore, the aim of this study was to investigate the correlation between both 
sTNFRs and eGFR in a CKD population stage 1-5 in order to explore the contribution 
of glomerular filtration rate to sTNFR concentration in CKD. In parallel, the leukocyte 
membrane expression of mTNFRs in hemodialysis patients (HD) was compared to 
that of healthy controls (C) ex vivo, in order to unravel possible differences between 
the two most extreme stages of kidney function in receptor expression at baseline 
unstimulated conditions. 
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5.2.3 Material and Methods 
Patient samples 
Clinical correlation study 
To investigate the correlation between sTNFR concentration and eGFR, fifty non-
diabetic patients with CKD stage 1-5, classified according to the creatinine-based 
CKD-EPI formula [17], ten in each stage, matched for age and gender, were included 
in this cross-sectional study and selected from the sample collection of the 
Nephrology Department of the Ghent University Hospital. Every patient not dialyzed 
or transplanted, attending the Nephrology outpatient clinic was eligible for 
recruitment. Plasma samples were collected between January 2012 and August 
2013, immediately centrifuged, aliquoted and stored at -80°C. The study was 
approved by the local ethics committee and written informed consent was obtained.  
Baseline clinical parameters (age, gender, blood pressure, heart rate, height and 
weight) and etiology of underlying kidney disease (renovascular, autosomal dominant 
polycystic kidney disease (ADPKD), glomerular disease/auto-immune, 
interstitial/postrenal and others) were registered. Body mass index (BMI) was 
calculated as weight/height² (kg/m²), mean arterial pressure (MAP) as the sum of 1/3 
of the systolic and 2/3 of the diastolic blood pressure and pulse pressure (PP) as the 
difference between systolic and diastolic blood pressure. To exclude acute infections 
or inflammatory syndromes, patients with a C-reactive protein (CRP) above 20 mg/l 
were excluded.  
 
Samples for leukocyte membrane labelling study 
For the labelling of leukocyte mTNFRs and mTNFα, whole blood samples were taken 
from healthy volunteers (C) (n = 8) and hemodialysis patients (HD) before the start of 
dialysis (n = 8) (3 men and 5 women in each group). Samples from C and HD 
patients were chosen to compare the two extremes with regard to kidney function. 
Controls had no known acute or chronic illnesses. HD patients were non-diabetics, 
had no history of malignancy, no acute or chronic infection and took no 
immunosuppressive drugs. Patients underwent online-hemodiafiltration 3 times 4 
hours a week. The quality of the dialysis fluid met the ultra pure standards (bacteria 
<0.1 CFU/ml, endotoxin <0.03 EU/ml) as checked on a regular basis. Samples were 
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immediately put on ice, until the start of the membrane labelling (at maximum within 
30 min after sampling).  
 
Concentration Measurements 
The concentrations of sTNFR1, sTNFR2 and sTNFα were determined on plasma 
samples of CKD patients of the correlation study and HD patients of the leukocyte 
membrane labelling study by ELISA (R&D Systems, Abingdon, United Kingdom) with 
a detection limit of 0.8 x 10-³ ng/ml, 0.6 x 10-³ ng/ml and 0.5 pg/ml respectively. 
Serum creatinine and CRP were measured by routine laboratory methods.  
 
Membrane labelling study 
Reagents 
Fluorochrome labelled antibodies against membrane tumor necrosis factor receptor 1 
(mTNFR1) (anti-mTNFR1-FITC, MBL International, Woburn, MA, USA), membrane 
tumor necrosis factor receptor 2 (mTNFR2) (anti-mTNFR2-AlexaFluor 700, R&D 
Systems, Abingdon, UK) and membrane tumor necrosis factor alpha (mTNFα) (anti-
mTNFα-PE, R&D Systems, Abingdon, UK) were used for ex vivo labelling of 
leukocytes.  
 
Protocol for membrane labelling of TNFα-receptors and membrane TNFα 
Whole blood of C and HD was incubated with the fluorochrome labelled antibodies at 
4°C to visualize the expression of mTNFRs and mTNFα on the leukocyte membrane 
at the time of sampling (Et0). To assess whether the expression of the receptors on 
the leukocyte membrane was in steady state in an unstimulated condition, the 
samples were incubated ex vivo at 37°C for 1 hour before addition of the 
fluorochrome labelled antibodies and afterwards labelled at 4°C (Et1).  
After labelling, samples were lysed (lysing solution, R&D Systems, UK), centrifuged 
and washed with staining buffer (R&D Systems, UK). After resuspension in staining 
buffer, the samples were analysed immediately by flow cytometry (FACSCanto, 
Becton Dickenson, Erembodegem, Belgium). First, all leukocytes were gated 
together and the mean fluorescence intensity (MFI) of the entire leukocyte cluster 
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was assessed. Based on forward and side scatter, monocytes, granulocytes and 
lymphocytes were identified and the MFI of each cluster was measured separately.  
 
Statistical analysis 
Clinical correlation study 
Continuous data were expressed as mean with standard deviation or median with 
interquartile range depending on their distribution, and analysed by Student’s t-test, 
ANOVA with pairwise comparisons, Mann-Whitney test or Kruskal-Wallis test with 
pairwise comparisons as appropriate. Linear regression analysis was performed 
between the reciprocals of the concentrations of sTNFR1 and sTNFR2 as dependent 
variables and eGFR as independent variable. Univariate linear regression analysis 
was also performed between receptor concentration and the clinical and biochemical 
covariates. Covariates that were correlated to the sTNFRs with a p-value < 0.2 in 
univariate analysis were analyzed with multiple linear regression analysis by a 
stepwise forward procedure. Pearson correlation coefficients (r) with their p-value 
and coefficients of determination (R²) were reported. A p-value < 0.05 was 
considered as statistically significant. 
 
Membrane labelling study 
Data were not normally distributed and as a consequence analysed with non-
parametric tests. C and HD were compared with a Mann-Whitney test. The different 
test conditions in C and HD were compared with a Wilcoxon signed ranks test.  
 
All statistical analyses were performed with SPSS statistics 22 (SPSS Inc., Chicago, 
IL, USA) for Windows (Microsoft Corp, Redmond, WA, USA). Graphs were made in 
GraphPad Prism 04 (GraphPad Software, LaJolla, CA, USA). A p-value of < 0.05 
was considered as significant.  
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5.2.4 Results 
Clinical Correlation study 
The etiology of the underlying kidney disease in this non-diabetic population CKD 
stage 1-5 (n = 50) was distributed as follows: ADPKD: 18%, glomerular: 34%, 
renovascular: 12%, interstitial/postrenal: 18% and other: 20%. The overall mean age 
was 49.9 ± 13.6 years with an equal gender distribution. The mean MAPs and PPs 
were 96 ± 11 mmHg and 47 ± 1 mmHg, respectively and increased when kidney 
function deteriorated (table 1). The concentrations of sTNFR1, sTNFR2 and sTNFα 
increased gradually over the different stages of CKD with an earlier rise for both 
soluble receptors compared to sTNFα for which the concentration only increased in 
CKD stages 4-5 (table 1). 
In univariate linear regression analysis, there was a strong correlation between eGFR 
and 1/sTNFR1 (r = 0.939, p < 0.001) and 1/sTNFR2 (r = 0.889, p < 0.001) (figure 1). 
Results of the univariate linear regression analysis between the receptors and other 
clinical and biochemical variables are shown in table 2. There was a strong mutual 
correlation between both receptors (r = 0.945, p < 0.001), and both receptors were 
also correlated to sTNFα, CRP, MAP and PP. sTNFR2 was correlated to age 
whereas only a trend was observed for sTNFR1.  
In a multiple linear regression model for sTNFR1 with eGFR, age, CRP, sTNFα, MAP 
and PP included as covariables, only eGFR remained a significant determinant in the 
model  (sTNFR1: r = 0.930, p < 0.001). Also, in a multiple linear regression model for 
sTNFR2 with eGFR, age, gender, CRP, sTNFα, MAP and PP as covariates, eGFR 
remained the strongest covariate, although CRP and gender were also significant 
covariables (table 3). 
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Figure 1: Dot plots with linear regression line between eGFR and 1/sTNFR1 (Panel A), 
1/sTNFR2 (Panel B). eGFR: estimated glomerular filtration rate, 1/sTNFR1, 1/sTNFR2: 
reciprocal of the concentration of soluble tumor necrosis factor receptor 1 and 2, R²: 
coefficient of determination.  
 
 
Membrane labelling study 
To evaluate the effect of uremia on the level of expression of receptors both in 
circulation and on the leukocyte membrane, the most extreme condition, being 
patients in CKD stage 5 on hemodialysis, was selected. The mean age of the HD 
patients was 68.6 ± 17.3 years. The HD patients had a mean urea and creatinine 
clearance of 1.8 ml/min) and the mean single pool Kt/Vurea was 1.75. The mean age 
of the controls was 41.4 ± 10.9 years. 
In comparison to the concentrations in CKD stage 5 not on dialysis, the 
concentrations of sTNFR1, sTNFR2, sTNFα were further increased in HD patients 
(sTNFR1: 9.8 vs. 5.8 ng/ml, p<0.01; sTNFR2: 18.2 vs. 8.7 ng/ml, p<0.001; sTNFα 9.4 
vs. 3.3 pg/ml, p<0.01). Despite this marked increase in plasma concentrations, the 
overall leukocyte membrane expression at baseline (Et0) in HD was not different 
compared to C, with MFI for mTNFR1: 335.0 vs. 306.1 (p = n.s.), mTNFR2: 67.8 vs. 
61.5 (p = n.s.) and mTNFα: 384.5 vs. 405.5 (p = n.s.) (figure 2). This was also 
observed for the different leukocyte subtypes separately, with the exception for a 
discrete difference for mTNFR2-expression on lymphocytes (HD: 11.0 vs. C: 17.5, p 
< 0.01) (table 4). 
Furthermore, when comparing  the overall leukocyte membrane expression between 
Et0 and Et1, there was no difference between both conditions in HD and C, indicating 
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steady state (figure 2). Analysis of the membrane expression on the different 
leukocyte subtypes after 1 hour incubation at 37 °C (Et1) revealed also no differences 
at all between HD and C. There were only some minor differences between Et1 and 
Et0 (mTNFR1, granulocytes in HD; mTNFR2, monocytes and granulocytes in 
controls; p=0.04 in all) (table 4). These findings make release of mTNFRs from the 
leukocyte membranes as an important mechanism for increased sTNFRs 
concentrations in HD patients less probable. 
 
 
Figure 2: Overall expression of membrane tumor necrosis factor receptor 1, 2 and 
membrane tumor necrosis factor alpha on all leukocytes gated together indicating steady 
state in HD and in controls. 
MFI: mean fluorescence intensity, mTNFR1: membrane tumor necrosis factor receptor 1, 
mTNFR2: membrane tumor necrosis factor receptor 2, mTNFα: membrane tumor necrosis 
factor receptor alpha. Et0: baseline expression of receptors expressed on membranes, Et1: 
Membrane expression of receptors after 1 hour incubation ex vivo at 37°C. C: healthy 
control, HD: hemodialysis patient. No differences between HD and C for Et0 and Et1. No 
significant differences for the comparison between Et1 and Et0 in C and HD. 
 
 
5.2.5 Discussion 
In the present study, we investigated the correlation between sTNFRs and eGFR as 
well as the leukocyte membrane expression of both TNFRs and TNFα. The main 
findings of the study are: 1) In a stable CKD population stage 1 to 5, the 
concentrations of sTNFR1 and sTNFR2 are strongly correlated to eGFR, suggesting 
that renal clearance is one of the major determinants for TNFα-receptor 
concentration. 2) CRP is correlated to both receptors in univariate analysis, but 
remains only a significant covariate for sTNFR2 concentration in multiple regression 
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analysis. 3) The leukocyte membrane expression of both receptors is not different 
between healthy controls and hemodialysis patients.  
In this study population with stable CKD-patients, sTNFR concentrations were largely 
dependent on eGFR (figure 1), which persisted after correction of covariates such as 
CRP, age, sTNFα, MAP, PP and gender. The concentration of both sTNFR further 
increased in HD. In contrast, the concentration of sTNFα (17kDa) rose only in the 
later stages of CKD (table 1), although also TNFα is at least partially cleared via the 
kidneys [18]. 
The soluble forms of TNFR1 and TNFR2 have a molecular weight of 30 kDa and 40 
kDa respectively [19], meaning that they theoretically could be filtered by the 
glomeruli. They also appear in circulation in exosomes in their transmembrane form 
with a molecular weight of 55kDa and 75kDa, respectively [12,13]. Studies in mice 
with a normal kidney function have demonstrated that TNFRs are cleared via the 
kidney: they have been found in urine, intact and as small fragments indicating 
degradation in the kidney [14,15]. To the best of our knowledge it has not been 
clarified whether, in analogy to other peptides, they are reabsorbed after their 
appearance in the primary urine for example by the cubulin megalin receptor complex 
[20]. 
Although patients with a CRP > 20 mg/l were excluded from this study to limit the 
influence of acute inflammatory syndromes, both receptors were significantly 
correlated to CRP in univariate analysis (table 2), which remained significant for 
sTNFR2 in multiple linear regression analysis (table 3). This indicates that 
inflammation is another contributor to sTNFR concentrations, caused by release of 
sTNFR1 and sTNFR2 from the cell surface membrane, a process mediated by TNFα 
converting enzyme (TACE). In acute inflammation, this process reduces the 
membrane expression of TNFRs and is as such one of the regulating mechanisms of 
TNFα signalling [11,14,21,22]. Whether this process also plays a role in chronic 
inflammation is less clear. TACE was found in microparticles derived from 
atherosclerotic plaques and was able to induce release of sTNFR1, sTNFR2 and 
sTNFα from endothelial cells, hinting towards a possible role in chronic inflammation 
[23]. In our study, however, we did not find any differences in receptor expression on 
leukocyte membranes in HD patients compared to C and the membrane expression 
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was in steady state in both groups in an unstimulated condition (figure 2), making 
release as an important contributor to the plasma concentrations of sTNFR in stable 
CKD unlikely.  
Hence in the view of the highly significant correlation found with eGFR, it seems that 
preserving kidney function will be the main approach to keep levels of sTNFR low. 
Still, release from the cell membrane is not entirely excluded and its possible 
contribution as a mechanism for increased sTNFR concentrations in CKD should be 
further elucidated, since this can provide additional information on the mechanisms 
regulating TNFα activity in CKD related micro-inflammation. The function of sTNFRs 
in circulation in CKD has not entirely been clarified: both receptors could block 
sTNFα activity [14,24] or prolong sTNFα half life [16,25], and thus act as a reservoir 
for sTNFα which could sustain its toxicity [26]. Which function is predominant in CKD 
is unclear and probably depends on receptor concentration [26]. 
The choice to match the patients for age and gender and exclude patients with 
markedly elevated CRP had mainly advantages but also some disadvantages. It 
allowed, especially in this small population, to isolate the effect of renal function on 
the different soluble receptors and to exclude the influence of other factors such as 
age, obesity, diabetes mellitus or inflammation which could be associated to TNFR 
concentration and CKD at the same time. The disadvantage might be that these 
findings cannot be generalized to e.g. older or diabetic populations. Due to the 
limitations in accuracy with the use of eGFR, one of the major limitations of this study 
is the lack of a measured GFR in the correlation study.  
In summary, in stable CKD-patients, the concentrations of sTNFR1 and sTNFR2 are 
mainly dependent on glomerular filtration rate, while leukocyte membrane expression 
of sTNFRs is unaltered.  
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5.2.6 Tables 
Table 1: Characteristics of the study population included in the correlation study 
according to CKD-stage. 
 CKD 1 
N= 10 
CKD 2 
N=10 
CKD 3 
N=10 
CKD 4 
N=10 
CKD 5 
N=10 
p-value 
Age (years) 43.0 ± 13.1 49.8 ± 10.6 49.5 ± 9.0 54.1 ± 10.8 55.8 ± 21.6 0.285 
Gender n (M/F) 5/5 5/5 5/5 5/5 5/5  
eGFR 
(ml/min/1.73m²) 
105.2  
± 10.2 
76.5  
± 4.7 
45.0  
± 7.8 
24.5  
± 4.1 
12.3  
± 2.1 
< 0.001 
MAP (mmHg) 90 ± 11 96 ± 11 94 ± 8 105 ± 10 99 ± 12 < 0.05 
PP (mmHg) 39 ± 9 44 ± 8 46 ± 17 52 ± 12 56 ± 12 < 0.05 
HR (/min) 68 ± 13 72 ± 22 63 ± 6 69 ± 11 65 ± 9 0.724 
BMI (kg/m²) 23.8  
[22.5-24.7] 
25.9  
[23.0-27.4] 
23.9  
[23.0-26.9] 
30.5  
[23.2-36.4] 
25.9  
[22.1-28.5] 
0.211 
sTNFR1 (ng/ml) 1.0 
 [0.9-1.1] 
1.1  
[1.1-1.3] 
2.3 
 [1.7-3.1] 
4.0  
[3.4-4.6] 
5.8  
[5.5-6.3] 
< 0.001 
sTNFR2 (ng/ml) 2.1  
[1.2-2.3] 
3.1  
[2.4-3.6] 
6.6  
[3.4-8.5] 
6.5  
[5.8-8.3] 
9.7  
[9.1-11.2] 
< 0.001 
sTNFα  
(pg/ml) 
< 0.5 < 0.5 < 0.5 0.5  
[<0.5-2.3] 
3.3  
[1.9-3.7] 
< 0.001 
CRP (mg/l) 0.9  
[0.4-1.3] 
1.3  
[0.6-2.0] 
1.0  
[0.5-2.5] 
2.0  
[1.2-2.0] 
3.0  
[1.0-7.8] 
0.123 
 
CKD: chronic kidney disease, M: male, F: female, eGFR: estimated glomerular filtration rate, 
MAP: mean arterial pressure, PP: pulse pressure, HR: heart rate, BMI: body mass index, 
sTNFR1: soluble tumor necrosis factor receptor 1, sTNFR2: soluble tumor necrosis factor 
receptor 2, sTNFα: soluble tumor necrosis factor alpha, CRP: C-reactive protein. Data 
expressed as mean ± standard deviation or median with interquartile range between 
brackets. N=number. 
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Table 2: Univariate linear regression analysis between soluble receptors and 
possible covariates 
Dependent 
variable 
1/sTNFR1 1/sTNFR2 
Independent 
variable 
r p-value r p-value 
eGFR 
(ml/min/1.73m²) 
0.932 <0.001 0.889 <0.001 
Age (years) -0.266 0.062 -0.290 <0.05 
Gender (F) 0.151 0.296 0.190 0.186 
BMI (kg/m²) -0.132 0.359 0.077 0.597 
MAP (mmHg) -0.362 <0.05 -0.422 <0.01 
PP (mmHg) -0.383 <0.01 -0.374 <0.01 
HR (/min) 0.090 0.536 0.042 0.770 
CRP (mg/l) -0.290 <0.05 -0.325 <0.05 
sTNFα (pg/ml) -0.530 <0.001 -0.494 <0.001 
1/sTNFR1 / / 0.945 <0.001 
1/sTNFR2 0.945 <0.001 / / 
 
R: correlation coefficient, sTNFR1: soluble tumor necrosis factor receptor 1, sTNFR2: soluble 
tumor necrosis factor receptor 2, eGFR: estimated glomerular filtration rate, BMI: body mass 
index, MAP: mean arterial pressure, PP: pulse pressure, HR: heart rate, CRP: C-reactive 
protein, sTNFα: soluble tumor necrosis factor alpha 
Chapter 5.2: sTNFR and eGFR 
 
181 
Table 3: Multiple linear regression model for 1/sTNFR2 
 
Model covariates B [95% CI] beta p-value 
constant 0.05 [0.002-0.097]  <0.05 
eGFR (ml/min/1.73m²) 0.004 [0.003-0.004] 0.844 <0.001 
Gender (F) 0.061 [0.020-0.102] 0.193 <0.05 
CRP (mg/l) -0.011 [-0.020- -
0.001] 
-0.147 <0.05 
Excluded variables: age, tumor necrosis factor alpha, mean arterial pressure, pulse pressure.  
sTNFR2: soluble tumor necrosis factor receptor 2, CI: confidence interval, eGFR: estimated 
glomerular filtration rate, F: female, CRP: C-reactive protein
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Table 4: Expression of tumor necrosis factor receptor 1, 2 and membrane tumor 
necrosis factor alpha on different leukocyte subtypes in healthy controls and 
hemodialysis patients  
 
Receptor  Baseline membrane expression at 4°C (Et0) Membrane expression, when labelling after 
1 hour incubation at 37 °C (Et1) 
MFI C HD p C HD p 
mTNFR1       
Monocytes 344.5 
[306.0-368.8] 
331.5 
[298.5-348.8] 
0.35 347.5
 
[310.5-368.3] 
324.0 
[306.0-359.0] 
0.71 
Granulocytes 409.5 
[398.8-452.8] 
388.5 
[307.5-433.5] 
0.46 451.0 
[413.3-469.0] 
419.0* 
[402.0-440.5] 
0.53 
Lymphocytes 108.5 
[99.8-114.3] 
111.5 
[101.0-120.8] 
0.38 110.5 
[106.3-116.3] 
109.5 
[100.8-115.0] 
0.96 
mTNFR2       
Monocytes 55.0 
[46.8-98.0] 
54.5 
[49.8-60.3] 
0.96 36.5*  
[32.0-42.8] 
43.0 
[34.5-47.8] 
0.29 
Granulocytes 83.0 
[70.8-101.0] 
77.0 
[68.3-92.0] 
0.79 90.5* 
[82.3-111.5] 
92.5 
[87.5-100.0] 
0.83 
Lymphocytes 17.5 
[13.8-24.0] 
11.0 
[10.8-11.0] 
<0.01 9.5 
[8.8-16.3] 
11.0 
[10.0-14.8] 
0.50 
mTNFα       
Monocytes 683.1 
[563.0-762.3] 
549.0 
[471.0-617.3] 
0.07 856.5 
[768.8-
1034.0] 
815.0 
[558.5-915.3] 
0.40 
Granulocytes 629.5 
[477.5-756.3] 
430.0 
[401.0-572.8] 
0.05 710.5 
[650.8-826.3] 
632.0 
[534.5-807.3] 
0.40 
Lymphocytes 125.0 
[116.3-134.8] 
120.0 
[106.8-159.3] 
0.96 129.0 
[125.0-135.5] 
121.5 
[92.8-197.0] 
0.88 
MFI: mean fluorescence intensity, Et0: baseline expression of receptors on membranes, Et1: 
expression on leukocyte membranes after 1 hour of incubation at 37°C and labelling 
afterwards at 4°C. mTNFR1: membrane tumor necrosis factor receptor 1, mTNFR2: 
membrane tumor necrosis factor receptor 2, mTNFα: membrane tumor necrosis factor 
receptor alpha. p: p-value: comparison between C and HD; *: p < 0.05 when analyzing Et0 vs. 
Et1 in C and HD respectively. 
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In this thesis, we first investigated the association between eGFR, the commonly 
used index to evaluate kidney function, and the concentration of well-known low 
molecular weight peptides (Chapter 2). We then explored the potential biological 
activity of selected low molecular uremic weight peptides and focused on marker 
molecules like β-2-microglobulin (Chapter 3), a prototype molecule for the class of 
uremic toxins called middle molecules (MW > 500 Da)1 and on pro-inflammatory 
cytokines, often used as markers of inflammation (Chapter 4). In chapter 5, tumor 
necrosis factor receptor 1 and 2, two peptides that recently gained more interest in 
the context of kidney disease and that are related to the TNFα-system, were 
investigated for their potential as markers for adverse outcome in CKD (Chapter 5.1), 
their biological role and the origin of their increased concentrations in uremia 
(Chapter 5.2).  
 
In chapter 2, the association between the concentration of different uremic low 
molecular weight peptides and eGFR, estimated with different formulae, was 
investigated in a population with CKD stage 2-5 not on dialysis (n = 95). Apart from 
cystatin C and β-2-microglobulin which correlated strongly with eGFR, calculated 
according to the CKD-EPICystC-crea formula, the association with the other evaluated 
uremic peptides (PTH, RbP, Myoglobin, IL6, TNFα, Leptin, FGF-23, Igκ and Igλ) was 
moderate to low (R² < 0.5). These results were similar irrespective of which other 
cystatin C-based or creatinine-based eGFR-formula was used, except for cystatin C 
and β-2-microglobulin, which were more strongly associated to cystatin-C based 
formulae than to creatinine-based formulae. Eloot et al.2 also found comparable low 
associations between eGFR and several protein-bound and small-water soluble 
uremic solutes. Furthermore, regardless of the gradual increase in concentration of 
these uremic peptides during the course of CKD (except for total immunoglobulin 
light chains), there was a large inter-individual variability of solute concentration 
within each of the different CKD stages. These two observations point towards 
important non-GFR determinants influencing the investigated uremic peptides, such 
as inflammation (β-2-microglobulin, cytokines, cystatin C) or hormonal homeostasis 
mechanisms (PTH, FGF-23, leptin). In analogy, in hemodialysis patients, Kt/Vurea, the 
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current marker assessing dialysis adequacy, was not associated to the concentration 
of several common uremic toxins. 3 
Despite the limitation that we did not assess a directly measured GFR, these findings 
challenge the use of GFR as single parameter for the evaluation of effects of renal 
function that have been linked to increased solute retention, which besides 
glomerular filtration also depends on renal tubular function, endocrine function, 
generation and metabolism. Findings from other studies also support this premise: in 
the Initiation of Dialysis Early versus Late (IDEAL) trial, a randomized controlled trial 
(RCT) investigating the timing of initiation of renal replacement therapy based on 
eGFR, 76% of the patients randomized to the late starting group (i.e. eGFR between 
5-7 ml/min/1.73m²) had to start earlier due to the presence of uremic symptoms, 
which are believed to be caused at least partially by uremic toxins.4 Likewise, Hsu et 
al. 5 found in a CKD population (CRIC cohort) that neither mGFR nor eGFR were 
associated to the prevalence of common CKD-complications (anemia, hyperkalemia, 
hyperphosphatemia and metabolic acidosis), which all showed an R² of 
approximately 0.1. Furthermore, β-2-microglobulin6 and FGF-237 have been shown 
to be associated to mortality in a CKD population, independent of eGFR, suggesting 
that these markers are linked to or reflect additional patho-physiological mechanisms 
important to outcomes in CKD patients.  
Further research is needed to investigate whether the concentration of one or a few 
uremic retention solutes might be representative for the concentration of other toxins, 
which would allow defining uremic retention with a limited number of markers. 
Therefore more knowledge is required on the relationship between GFR, the 
mechanisms of renal and extra-renal clearance of uremic retention solutes and their 
plasma concentrations. Whether uremic peptides could be useful markers in this 
context still needs to be determined.  
It should be noted that with regard to the evaluation of certain aspects of kidney 
function, it could be more useful to measure the concentration of these uremic 
peptides in urine. Peptides with MW < 58000 Da and that are not protein-bound, are 
freely filtered through the glomerular membrane and reabsorbed via the 
cubulin/megalin complex in the proximal tubules. When kidney function is normal 
their concentration in urine is low.8,9 It has been shown that the urinary 
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concentrations of β-trace-protein, β-2-microglobulin and cystatin C rise when GFR 
decreases. However, this is to a large extent an indicator of tubular dysfunction10,11, 
whereas the tubules may be affected independently of the rest of the kidneys (e.g. 
with ingestion of nephrotoxic substances). Therefore, measuring urinary 
concentrations, does not necessarily provide information on uremic retention and 
potential systemic toxicity. 
It is probably too optimistic to search for a unique marker which could cover all 
aspects of kidney function of interest, but it would be useful if a panel of markers 
could be defined covering the broad array of kidney functions. One could argue that 
adding new markers is in fact nothing else than a ‘multimarker approach’ which is 
already adopted in clinical practice by for instance measuring PTH, albuminuria and 
hemoglobin levels in the evaluation of patients with chronic kidney disease. However, 
these parameters are rather indicators of CKD complications and are not direct 
measures of uremic retention. Furthermore, regarding the evaluation of kidney 
function itself, markers which could distinguish patients at risk for progression or be 
informative on definite renal tubular damage would be a useful diagnostic addition to 
the current arsenal as well as a possible therapeutic target.  
 
In chapters 3 and 4, we focused on the biological activity of β-2-microgloblin and pro-
inflammatory cytokines, like TNFα, IL6, IL1β and IL18, which is screened in our 
laboratory by assessing their impact on the induction of leukocyte ROS via activation 
of NADPH-oxidase. This mechanism is relevant in uremia since increase in ROS 
contributes to the inflammatory burden in CKD and is considered as a non-traditional 
cardiovascular risk factor on one hand12,13, while on the other, the continuous 
activation of the immune system can impair host defense upon activation by e.g.  
infectious stimuli.14    
The in vitro assays on leukocyte oxidative stress to test the toxicity of individual 
uremic retention solutes were performed in whole blood of healthy donors. The 
advantage of this strategy is to allow interactions between different cell types and 
other plasma solutes during the experiment and to avoid possible activation of cells 
due to isolation procedure. It should however be noted that by doing this the final 
concentration of the added uremic retention solute in the donor blood is slightly 
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higher than the concentrations aimed for, since most of the uremic retention solutes 
are already present in low concentrations in healthy control sera. In our opinion, it is 
unlikely that this background concentration has a significant influence on the results, 
since the added test concentrations are several times above the expected 
background concentration.  
 
In chapter 3, we demonstrated that unmodified β-2-microglobulin, the reference 
molecule for middle molecule/uremic peptide retention in uremia, did not have an 
effect on leukocyte oxidative burst activity. An evaluation on the potential patho-
physiological role of β-2-microglobulin in other cell systems related to cardiovascular 
disease, such as endothelium, vascular smooth muscle cells, should be further 
encouraged since on the clinical level β-2-microglobulin is associated to adverse 
cardiovascular outcomes and/or mortality in the general15-17 and high cardiovascular 
risk populations18-20 as well as in CKD6 and hemodialysis patients.21,22 Also in kidney 
transplant patients, higher β-2-microglobulin concentrations post-transplantation were 
associated to higher mortality risk and graft loss.23  
Although of course other cell systems are also of importance, the lack of biological 
impact on leukocytes could somehow be considered in line with the discrepancy 
between therapies which have shown to improve β-2-microglobulin removal and their 
effect on patient outcomes in large RCTs. Since many years we use the 
concentration of β-2-microglobulin as an index of removal of difficult to remove 
molecules. High-flux hemodialysis24,25, hemodiafiltration24,25 or longer dialysis 
sessions improve the removal of β-2-microglobulin25-27 compared to standard 
dialysis. However, none of the large RCTs investigating these treatment strategies 
could demonstrate a convincing and undisputable impact on outcome.  
Compared to low-flux hemodialysis, high-flux hemodialysis improved survival only in 
the subgroups of patients with a dialysis vintage of > 3.7 years in the Hemodialysis 
(HEMO)-trial28, and in those with an albumin of < 4 g/dl or with diabetes in the 
Membrane Permeability Outcome (MPO)-trial29 Online-hemodiafiltration did not 
reduce mortality risk compared to low-flux hemodialysis in the Convective Transport 
Study (CONTRAST)30 or compared to high- flux hemodialysis in the Turkish Study.31 
The subgroups of patients in these studies treated with the highest convective 
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volumes had however a survival benefit.30,31 Only the Online Hemodiafiltration 
Survival Study (ESHOL)32 found a reduction in all-cause mortality in the patient group 
randomized to high volume post-dilution hemodiafiltration (HR 0.7, 95% CI 0.53-
0.92). Importantly, patients who were randomized to the hemodiafiltration study group 
and who could not maintain the requested exchange volume were excluded from the 
study, which could have introduced bias in terms of patient characteristics between 
the two treatment groups, such as better vascular status in the hemodiafiltration 
arm.32 This apparently weak to absent effect of hemo(dia)filtration with large pore 
filters was confirmed in recent meta-analyses.33-36    
In the studies in which the control group was uniquely treated with low-flux dialysis, 
the β-2-microglobulin removal was indeed superior in the intervention arm, being 
high-flux dialysis in the HEMO-22 and MPO-study29 and online-hemodiafiltration in the 
CONTRAST-study.30 In the two other RCTs investigating hemodiafiltration as 
intervention, the β-2-microglobulin levels were not different in both treatment arms, 
which is not surprising since the entire31 or the majority32 of the control groups in 
those studies were treated with high-flux hemodialysis. In longitudinal follow-up, the 
β-2-microglobulin concentrations rose in the majority of these RCTs (in all, except the 
Turkish Study) which was probably rather due to other factors, such as loss of 
residual renal function. It should also be taken into consideration that the removal 
pattern of other uremic peptides can be different from that of β-2-microglobulin, as 
was demonstrated for complement factor D by Ward et al.37 Taken together, these 
data suggest that β-2-microglobulin is maybe not the only peptide that should be 
considered when evaluating the removal capacities of hemodialysis strategies, 
especially if the purpose would be to use β-2-microglobulin removal or concentration 
as a surrogate for hard endpoints.  
 
Additionally, in chapter 3, the importance of a critical analysis of results of biological 
in vitro studies is illustrated. Our initial results obtained with β-2-microglobulin 
solutions, based on the products as they were purchased from commercial providers, 
revealed a much stronger effect on oxidative stress than expected. After purification 
of the commercial β-2-microglobulin solution by micro-dialysis, the stimulatory effects 
of β-2-microglobulin had disappeared while the dialysis fluid now induced ROS. 
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Unfortunately, we could not identify the contaminant responsible for the observed 
pro-oxidative effects.  
 
In chapter 4, we studied the potential to exert pro-oxidative effects of four pro-
inflammatory cytokines (TNFα, IL6, IL18, IL1β) of which the concentrations increase 
during the course of CKD. They have been shown to increase free radical production 
when applied at substantially higher concentrations than the ones found in uremia.38-
41 However, in a uremic concentration range, IL6, IL1β and IL18 did not increase 
leukocyte ROS at all. Only TNFα was pro-oxidative in monocytes and granulocytes at 
baseline and after fMLP-stimulation but at concentrations that were at the upper 
extreme of what has been observed in uremia (400 and 1400 pg/ml), and also way 
above the concentrations measured nowadays in the samples of our hemodialysis 
patients (approximately 10 pg/ml). Interestingly, a mixture of these cytokines already 
increased leukocyte oxidative stress at concentrations at which none of the individual 
cytokines had any effect, suggesting synergistic effects if individual uremic toxins are 
combined. In future experiments it would be of interest to combine currently observed 
uremic concentrations of cytokines with uremic toxins such as p-cresylsulfate42 or 
phenyl acetic acid43 which have already been shown to increase leukocyte ROS, or 
SDMA which both increased leukocyte ROS44 and intracellular TNFα and IL6 
concentrations.45  
 
These findings also highlight the importance of the use of average uremic retention 
solute concentrations and of a dose response analysis when investigating them in 
biological assays. Testing only the highest reported uremic concentrations can be 
misleading since those do not necessarily represent the effect provoked at lower 
concentrations. Therefore it is important that the clinically relevant concentrations of 
uremic retention solutes are regularly reviewed and updated since therapies evolve 
leading to a reduction of uremic solute concentration with time, while also analytical 
techniques improve, resulting in more accurate concentration measurements. An 
updated list of uremic retention solutes, containing an addition of newly detected 
solutes but also corrections of reported solute concentrations compared to what was 
reported earlier1, was recently published by the European Uremic Toxins Work Group 
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(EUTox)46 in the period during which the experiments for this thesis were conducted. 
The authors recognize the relevance of mean uremic concentrations since they 
choose to report only the average and highest value of reported mean uremic 
concentrations as found in clinical studies. In contrast, in the first key publication by 
the same group on the classification of uremic retention solutes in 20031, mean 
concentrations and the maximum concentration as ever reported in individual 
patients, were listed. As a consequence, in the most recent overview46, the 
concentrations suggested as relevant for most of the uremic retention solutes were 
lower than in the original one.1 This evolution towards a decrease in concentration is 
certainly applicable to cytokines and explains the broad and variable range of 
concentrations that were tested in our dose response experiments, which were 
started before the update on uremic retention solutes 46 was published. We still 
based the choice of solute concentration on the classification of 20031, but since we 
noted that concentrations subsequently reported in more recent studies were 
substantially lower, we added experiments with lower cytokine concentrations, which 
were close to the concentrations published afterwards in the review of 2012.46 
 
Furthermore, in chapter 4 we also investigated the effect of adalimumab, a 
commercially available human monoclonal antibody against TNFα which is used for 
the treatment of patients with rheumatoid arthritis and inflammatory bowel disease. 
Although this TNFα-blocker could neutralize TNFα-induced ROS in normal 
leukocytes, it had no effect on uremia-related ROS in samples of hemodialysis 
patients not treated with TNFα.  
These results suggest that therapeutic interventions to reduce the inflammatory 
burden in CKD should probably not focus on targeted anti-cytokine therapy. This is 
also supported by the findings in a small RCT in hemodialysis patients by Don et al. 
47, which found no effect on inflammatory markers such as CRP and IL6 after 44 
weeks of treatment with the TNFα-blocker, etanercept. Due to the interaction 
between oxidative stress and inflammation, anti-oxidant therapy could be a more 
rational strategy to diminish oxidative stress and related inflammation in CKD on 
dialysis or not yet dialyzed. However, in a recent RCT in hemodialysis patients, the 
administration of a combination of tocopherols and α-lipoic acid failed to decrease 
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inflammatory markers, such as IL6 and hsCRP, and oxidative stress markers, such 
as F2 isoprostane and F2 isofurane.48  
As several uremic toxins, such as indoxylsulfate, p-cresyl sulfate, ADMA and SMDA 
have shown to have a pro-inflammatory effect 49,50, future research to develop 
strategies to decrease inflammation in CKD should probably rather focus on reducing 
generation of uremic toxins with pro-inflammatory effect51 for example at the 
intestinal level, on maintaining uremic toxin removal in the renal tubules52,53 or on 
extracorporeal removal by dialysis or non-dialysis strategies such as adsorption.54,55  
 
In the last section of this thesis containing original data (Chapter 5), we focused on 
tumor necrosis factor receptors (TNFR) 1 and 2, of which the soluble (sTNFR) as well 
as the membrane (mTNFR) bound forms possibly interact and modulate the effects 
of TNFα in the context of chronic inflammation in CKD. Until now, in the field of 
kidney disease, sTNFRs were mainly investigated for their potential role as predictive 
markers of progression of kidney disease or mortality, and predominantly in the 
context of diabetic nephropathy 56-58. mTNFRs on the other hand were assessed for 
their role in local inflammation at the site of the kidneys.59-61  
In the first study (Chapter 5.1), we investigated the association between both 
sTNFRs and the composite endpoint of mortality or first non-fatal cardiovascular 
event. To the best of our knowledge this is the first study evaluating the value of 
sTNFRs in predicting adverse outcomes in established CKD independent of the 
cause of underlying kidney disease. Although the eGFR-range was intentionally kept 
narrow (eGFR < 30 ml/min/1.73m²) in order to minimize the impact of eGFR on 
outcomes, we still found significant correlations between the concentrations of both 
receptors and eGFR (sTNFR1: r = -0.639, p<0.001; sTNFR2: r = -0.504, p<0.001). 
While, due to the design of the study, lower eGFR was not associated to worse 
outcome, higher concentrations of both sTNFRs were in multivariate analysis 
associated to the composite endpoint even after correction for relevant covariables 
such as age, eGFR, CRP, history of cardiovascular disease, diabetes mellitus and 
pulse pressure (HR: TNFR1 (per ng/ml): 1.51, 95% CI: 1.31-1.75; TNFR2 (per ng/ml): 
1.13, 95% CI: 1.06-1.20). These results were confirmed in the non-diabetic 
subpopulation of this study, while in the subpopulation with diabetes we found a 
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significant association between sTNFR1 and outcome. This contrasts to TNFα, which 
was not associated to all-cause mortality and the composite endpoint (Chapter 4). 
The association between adverse outcome and sTNFR1 or sTNFR2 was already 
demonstrated in the general population and patients with diabetic nephropathy.57,58,62-
64 
In the second study (Chapter 5.2.) we further explored the cause of the increased 
concentrations sTNFRs in CKD in an attempt to gain information on their possible 
biological function. Theoretically their concentrations in circulation could increase due 
to decreased renal clearance and/or due to increased release from the cell surface, 
which has been demonstrated to occur in the context of inflammation.  
The reciprocals of the concentrations of sTNFR1 and sTNFR2 were strongly 
correlated to eGFR in an age and gender matched non-diabetic CKD population 
stage 1 to 5, with r = 0.932 and r = 0.889 respectively. Based on these findings, 
especially sTNFR1 could be considered as a more than acceptable glomerular 
filtration marker. However, this should be interpreted with caution since this was a 
selected study population and even if patients with manifest inflammation (CRP > 20 
mg/l) were excluded, there was still a significant correlation between both receptors 
and CRP (1/sTNFR1: -0.290 and 1/sTNFR2: -0.325). It is known that TNFRs are 
released from the cell membranes after a pro-inflammatory stimulus, resulting in an 
acute decrease of membrane expression.65,66 Our results indicate however that the 
membrane expression of TNFR1 and TNFR2 is not different in hemodialysis patients 
vs. healthy controls and that mTNFRs are in steady state in both groups, making 
release of TNFRs from leukocyte membranes as a primary mechanism for the 
increased concentrations of sTNFRs in CKD less probable.  
Together with the results of the last part of our study on sTNFRs (Chapter 5.2), the 
data of the outcome study (Chapter 5.1) suggests that sTNFRs are valuable potential 
markers in CKD and could be informative about kidney function as well as 
inflammatory status. However, further research is needed to determine whether these 
receptors are only markers in CKD or also biologically active. In view of these 
findings it would be also of interest to gain more knowledge on the biological function 
of these soluble receptors in the context of CKD. To investigate this, it will be 
necessary to perform in vitro experiments whereby relative concentrations of both 
Chapter 6: Discussion and future perspectives  
196 
receptors and of TNFα as occurring in CKD are taken into account simultaneously. In 
a second step possibly also the concentrations of other uremic retention solutes 
should be considered in an attempt to mimic real-life conditions in the experimental 
set-up and to obtain relevant results. In this context, other cell types in close contact 
with circulation such as endothelium should be evaluated as well.  
 
Summary 
In summary, in this thesis we demonstrated a discrepancy between the presence of 
uremic peptidic markers or potential markers of CKD and biological impact. First, we 
have shown that eGFR, the widely used index of kidney function, is a weak indicator 
for the concentration of several low molecular weight peptides, except for the already 
known filtration markers (Cystatin C and β2-microglobulin). Second, β-2-
microglobulin, the prototype molecule for the uremic middle molecules, has no effect 
on induction of leukocyte ROS production, an important trigger for micro-inflammation 
in CKD contributing to the patho-physiology of cardiovascular disease. Third, out of 
four pro-inflammatory cytokines of which the concentrations are moderately elevated 
in CKD and which are often used as markers to demonstrate inflammation, only 
TNFα was pro-oxidative but only at concentrations that were in the high upper range 
of those ever observed in uremia. We further demonstrated that TNFα blockade had 
no effect on uremia-related oxidative stress in vitro. However, when we assessed the 
role of sTNFR1 and sTNFR2 in CKD, two peptides that are part of the TNFα system, 
both were strongly correlated to eGFR in a CKD population stage 1-5 and were 
associated to adverse outcome in a CKD population stage 4-5, even after adjustment 
for eGFR and CRP. This makes them valuable candidates to be further evaluated as 
markers and for their patho-physiological role in CKD. 
 
These data indicate that our knowledge on the role of middle molecules in uremia still 
is incomplete and that we cannot take their patho-physiological role as granted, even 
not that of molecules that are generally considered as valid markers of the uremic 
status. On one hand, current indices like eGFR or β2-microglobulin or cytokine 
concentrations do not automatically and indisputably result in the expected effects 
that would have proven their biological relevance. On the other hand however, our 
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research elucidated a number of novel findings about TNFα receptors which up to 
now have insufficiently been explored in CKD.  
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In deze thesis, hebben we eerst de associatie onderzocht tussen eGFR, de courante 
parameter om nierfunctie te evalueren, en de concentratie van verschillende laag 
moleculair gewicht peptiden (Hoofdstuk 2). De biologische activiteit van enkele laag 
moleculair gewicht uremische peptiden werd gescreend, waarbij we ons 
geconcentreerd hebben op molecules die als merkers gebruikt worden, zoals β-2-
microglobuline (Hoofdstuk 3), de prototype molecule van de groep van uremische 
toxines die tot de middelgrote moleculen behoren (MW > 500 Da) 1 en zoals 
cytokines, die gebruikt worden als merkers van inflammatie (Hoofdstuk 4). In 
hoofdstuk 5, onderzochten we de  prognostische waarde van tumor necrosis factor 
receptor 1 en  2 voor mortaliteit en cardiovasculaire ziekte (Hoofdstuk 5.1), hun 
biologische functie en de origine van hun gestegen concentraties in uremie 
(Hoofdstuk 5.2). 
 
In een CKD-populatie stadium 2-5 niet aan dialyse (n = 95) werd de associatie 
onderzocht tussen de concentraties van verschillende laag moleculair gewicht 
peptiden en eGFR, geschat op basis van verschillende formules (Hoofdstuk 2). Met 
uitzondering van cystatine C en β-2-microglobuline die een sterke correlatie 
vertoonden met eGFR (CKD-EPICystC-crea ), was de associatie met de andere 
onderzochte molecules (PTH, RbP, myoglobin, IL6, TNFα, leptin, FGF-23, Ig-λ en Ig-
κ) matig tot zwak (R² < 0.5). Ongeacht de gebruikte formule, of ze nu op cystatine C 
of creatinine gebaseerd was, waren de resultaten zeer gelijkaardig, behalve voor 
cystatine C en β-2-microglobuline die sterker geassocieerd waren met een op 
cystatine C in vergelijking met op creatinine gebaseerde formule. Eloot et al.2 stelde 
eveneens lage associaties vast tussen eGFR en verschillende kleine wateroplosbare 
en proteïne gebonden uremische toxines. Daarenboven vertoonden de concentraties 
van de uremische peptiden een grote inter-individuele variabiliteit binnen eenzelfde 
CKD-stadium, ongeacht het feit dat hun concentraties gradueel stegen wanneer de 
nierfunctie achteruitging (behalve totaal Ig-λ en Ig-κ). Deze twee vaststellingen wijzen 
erop dat andere factoren dan eGFR de concentraties van de onderzochte uremische 
peptiden beïnvloeden, zoals inflammatie (β-2-microglobulin, cytokines, cystatine C) 
of hormonale homeostase mechanismen (PTH, FGF-23, leptin). In analogie met de 
bevindingen met eGFR, werd er geen correlatie gevonden tussen Kt/Vurea, de actuele 
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merker voor de evaluatie van dialyse-efficiëntie en de concentratie van verschillende 
uremische toxines.3 
Ondanks de beperking dat we geen gemeten GFR hebben geanalyseerd in deze 
studie, stellen deze resultaten het gebruik van GFR als enige parameter om de 
effecten van nierfunctie te evalueren die gerelateerd zijn aan retentie van uremische 
toxines in vraag. Uremische retentie hangt namelijk ook af van renale tubulaire 
functie, endocriene functie, generatie en metabolisme. Data uit andere studies 
ondersteunen deze stelling: de Initiation of Dialysis Early versus Late (IDEAL) studie 
is een gerandomiseerde gecontroleerde studie (RCT) die de timing van het opstarten 
van nierfunctievervangende therapie onderzocht. Zesenzeventig procent van de 
patiënten die gerandomiseerd werden in de late starters groep (eGFR tussen 5 en 7 
ml/min/1.73m²) dienden vroeger met dialyse te starten omwille van uremische 
symptomen, die gedeeltelijk veroorzaakt worden door uremische toxines.4 
Gelijkaardige bevindingen werden gedaan in een CKD-populatie (CRIC cohort) 
waarbij mGFR noch eGFR waren geassocieerd met de prevalentie van frequente 
uremische complicaties (anemie, hyperkaliëmie, hyperfosfatemie en metabole 
acidose) (R² bij benadering 0.1).5 Daarenboven is aangetoond dat β-2-
microglobuline6 en FGF-237 geassocieerd zijn met mortaliteit in een CKD populatie, 
onafhankelijk van eGFR, wat erop wijst dat deze merkers gerelateerd zijn aan andere 
pathofysiologische mechanismen die de prognose van CKD patiënten beïnvloeden.  
Verder onderzoek is nodig om na te gaan of de concentratie van één of enkele 
uremische retentiestoffen representatief zijn voor de concentratie van andere toxines, 
zodat uremische retentie met een beperkt aantal merkers zou kunnen gedefinieerd 
worden. Daarvoor is meer kennis nodig over de relatie tussen GFR, renale en extra-
renale klaring van uremische retentiestoffen en hun plasmaconcentraties. De 
mogelijke bijdrage van uremische peptiden als merkers in deze context moet nog 
bepaald worden.  
Hierbij dient ook opgemerkt te worden, dat om bepaalde aspecten van nierfunctie te 
evalueren, het meten van de urinaire concentratie van uremische peptiden misschien 
nuttiger zou kunnen zijn. Peptiden met een MW van < 58000 Da en die niet proteïne-
gebonden zijn, worden vrij gefilterd via de glomerulaire basale membraan en 
gereabsorbeerd via cubuline/megaline receptoren in de proximale tubulus. Wanneer 
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de nierfunctie normaal is, is de concentratie van peptiden in urine laag.8,9 Wanneer 
de GFR daalt, stijgen de urinaire concentraties van β-trace proteïne, β-2-
microglobuline en cystatine C.10,11 Dit is dus in grote mate een weerspiegeling van 
tubulaire functie die kan aangetast zijn onafhankelijk van andere functies van de 
nieren (b.v. door inname van nefrotoxische substanties). Daardoor biedt het meten 
van urinaire concentraties niet noodzakelijk informatie over uremische retentie en 
potentieel systemische toxiciteit. 
Het is waarschijnlijk te optimistisch om ervan uit te gaan dat één enkele merker alle 
aspecten van nierfunctie kan omvatten, maar het zou een diagnostische aanwinst 
zijn, mocht een panel van merkers kunnen gedefinieerd worden die een brede waaier 
van aspecten van nierfunctie weerspiegelt. Men zou kunnen stellen dat er in de 
klinische praktijk al een soort ‘multimarker aanpak’ wordt toegepast door het meten 
van PTH, albuminurie en hemoglobine in de evaluatie van patiënten met CKD. Deze 
parameters zijn echter indicatoren van CKD complicaties en niet onmiddellijke 
maatstaven van uremische retentie. Daarenboven, voor wat betreft de evaluatie van 
nierfunctie op zich, zouden merkers die patiënten met een verhoogd risico op CKD 
progressie kunnen identificeren of die informatie over definitieve renale tubulaire 
schade zouden verschaffen, niet alleen nuttige diagnostische instrumenten kunnen 
zijn maar ook potentiële therapeutische targets. 
 
In hoofdstuk 3 en 4 hebben we ons geconcentreerd op de biologische activiteit van 
β-2-microglobuline en pro-inflammatoire cytokines zoals TNFα, IL6, IL1β en IL18, die 
in ons laboratorium getest wordt door middel van inductie van vrije zuurstofradicalen 
in leukocyten. Dit mechanisme is belangrijk in de context van uremie aangezien een 
verhoogde oxidatieve stress langs de ene kant bijdraagt tot inflammatie in CKD en 
beschouwd wordt als een niet-traditionele cardiovasculaire risicofactor.12,13 Langs de 
andere kant zorgt deze chronische immuunactivatie ervoor dat de immuunafweer 
verstoord is wanneer het immuunsysteem wordt geactiveerd door bv. infectieuze 
stimuli. 14 
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In hoofdstuk 3 toonden we aan dat ongemodificeerd β-2-microglobuline, de 
referentiemolecule voor de middelgrote moleculen/uremische peptiden, geen effect 
had op leukocyt oxididatieve burst activiteit. Een verdere evaluatie van biologische 
activiteit van β-2-microglobuline in andere cardiovasculaire celsystemen, zoals 
endotheel en vasculaire gladde spiercellen, is aan te moedigen aangezien de 
concentratie van β-2-microglobuline geassocieerd is met een slechtere 
cardiovasculaire prognose en/of mortaliteit in de algemene bevolking 15,16,17 en 
populaties met een verhoogd cardiovasculair risico18,19,20, alsook in patiënten met 
CKD 6 of aan hemodialyse.21,22 Ook bij niertransplantpatiënten was een hogere β-2-
microglobuline concentratie posttransplantatie geassocieerd aan een hoger 
mortaliteitsrisico of risico op transplantfalen.23 
Uiteraard zijn ook andere celsystemen belangrijk, maar de afwezigheid van 
biologisch effect in leukocyten ondersteunt als pathofysiologische bevinding de 
discrepantie die er bestaat tussen therapieën die β-2-microglobuline verwijdering 
optimaliseren en hun effect op harde eindpunten bij patiënten. Beta-2-microglobuline 
wordt als referentie gebruikt om de verwijdering van de zogenaamde ‘moeilijk te 
verwijderen uremische retentiestoffen’ te evalueren. Het gebruik van een high-flux 
kunstnier 24,25, hemodiafiltratie24,25 of langere hemodialyse-sessies26,27,25 verbeteren 
de verwijdering van β-2-microglobuline in vergelijking met standaard hemodialyse. 
Desondanks kon geen enkele grote RCT die deze technieken onderzocht 
ontegensprekelijk en overtuigend een gunstig effect op prognose aantonen.  
Vergeleken met low-flux hemodialyse, verbeterde high-flux dialyse de overleving 
enkel in subgroepen van patiënten die al > 3.7 jaar werden gedialyseerd (HEMO-
studie) 28, die een albumine van < 4 g/dl of diabetes mellitus hadden (MPO-studie).29 
Online-hemodiafiltratie verminderde het mortaliteitsrisico niet vergeleken met low-flux 
dialyse (CONTRAST-studie)30 of high-flux dialyse (Turkish HDF-studie).31 Enkel de 
patiënten die behandeld werden met de hoogste convectievolumes hadden een 
overlevingsvoordeel.30,31 Enkel in de ESHOL-studie32 werd een reductie van de 
mortaliteit gevonden bij de patiënten die gerandomiseerd werden in de groep van 
hoog-volume postdilutie hemodiafiltratie (HR 0.7, 95% CI 0.53-0.92). Een belangrijke 
kanttekening hierbij is dat de patiënten die gerandomiseerd waren in de groep van 
hemodiafiltratie en die het gevraagde substitutievolume niet bereikten, geëxcludeerd 
werden uit de studie. Dit kan bias veroorzaakt hebben voor wat betreft de 
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patiëntenkarakteristieken tussen beide patiëntengroepen, zoals bv. een betere 
vasculaire status in de hemodiafiltratiegroep.32 Recente meta-analyses die deze drie 
RCT’s samen analyseerden met kleinere RCT’s vonden evenmin een reductie in 
mortaliteit voor patiënten die behandeld werden met hemo(dia)filtratie 33,34,35,36, al 
konden Nistor et al.34 een mogelijk gunstig effect van convectieve therapieën op 
cardiovasculaire mortaliteit niet uitsluiten.  
In de studies waarin de controle groep enkel met low-flux dialyse werd behandeld, 
was de β-2-microglobuline verwijdering inderdaad superieur in de interventie-arm, 
zijnde high-flux dialyse in de HEMO-22 en MPO-studie29 en online-hemodiafiltratie in 
de CONTRAST-studie.30 In de andere twee RCTs die hemodiafiltratie als interventie 
bestudeerden, waren de β-2-microglobuline concentraties niet verschillend tussen 
beide groepen. Dit is misschien niet zo verwonderlijk aangezien de volledige 31 of de 
meerderheid32 van de controlegroep werd behandeld met high-flux dialyse. Tijdens 
de longitudinale follow-up steeg de β-2-microglobuline concentratie in de 
meerderheid van de RCTs (i.e. in alle behalve de ‘Turkish Study’) wat waarschijnlijk 
meer te wijten is aan andere factoren zoals het verlies van residuele nierfunctie. Een 
ander punt dat hierbij het vermelden waard is, is de vaststelling dat het 
eliminatiepatroon van andere uremische peptiden verschillend kan zijn dan dat van 
β-2-microglobuline, zoals werd aangetoond voor complement factor D 37 
Alles samen suggereren deze gegevens dat misschien niet alleen β-2-microglobuline 
moet geëvalueerd worden om dialysestrategieën voor wat betreft eliminatie van 
retentiestoffen te bestuderen. Dit voornamelijk als het de bedoeling is om β-2-
microglobuline verwijdering of concentratie als een surrogaat te gebruiken voor harde 
klinische eindpunten. 
 
Een andere vaststelling in hoofdstuk 3 illustreert het belang van een kritische 
evaluatie van resultaten van in vitro studies. Initieel vertoonde β-2-microglobuline, 
zoals aangekocht van de firma, een veel sterker effect of ROS productie in 
vergelijking met het verwachte resultaat. Na opzuivering van de oplossing door 
middel van micro-dialyse verdwenen de pro-oxidatieve effecten van β-2-
microglobuline terwijl het dialysaat nu wel ROS induceerde. Jammer genoeg konden 
we de contaminant(en) niet identificeren.  
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In hoofdstuk 4 bestudeerden we de pro-oxidatieve effecten van vier pro-
inflammatoire cytokines (TNFα, IL6, IL1β, IL18) waarvan de concentraties stijgen in 
het verloop van CKD. Van deze cytokines werd reeds aangetoond dat ze vrije 
radicalen productie konden induceren wanneer ze getest werden in veel hogere 
concentraties dan deze die in uremie worden vastgesteld.38,39,40,41 In tegenstelling 
hiermee stelden we vast dat in een uremische concentratie range, IL6, IL1β en IL18 
geen leukocyte ROS konden induceren. Alleen TNFα was pro-oxidatief in monocyten 
en granulocyten, maar enkel in extreem hoge uremische concentraties (400 en 1400 
pg/ml), die meerdere malen hoger zijn dan de concentraties die actueel in 
hemodialysepatiënten worden vastgesteld. Ter vergelijking, in de stalen van de 
hemodialysepatiënten in onze studie bedroeg de gemiddelde TNFα concentratie 10 
pg/ml. Opmerkelijk, een combinatie van deze cytokines verhoogden de burst activiteit 
in leukocyten al in concentraties waarbij de individuele cytokines nog geen effect 
hadden, wat synergisme tussen cytokines suggereert. Daarom is het interessant om 
in toekomstige experimenten, cytokines in uremische concentraties te combineren 
met uremische toxines zoals p-cresylsulfate42 of phenylacetaat43 waarvan al pro-
oxidatieve effecten zijn aangetoond of SDMA waarvan is aangetoond dat het zowel 
ROS induceert44 als dat het de intracellulaire concentraties van TNFα en IL6 
verhoogt.45 
 
Deze bevindingen wijzen eveneens op het belang van het gebruik van gemiddelde 
concentraties van uremische retentiestoffen en van een dosis antwoord analyse in 
biologische experimenten. Enkel de maximum uremische concentratie testen kan 
misleidend zijn aangezien dit niet noodzakelijk het effect van lagere concentraties 
weerspiegelt. Daarom is het ook belangrijk dat de klinisch relevante concentraties 
van uremische toxines regelmatig geüpdatet worden aangezien therapieën evolueren 
wat leidt tot een reductie van de toxine concentratie, terwijl tegelijkertijd de 
analytische technieken verbeteren waardoor een meer accurate concentratiebepaling 
mogelijk is. Een update van de lijst met uremische retentiestoffen werd recent 
gepubliceerd door de European Uremic Toxins Work Group (EUTox)46 in de periode 
dat de experimenten van deze thesis werden uitgevoerd. Deze lijst bevat enerzijds 
nieuw gedetecteerde uremische retentiestoffen en anderzijds ook correcties van de 
concentraties van stoffen die al eerder werden gepubliceerd.1 De auteurs erkennen 
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hierbij ook het belang van gemiddelde uremische concentraties aangezien ze ervoor 
kozen om gemiddelde concentraties op te lijsten zoals die in studiepopulaties werden 
vastgesteld. Dit is in tegenstelling tot de eerste publicatie door dezelfde auteurs in 
verband met de classificatie en concentratie van uremische retentiestoffen, waarbij 
een gemiddelde concentratie werd weergegeven en de maximale uremische 
concentratie die ooit werd gerapporteerd in een individuele patiënt.1 Als een gevolg 
hiervan zijn de meeste concentraties die als relevant worden beschouwd, lager in de 
meest recente publicatie.46 De trend dat de concentraties dalen is zeker ook 
toepasbaar op cytokines en verklaart de brede en variabele concentratie ranges die 
in onze dosis antwoord experimenten werden gebruikt, aangezien deze startten voor 
de update over uremische retentiestoffen46 werd gepubliceerd. Wij hebben ons nog 
steeds gebaseerd op de concentraties zoals beschreven in de classificatie van 
2003.1 Aangezien we echter vaststelden dat de nadien gepubliceerde concentraties 
merkbaar lager waren, voegden we experimenten toe met lagere cytokine 
concentraties, die uiteindelijk dicht aanleunden bij de concentraties die nadien 
werden gepubliceerd in de review van 2012.46 
 
In hoofdstuk 4 onderzochten we ook het effect van adalimumab, een commercieel 
beschikbaar monoclonaal antilichaam tegen TNFα, dat gebruikt wordt in de 
behandeling van patiënten met reumatoïde arthritis en inflammatoire darmziekten. 
Ook al kon deze TNFα-blocker TNFα-geïnduceerde ROS productie blokkeren in 
normale leukocyten, deze had geen effect op uremie-gerelateerde oxidatieve stress 
in stalen van hemodialysepatiënten.  
Deze resultaten suggereren dat therapeutische interventies om inflammatie in CKD 
te reduceren, zich waarschijnlijk niet moeten richten op anti-cytokine therapie. Dit 
wordt ook ondersteund door de resultaten van een kleine RCT in hemodialyse 
patiënten, waarbij 44 weken behandeling met de TNFα-blocker, etanercept, geen 
effect had op inflammatoire merkers zoals CRP en IL6.  Omwille van de interactie 
tussen inflammatie en oxidatieve stress, zou anti-oxidatieve therapie een andere 
strategie kunnen zijn om oxidatieve stress en gerelateerde inflammatie in CKD te 
kunnen verminderen. In een recente RCT echter, had de toediening van een 
combinatie van tocopherols en α-lipoidzuur geen effect op inflammatoire parameters 
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zoals IL6 en CRP, en oxidatieve stress markers zoals F2-isoprostaan en F2-
isofuraan.47  
Aangezien verschillende uremische toxines zoals indoxylsulfaat, p-cresylsulfaat, 
ADMA en SDMA, pro-inflammatoire eigenschappen hebben, zal toekomstig 
onderzoek dat zich toespitst op therapieën om inflammatie te verminderen, zich 
vermoedelijk eerder moeten richten op strategieën om de generatie van uremische 
toxines te verminderen vb. ter hoogte van de darm48, om de eliminatie ervan in de 
niertubuli te behouden49,50 of op de verdere ontwikkeling van extra-corporele 
technieken zoals dialyse of adsorptie.51,52 
 
In het laatste deel van deze thesis met originale data (Hoofdstuk 5), concentreerden 
we ons op tumor necrosis factor receptor (TNFR) 1 en 2, waarvan zowel de 
receptoren in circulatie (sTNFR) als de membraangebonden receptoren (mTNFR) 
mogelijk de effecten van TNFα kunnen moduleren in de context van inflammatie in 
CKD. Tot hiertoe werden, in het domein van de nefrologie, de sTNFRs voornamelijk 
onderzocht voor hun prognostische waarde als merker voor progressie van CKD of 
mortaliteit, voornamelijk in populaties met diabetische nefropathie53,54,55 en de 
mTNFRs voor hun functie bij lokale inflammatie ter hoogte van de nier. 56,57,58 
In de eerste studie (Hoofdstuk 5.1), werd de associatie onderzocht tussen beide 
sTNFRs en het samengestelde eindpunt mortaliteit of non-fatale cardiovasculaire 
ziekte. Voor zover we weten, is dit de eerste studie die de prognostische waarde van 
sTNFRs onderzocht in een populatie met gevorderd nierlijden onafhankelijk van de 
onderliggende oorzaak van de nierziekte. Ook al was er een nauwe eGFR-range (< 
30ml/min/1.73m²), bedoeld om de invloed van eGFR op het onderzochte eindpunt te 
beperken, toch was er een significante correlatie tussen beide receptoren en eGFR 
(sTNFR1: r = -0.639, p<0.001; sTNFR2: r = -0.504, p<0.001). En terwijl, door de 
opzet van de studie, een lagere eGFR niet geassocieerd was met een hoger risico op 
het bereiken van het eindpunt, was een hogere concentratie van beide receptoren in 
multivariate analyse wel geassocieerd aan het samengestelde eindpunt, zelfs na 
correctie voor relevante covariabelen zoals leeftijd, eGFR, een voorgeschiedenis van 
cardiovasculaire ziekte, diabetes mellitus en polsdruk (HR: TNFR1 (per ng/ml): 1.51, 
95% CI: 1.31-1.75; TNFR2 (per ng/ml): 1.13, 95% CI: 1.06-1.20). De resultaten 
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werden eveneens bevestigd in de subpopulatie van niet-diabetes patiënten. In de 
subgroep van diabetespatiënten was er enkel een significante associatie tussen 
sTNFR1 en het onderzochte eindpunt. Deze resultaten zijn in contrast met TNFα dat 
niet was geassocieerd met mortaliteit en het gecombineerde eindpunt (Chapter 4). 
De associatie tussen een slechtere prognose en sTNFRs was al gevonden in de 
algemene populatie en patiënten met diabetische nefropathie.53,59,55,60,61 
In de tweede studie (Hoofdstuk 5.2) onderzochten we de oorzaak van de gestegen 
TNFR concentraties in CKD met de bedoeling informatie te vergaren over hun 
mogelijke biologische functie. Theoretisch kan hun concentratie in circulatie stijgen 
door verminderde renale klaring en/of ten gevolge van hun toegenomen vrijlating van 
de celmembraan, wat gelinkt is aan inflammatie en wat kan leiden tot een 
verandering in membraanexpressie van de receptoren. De reciproque van de 
sTNFR1 en sTNFR2 concentraties waren sterk gecorreleerd met eGFR in een leeftijd 
en geslacht gematchte niet-diabetes CKD populatie stadium 1 tot 5 (r = 0.932 en r= 
0.889, respectievelijk). Deze bevindingen zouden kunnen doen uitschijnen dat vooral 
sTNFR1 een acceptabele glomerulaire filtratie marker is. Dit dient echter met enige 
voorzichtigheid geïnterpreteerd te worden omdat dit een sterk geselecteerde 
studiepopulatie was. Zelfs al werden patiënten met manifeste inflammatie (CRP > 
20mg/l) geëxcludeerd, was er toch een significante correlatie tussen beide 
receptoren en CRP ((1/sTNFR1: -0.290 and 1/sTNFR2: -0.325). Het is gekend dat 
TNFR van het celmembraan wordt vrijgesteld ten gevolge van een pro-inflammatoire 
stimulus, hetgeen resulteert in een acute daling van de membraanexpressie.62,63 Wij 
vonden echter geen verschil in de membraanexpressie van TNFR1 en TNFR2 tussen 
hemodialysepatiënten en gezonde controles. Daarenboven was de expressie van 
beide mTNFR in beide groepen in steady state. Het is dus onwaarschijnlijk dat 
vrijstelling van het celmembraan het primaire mechanisme is dat bijdraagt tot de 
verhoogde concentraties van sTNFR in CKD.  
Samen met de resultaten van het laatste deel van onze studie naar TNFα-receptoren 
(Hoofdstuk 5.2), suggereren de bevindingen uit de eerste studie (Hoofdstuk 5.1) dat 
sTNFRs potentiële prognostische merkers kunnen zijn in CKD en dat ze zowel 
informatie zouden kunnen verschaffen over nierfunctie als inflammatoire status,. 
Verder onderzoek is echter nodig om uit te maken of deze receptoren enkel merkers 
zijn of dat ze ook een biologische functie hebben. In het kader van deze bevindingen, 
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zou het interessant zijn om de kennis betreffende hun biologische functie in de 
context van CKD uit te breiden. Om dit te doen zal het nodig zijn om experimenten op 
te stellen waarbij er rekening gehouden wordt met de relatieve concentraties van 
sTNFRs en TNFα zoals die voorkomen in CKD. In een volgende stap, zullen 
vermoedelijk ook de concentraties van andere uremische toxines in overweging 
moeten genomen worden in een poging om de reële situatie na te bootsen in een 
experimentele setting en aldus relevante resultaten te bekomen. Daarenboven zou 
het ook interessant zijn om hun effecten te bestuderen in andere celtypes zoals 
endotheelcellen aangezien deze cellen ook rechtstreeks in contact staan met 
bloed/plasmacomponenten.  
 
Samenvatting 
In deze thesis toonden we een discrepantie aan tussen de aanwezigheid van 
uremische peptide merkers of potentiële merkers van CKD en biologische impact. 
Ten eerste hebben we beschreven dat eGFR, de algemeen aanvaarde parameter 
van nierfunctie, zwak geassocieerd is met de concentratie van verschillende laag 
moleculair gewicht uremische peptiden, uitgezonderd voor al gekende filtratiemerkers 
(cystatine C en β-2-microglobuline). Ten tweede had β-2-microglobuline, het 
prototype van de uremische middelgrote molecules, geen effect op de inductie van 
leukocyt ROS productie, een proces dat een belangrijke trigger is van micro-
inflammatie in CKD en bijdraagt tot de pathofysiologie van cardiovasculair lijden. Ten 
derde, van de vier onderzochte pro-inflammatoire cytokines, waarvan de concentratie 
licht gestegen is in CKD en die vaak gebruikt worden als merker voor inflammatie, 
was enkel TNFα pro-oxidatief, maar dan enkel in hoog uremische concentraties. 
Hierbij toonden we ook aan dat TNFα-blockade geen effect had op uremie-
gerelateerde oxidatieve stress in vitro. Wanneer we tenslotte de rol van beide TNFα-
receptoren, die deel uitmaken van het TNFα-systeem, in CKD exploreerden, vonden 
we dat beide sterk gecorreleerd waren met eGFR in een populatie met CKD stadium 
1-5 en geassocieerd waren met een negatieve prognose in een CKD populatie 
stadium 4-5, zelfs na correctie voor eGFR en CRP. Dit maakt van hen kandidaten om 
hun pathofysiologische rol in CKD verder uit te diepen. 
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Deze data wijzen erop dat onze kennis omtrent de pathofysiologische rol van 
uremische peptiden in uremie nog steeds onvolledig is en dat we hun biologische 
impact niet zomaar kunnen voor waar aannemen, zelfs niet van molecules waarvan 
is aangenomen dat het valabele merkers zijn voor de uremische status. Aan de ene 
kant, kunnen we uit onze bevindingen niet ontegensprekelijk besluiten dat 
welgekende parameters zoals eGFR, β-2-microglobulin en cytokines hun biologische 
relevantie hebben aangetoond. Aan de andere kant, deden we enkele nieuwe 
vaststellingen in verband met TNFα-receptoren, die aangeven dat dit interessante 
molecules zijn om verder te onderzoeken in de context van CKD. 
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